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Bladder cancer epidemiology
Urinary bladder cancer (UBC) is a common malignancy, which ranks ninth in worldwide 
cancer incidence with approximately 430,000 new cases and 165,000 deaths in 2012 (1). 
In the Netherlands, roughly 5,300 men and 1,650 women were newly diagnosed in 2017 (2). 
This difference in UBC incidence between men and women is probably a reflection of 
historical gender differences in smoking behavior and occupational exposures. Even though 
the highest incidence rates of UBC are found in Western countries, both incidence and 
mortality rates among men have been slowly declining in the United States and large parts of 
Europe since the 1990s (3). Interestingly, incidence rates in women have been increasing in 
many European countries, as well as in other parts of the world (3). These trends may reflect 
changes in smoking behavior and protective measures to occupational exposures (3). 
Established risk factors 
The most important risk factor for UBC is tobacco smoking, and 43% of all cases in men 
and 26% of all cases in women in Europe are attributable to smoking (4). Compared to 
never smokers, current smokers have an over three-fold increased risk of UBC (95% 
confidence interval (CI): 2.53-3.75) (4). Smoking cessation can lower UBC risk, and a slight 
decrease in risk to less than three-fold that of never smokers can already be observed after 
5 years of cessation (4). However, even 25 years after smoking cessation, UBC risk remains 
1.5 times higher than the risk of never smokers (4). Occupational exposure to aromatic 
amines, polycyclic aromatic hydrocarbons and chlorinated hydrocarbons have played an 
important role in UBC etiology for decades, with an estimated population attributable 
fraction of 20% (5). Nowadays, the population attributable fraction has dropped to 10% 
due to more hygienic working environments and work-safety guidelines in industries using 
these substances (6).
 There is a growing understanding of the involvement of genetics in UBC development. 
Having a first-degree relative with UBC, independent of age at diagnosis, has been 
associated with a two-fold increase in risk (7). Genome-wide association studies identified 
multiple independent loci associated with UBC risk (8-11). Also, genetic factors can affect 
individual susceptibility to other risk factors, and thereby increase the risk of UBC (12). For 
example, ever smokers with a slow acetylation genotype for N-acetyltransferase 2 (NAT2) 
have consistently been shown to have a higher UBC risk (13).  
 Other risk factors include arsenic in drinking water, schistosomiasis infection, exposure 
to radiation in the pelvic area, cyclophosphamide treatment, and chronic urinary tract 
infections (12, 14). A long history of chronic infections of the bladder are more associated 
with squamous cell carcinoma of the bladder, a histological subtype of UBC, than with 
urothelial carcinoma (12). 
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Lifestyle factors and UBC risk
Evidence on the association of lifestyle factors, other than smoking, with UBC risk was 
summarized by the World Cancer Research Fund / International American Institute for 
Cancer Research in 2015 (15-17). They concluded that there is limited suggestive evidence 
that a greater consumption of fruit, vegetables, and tea decreases the risk of UBC (14). 
No conclusions could be drawn for other dietary factors, physical activity or BMI (14). 
However, other recent meta-analyses of prospective cohort studies partly including different 
studies did find small increased UBC risks with a higher BMI (overweight vs. normal weight; 
pooled relative risk (RR)=1.07, 95% CI 1.01-1.14, I2=37.6%, p=0.03; obesity vs. normal weight: 
pooled RR=1.10, 95% CI 1.06-1.14, I2=15.5%, p=0.24) (18), and decreased risks with higher 
levels of physical activity (high vs. low level; pooled RR=0.89, 95% CI 0.80-1.00, I2=64%) (19) 
and vitamin E (high vs. low intake; pooled RR=0.80, 95% CI 0.69-0.91, I2=21.1%) (20). 
 Since diet consists of many macro- and micronutrients that are correlated and can 
potentially interact with each other in a complex way, it may be better to evaluate dietary 
patterns rather than single nutrients when estimating diet-disease associations (21). 
However, to our knowledge, only one study investigated dietary intake patterns in relation 
to UBC risk (22). This study found that a pattern characterized by consumption of high vs. 
low amounts of coffee, tea, and added sugar (odds ratio (OR)=3.27, 95% CI 1.96-5.45), 
as well as a pattern high vs. low in red meat, fried eggs, potatoes, and red wine (OR=2.35, 
95% CI 1.42-3.89) were associated with a higher risk of UBC.
 There are several hypotheses about mechanisms by which lifestyle habits can influence 
UBC risk. Potentially harmful substances from food, such as N-nitroso- compounds, polycyclic 
aromatic hydrocarbons and heterocyclic aromatic amines in red meat, are excreted through 
the urinary tract. They come into close contact with urothelial cells and may be involved 
in carcinogenesis by directly acting on the urothelium and causing DNA damage (23-29). 
For example, a study in normal human urothelial mucosa and bladder tumor tissue 
showed that the levels of urothelial DNA adducts, a marker for carcinogen exposure, 
increased after exposure to the carcinogens 4-aminobiphenyl and acrolein (30). A larger 
fluid volume intake is thought to be protective as it dilutes carcinogens in the urine, and 
decreases contact time with the urothelium through an increased micturition frequency 
(26). However, the investigation of fluid volume intake in relation to UBC risk is complicated 
as it provides no information about the composition of the urine and micturition 
frequency (26).
 Multiple nutrients with a potential protective effect, such as vitamin A and E, phenols, 
flavonoids and phytochemicals, are also excreted in the urine and can be involved in 
numerous carcinogenic pathways as well (29). Examples are the reduction of oxidative 
stress and DNA damage, the inhibition of cell proliferation, and enhancement of the 
immune response (27-29).
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Further, body fatness, often measured by body mass index (BMI), and physical activity are 
independently linked to several biochemical and immunological changes involved in 
carcinogenesis (31). For example, a higher amount of body fat is related to an elevated 
secretion of pro-inflammatory cytokines which induces chronic inflammation. Inflammation 
in turn leads to increased cell proliferation and worsening of insulin sensitivity, both of 
which are related to increased cancer risk (31). Physical activity on the other hand improves 
insulin sensitivity, enhances both innate and acquired immunity, and can decrease 
oxidative stress (31).
Clinical presentation, prognosis and treatment
Urothelial carcinoma accounts for 90-95% of all bladder tumours in western countries (32). 
Other less frequent histological subtypes are squamous cell carcinoma (2-5%), adenocarcinoma 
(1-2%), and numerous very rare subtypes (32, 33). However, in recent years more and more 
histological variants are being described (34).
 Approximately 75% of bladder cancer patients present with non-muscle-invasive 
bladder cancer (NMIBC), where the tumour is confined to the mucosa (stages Ta and 
carcinoma in situ (CIS)) or submucosa (stage T1) of the bladder wall (Figure 1) (6). The 
remainder is diagnosed with muscle-invasive or metastatic bladder cancer (MIBC), where 
the tumour is invading the muscle layer of the bladder, perivesical tissue, or surrounding 
organs (6). Women are more likely to present with more advanced tumours, at least partly 
because of a longer diagnostic delay (35).
Figure 1   Illustration showing T staging of bladder cancer.
Source: http://oncolex.org/bladder-cancer/background/staging
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NMIBC and MIBC have been traditionally viewed as separate disease entities, since clinical 
behaviour is very different. NMIBC is especially characterized by a high but relatively 
benign recurrence risk, whereas cancer-specific mortality is the most relevant outcome 
for MIBC patients (6). This thesis will be focused on NMIBC. 
 Also within NMIBC, there is a large heterogeneity with regard to prognosis. NMIBC 
patients can be divided into risk groups based on stage, grade, prior recurrence rate, and 
number of tumours (36). Low-risk tumours are defined as primary, solitary, low-grade/
grade 1, stage Ta tumours smaller than three centimeters and without concomitant 
carcinoma in situ. High-risk tumours are either high-grade/grade 3, stage T1, carcinoma in 
situ, or multiple and recurrent Ta grade 1 or 2 tumours larger than three centimeters. 
Tumours that cannot be classified in one of the two categories are classified as intermediate 
risk (6). One- and five year risks of tumour recurrence are 14% and 28% for NMIBC patients 
with low-risk tumours and 33% and 52% for patients with high-risk tumours, respectively 
(36). Often, multiple recurrences per patients are observed in patients with low-risk as well 
as in patients with high-risk tumours (36). Even though recurrence rates decreased in the 
last decades due to improvement in treatments, they are still high, indicating the need to 
identify additional prognostic factors that may support treatment. The five-year disease- 
specific survival is generally high, ranging between 89 and 99% (36). However, 21% of the 
high-risk tumours may invade the muscle, which dramatically worsens the prognosis and 
decreases five-year disease-specific survival to 35% (37). 
 NMIBC is treated with a transurethral resection of the tumour, preferably followed by 
an intravesical instillation of chemotherapy within 24 hours (6). For patients with a low-risk 
tumour, this combination is considered as a complete treatment, but other patients 
should be further treated with adjuvant chemotherapy (generally mitomycin C or epirubicin) or 
immunotherapy (bacillus Calmette-Guerin; BCG) (6). In a sub-group of high-risk patients 
and in patients with BCG failure, radical cystectomy should be considered (6).
 Due to the high risk of recurrence, patients need regular long-term follow-ups with 
minimally invasive cystoscopies and treatment, making bladder cancer one of the most 
expensive tumours per patient per year (38). 
Lifestyle and UBC prognosis 
Research on lifestyle and cancer to date has mainly focused on primary prevention of 
cancer. Due to earlier diagnosis, more effective treatments and an ageing population, 
survival rates and the number of survivors in the Western world are rapidly increasing (39). 
Although evidence for an association of different lifestyle factors with cancer prognosis is 
increasing, the role of lifestyle in UBC prognosis has hardly been investigated (40). Also, 
prospective studies investigating lifestyle before and after diagnosis, and the impact of 
lifestyle modifications after diagnosis are currently lacking. Especially for NMIBC patients, 
13
General introduction
1
it may be beneficial to alter their lifestyle to influence disease prognosis, since they have a 
high risk of recurrence, but high survival rates. Apart from a potential effect on NMIBC 
prognosis, improvements in lifestyle can have a beneficial effect on lifestyle-related 
comorbidities such as type II diabetes mellitus and cardiovascular disease (41). 
 Most studies on lifestyle and NMIBC prognosis conducted to date were focused on 
smoking. A meta-analysis of historical cohort studies suggests that both former and 
current smokers are at an over 20% higher risk of disease recurrence than non-smokers 
(42). Evidence for an association of smoking with risk of progression is still weak, but results 
do suggest an increased risk of disease-specific mortality in smokers (42-44). Smoking 
cessation may limit the detrimental effects of smoking, but there is no conclusive evidence 
yet whether smoking cessation after diagnosis can favorably alter the course of disease 
(43, 45, 46). However, almost all research that has been performed on smoking and UBC 
prognosis to date is based on historical cohort studies. These studies often suffer from 
several methodological disadvantages, such as selection bias due to differential loss to 
follow-up, and poor quality of the data when data is collected from medical records. Also, 
no evidence for a dose-response association across cumulative smoking exposure is 
available yet (47). However, since studies generally suggest an increased risk of recurrence 
and an impaired response to immunotherapy for active smokers, the European Association 
of Urology guidelines on NMIBC currently recommend smoking cessation counseling (48). 
 Other lifestyle factors, such as fluid intake, and fruit and vegetable consumption, 
could also be associated with UBC prognosis through mechanisms comparable to those 
involved in etiology. Further, lifestyle factors that are associated with systemic inflammation, 
e.g. BMI and physical activity, could thereby possibly influence UBC prognosis as well (49, 50). 
However, research on lifestyle and UBC prognosis is still limited. 
Health-related quality of life
With the increasing numbers of cancer survivors, patient-reported health-related quality of 
life (HRQoL) is increasingly being appreciated as an indication of long-term effects of cancer 
and cancer treatment (39). In NMIBC patients, the frequent and invasive follow-up visits and 
treatments, which are often accompanied by side-effects, could potentially have a large 
impact on HRQoL (51, 52). Several studies compared different follow-up regimes and 
treatment options in terms of HRQoL, showing that patients often have emotional concerns 
and complaints related to urinary symptoms that are partially dependent on the type of 
treatment (53-55). In comparison to a normative population, patients with NMIBC were 
shown to have a worse mental and/or physical health (55-57). However, most of the studies 
conducted to date had a retrospective or cross-sectional design, may be subject to recall 
bias, and did not study development of HRQoL over time. Therefore, no firm conclusions 
about changes in HRQoL after diagnosis and effects of treatment on HRQoL can be drawn.
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Lifestyle and UBC health-related quality of life
Several health behaviors have been linked to better HRQoL in survivors of numerous 
cancers. Exercise, smoking cessation, maintaining a healthy weight, and eating a healthy 
diet have all been associated with a better quality of life (58-67). A systematic review of 
studies investigating the association between diet, physical activity, and smoking status 
with HRQoL in UBC survivors showed that there is suggestive evidence for a positive 
association of higher physical activity levels with certain HRQoL domains such as general 
health, functional well-being, and emotional well-being (68). However, differences were 
often small and not clinically relevant. Interestingly, a recent study not included in the 
review found an over 2 times increased chance of a higher HRQoL for patients reporting 
high compared to low physical activity levels (69). For diet, smoking status, and BMI the 
evidence is insufficient to draw conclusions (68, 70). 
Behaviour change after diagnosis
A sustained change of lifestyle behaviours is difficult to attain (71-73). A cancer diagnosis 
may provide a so-called ‘teachable moment’, an event which may lead to a high motivation 
of the patient to change his or her behaviour (74, 75). Therefore, it might be an important 
window of opportunity to have a meaningful impact on lifestyle and thereby prognosis 
and quality of life. Also, by changing lifestyle habits patients can become actively involved 
in the management of their own disease.
 An important first step in behaviour change is awareness of risk factors for disease 
and awareness of one’s own behaviour with regard to that risk factor. This is related to an 
individual’s perceived susceptibility to a risk and the perceived severity of that risk (71). 
Previous research suggests that awareness of smoking as UBC risk factor among patients 
was generally low, but estimates were highly divergent (10-85%) (76-79). Less is known 
about NMIBC patients’ awareness of other risk factors and what they perceive as being the 
cause of their own disease (77). Also, it is important to know whether patients are open 
towards receiving lifestyle advice and whether they already receive advice from their 
physician. The European Association of Urology guidelines on NMIBC recommend 
smoking cessation counseling (48), but to what extent this guideline is followed and 
whether urologists give other lifestyle advice is unknown. 
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Aim and outline of thesis
The aim of this thesis is to investigate the association of smoking, fluid intake, and dietary 
patterns with risk of recurrence and HRQoL in NMIBC patients, and to investigate patients’ 
awareness of, adherence to and interest in lifestyle recommendations for cancer prevention. 
We focused on smoking and fluid intake, since most research with regard to lifestyle and 
NMIBC prognosis was available for smoking, and the hypotheses regarding both smoking 
and fluid intake were well-founded in literature. Further, patients seem to be most often 
advised on these factors when receiving lifestyle advice from their physician. 
 First, an overview is given of the body of existing evidence on the associations of BMI, 
diet, and dietary supplements with bladder cancer recurrence, progression, and mortality 
in the form of a systematic review and meta-analysis (Chapter 2). 
 In Chapter 3, we address the association of smoking status, smoking cessation, 
cumulative smoking exposure, and fluid intake with risk of NMIBC recurrence in the UroLife 
study, a prospective cohort study on the association between dietary and lifestyle factors 
and NMIBC prognosis and HRQoL. 
 Evaluation of the association of different empirically derived dietary patterns with risk 
of recurrence and progression in NMIBC was described in Chapter 4, using data from a 
large ongoing cohort study performed at M.D. Anderson Cancer Center and Baylor 
College of Medicine.
 Chapter 5 describes the health-related quality of life of NMIBC patients participating 
in the UroLife study, and whether this is associated with smoking behavior and fluid intake.
What factors bladder cancer patients thought contributed to the development of their 
own disease is described in Chapter 6 with data from the Nijmegen Bladder Cancer 
Study. In Chapter 7, we investigated whether NMIBC patients are aware of certain (bladder) 
cancer risk factors and whether they adhere to several lifestyle recommendations for 
cancer prevention within the UroLife study. Also, we evaluated whether they received 
lifestyle advice, and their attitudes towards receiving lifestyle advice from their physician.
 This thesis ends with a general discussion of the studies described in this thesis in the 
context of relevant existing literature including recommendations for future research to 
deepen our understanding of the role of lifestyle in the prognosis and quality of life of 
NMIBC patients (chapter 8).
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Abstract
Background: Urologists are frequently confronted with questions of urinary bladder 
cancer (UBC) patients about what they can do to improve their prognosis. Unfortunately, 
it is largely unknown which lifestyle factors can influence prognosis. 
Objective: To systematically review the available evidence on the association between 
body mass index (BMI), diet, dietary supplements, and physical activity and UBC prognosis. 
Methods: We searched  PubMed and Embase up to May 2017. We included thirty-one 
articles reporting on observational and randomized controlled trials investigating BMI, 
diet and dietary supplements in relation to recurrence, progression, cancer-specific or 
all-cause mortality in UBC patients.
Results: In non-muscle invasive bladder cancer (NMIBC) patients, both overweight 
(3 studies, pooled hazard ratio (HR) 1.29, 95% CI 1.05-1.58, I2=0%) as well as obesity 
(3 studies, pooled HR 1.82, 95% CI 1.12-2.95, I2=79%) were associated with increased risk 
of recurrence when compared to normal weight. No association of BMI with risk of 
progression was found. Results for BMI and prognosis in muscle-invasive or in all stages 
series were inconsistent. Observational studies on diet and randomized controlled trials 
with dietary supplements showed inconsistent results. No studies on physical activity and 
UBC prognosis have been published to date. 
Conclusions: Evidence for an association of lifestyle factors with UBC prognosis is limited, with 
some evidence for an association of BMI with risk of recurrence in NMIBC. Well-designed, 
prospective studies are needed to develop evidence-based guidelines on this topic.
Keywords: Body mass index; Diet; Dietary Supplements; Prognosis; Urinary bladder cancer
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Introduction
Urologists are frequently confronted with questions by urinary bladder cancer (UBC) 
patients how they can influence the course of their disease, for example by changing 
habits concerning smoking, diet, and physical activity. As lifestyle factors have been linked 
to cancer-specific prognosis of many common malignancies (1), it is important to gain 
more knowledge about the association of lifestyle factors with urinary bladder cancer 
(UBC) prognosis as well. 
 The impact of tobacco smoking on prognosis has recently been reviewed (2, 3). 
Smoking status was found to be associated with increased risk of disease recurrence in 
both non-muscle-invasive bladder cancer (NMIBC) (3) and all stages series (2). Evidence for 
an association of smoking with risk of progression, cancer-specific mortality and all-cause 
mortality was weak in the review of Crivelli et al. (3), but the more recent meta-analysis of 
Hou et al. (2) found an increased risk of cancer-specific mortality. Interestingly, some 
studies showed that former smokers had a lower risk of recurrence or progression than 
current smokers (3). There is no conclusive evidence yet whether smoking cessation after 
UBC diagnosis will favorably influence clinical outcomes.  However, the European 
Association of Urology guidelines on NMIBC recommend smoking cessation counseling. 
This is based on studies suggesting increased risk of recurrence and progression and 
impaired response to immunotherapy for active smokers (4). 
 Besides smoking, a high body mass index (BMI) and certain dietary factors have also 
been hypothesized to be associated with UBC prognosis. Excess body fat is associated 
with increased circulating concentrations of insulin and insulin-like growth factor-1, as well 
as systemic inflammation, all of which may be related to worse UBC outcomes (5). Also, 
certain examinations and surgical procedures might be more complicated in obese 
patients (6). Dietary factors such as vegetables and fruits are hypothesized to influence 
UBC prognosis, as favorable components from these foods come into close contact with 
urothelial cells when excreted via urine (7, 8). A high fluid intake may reduce exposure to 
carcinogens by diluting the urine and reducing the contact time through increased 
micturition frequency (9). On the other hand, potential carcinogens in the urine can come 
into contact with deeper layers of the bladder when the bladder wall is extended because 
of high fluid intake or low micturition frequency (10). 
 Thus far, except for smoking, no systematic review of studies on the association 
between lifestyle factors and prognosis of patients with UBC has been performed. This 
information is important since it may provide a means to patients to get some control 
over their disease. The aim of this systematic review is to summarize the available evidence 
regarding the association of BMI, diet, dietary supplements and physical activity with UBC 
prognosis and to identify necessary next steps in research.
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Methods
Search strategy
A systematic search of the literature up to May 2017 in the PubMed and Embase databases 
was conducted by using a combination of MeSH and Emtree terms and related key words 
in title and abstract. The complete search strategy is attached as supplementary material 
(Appendix A). No limits were applied on publication date or type of study during this 
search. Reference lists of included articles were checked to identify potentially relevant 
studies that were missed in the initial search.
 We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) criteria (Figure 1)(11) for evaluating records identified during the literature search. 
To warrant integrity, the retrieved references were checked independently by two authors 
(E.W. and A.V.), and disagreements were discussed and resolved. 
Study eligibility
Studies were considered relevant to this review if they reported on observational or 
intervention studies in UBC survivors with respect to BMI, dietary factors or supplements, 
or physical activity before, at the time of or after diagnosis in relation to recurrence, 
progression, cancer-specific mortality (CSM), or all-cause mortality (ACM) (Appendix II). 
Only articles written in the English language were considered for inclusion. When multiple 
articles reported on the same study, only the most recently published article was taken 
into consideration unless there were differences in the endpoints or subgroups reported. 
Animal studies, and investigation of BMI, diet or physical activity with intermediate endpoints 
of disease or with tumor characteristics only without addressing recurrence, progression, 
or mortality were excluded. 
Data extraction
Information extracted from the selected studies included, wherever available, the first 
author, year of publication, country, sample size and sample characteristics, years of 
diagnosis, follow-up time, outcome, variable of interest, risk estimates with 95% confidence 
intervals (CI) or p-values, and factors that were adjusted for in the analysis. When necessary, 
authors were contacted for additional data. 
Statistical analysis
Meta-analysis was performed using Review Manager 5.3 (12). The inverse variance technique 
was used for meta-analysis of hazard ratios. Due to the clinical heterogeneity inherent in 
our data, random-effects models were used for all meta-analyses. Statistical heterogeneity 
was assessed with I2 values. When no meta-analysis could be performed, we narratively 
described the study results separately for BMI, dietary factors, dietary supplements and 
physical activity. 
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Results
The initial search retrieved 14,126 articles of which 31 were considered relevant for this 
review (5, 6, 9, 13-40). These articles reported on BMI (n=13), dietary factors (n=4) or dietary 
supplements (n=14) in UBC survivors. Studies on physical activity were not available. 
Meta-analysis could be performed for BMI in relation to risk of recurrence and progression 
in NMIBC patients and in all stages series. The results of these meta-analyses and retrieved 
studies are discussed in detail below. 
Figure 1  PRISMA flow diagram for the study selection process.
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Body mass index
Twelve historical cohort studies (5, 6, 16, 18, 19, 22, 23, 25, 29, 33, 39, 40) and one prospective 
cohort study (38) investigated the association of BMI with the prognostic endpoints of 
interest (Table 1). Nine studies assessed BMI at time of diagnosis or at time of surgery 
(6, 16, 18, 19, 22, 23, 25, 38, 39) and four studies did not report on the timing of BMI 
assessment (5, 29, 33, 39). 
 Three studies including 892 T1 high grade (5), 338 Ta, T1, Tis (38), and 403 Ta, T1 NMIBC 
patients (39) reported or provided sufficient data to be subjected to meta-analysis. Both 
overweight (pooled hazard ratio (HR) 1.29, 95% CI 1.05-1.58, p=0.02, I2=0%; Fig. 2A) as well 
as obesity (pooled HR 1.82, 95% CI 1.12-2.95, p=0.02, I2=79%; Fig. 2B) were statistically 
significantly associated with increased risk of recurrence when compared to normal 
weight. Based on two studies (5, 39), neither overweight (pooled HR 1.03, 95% CI 0.63-1.70, 
p=0.91, I2=0%; Fig. 2C) nor obesity (pooled HR 1.90, 95% CI 0.93-3.88, p=0.08, I2=51%; 
Fig. 2D) were statistically significantly associated with risk of progression. 
 Six studies were performed in NMIBC and muscle-invasive bladder cancer (MIBC) 
patients combined, which results are more difficult to interpret because of the difference 
in relevant disease outcomes (i.e., risk of recurrence and CSM, respectively). Four studies 
investigated BMI in relation to recurrence. Three studies reported sufficient data to be 
subjected to meta-analysis (18, 19, 23). Neither overweight (pooled HR 0.87, 95% CI 0.67-1.14, 
p=0.31, I2=60%; Fig. 3A), nor obesity (pooled HR 1.12, 95% CI 0.54-2.31, p=0.76, I2=95%; 
Fig. 3B) were statistically significantly associated with risk of recurrence. One study did not 
find an association for continuous BMI (16). Four studies investigated CSM, three of 
them reporting sufficient data to be included in a meta-analysis (18, 19, 23). Neither 
overweight (pooled HR 0.82, 95% CI 0.65-1.02, p=0.08, I2=45%; Fig. 3C), nor obesity (pooled 
HR 0.98, 95% CI 0.46-2.10, p=0.97, I2=94%; Fig. 3D) were statistically significantly associated 
with CSM. One study did not find an association for continuous BMI (16). Four studies 
investigated ACM (6, 16, 18, 33). One study reported an association of overweight and 
obesity compared to normal weight with higher risk of ACM (HR 1.40, 95% CI 1.23-1.57 and 
HR 1.81, CI 95% CI 1.60-2.05, respectively)(18), while three studies did not find an association 
(6, 16, 33). Progression was not investigated in any of these studies. 
 Four historical cohort studies investigated clinical outcomes exclusively in MIBC 
patients. Three studies investigated ACM (22, 29, 40), two of them reporting a lower ACM 
for higher BMI (26.3-29.1 compared to <23.6: HR 0.80, 95% CI 0.69-0.93 and ≥31.2 compared 
to <31.2: HR 0.46, 95% CI 0.26-0.83, respectively)(29, 40) and the other not showing an 
association for ACM and CSM (22). One study found no differences in risk of progression or 
ACM when comparing overweight or obesity with underweight (25).
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Dietary factors
Four small cohort studies evaluated the association of dietary factors with UBC outcomes 
(Table 2). These studies examined the effects of vitamin A intake (27), intake of different 
(alcoholic) drinks (37), fluid intake (9), and fruit and vegetable intake (36).
 In a study of 102 NMIBC patients, patients with a prediagnosis dietary intake of vitamin A 
below the median (not specified) were found to have a 1.8 times higher recurrence rate 
per 1000 person-months (p =0.02), but no statistically significantly increased risk of recurrence 
(RR 1.34, 95% CI 0.5-3.34) compared to patients having a dietary intake of vitamin A above 
the median (27). 
 Three studies were performed in NMIBC and MIBC patients combined (9, 36, 37). 
A Japanese study in 258 patients found an inverse association for ever versus never 
prediagnostic consumption of alcoholic beverages with 5-year ACM (HR 0.46, 95% CI 
0.26-0.79)(37). No associations for non-alcoholic beverages and artificial sweeteners were 
found. Daily post-diagnostic total fluid intake measured using repeated fluid intake 
questionnaires was not associated with risk of recurrence in a US study in 267 patients (9). 
A US study in 239 patients investigated self-reported prediagnostic intake of fruits and 
vegetables in relation to CSM and ACM (36). Patients consuming ≥1compared to those 
consuming <1 serving per month of raw broccoli had a lower CSM (HR 0.43, 95% CI 0.25-0.74) 
and ACM (HR 0.57, 95% CI 0.39-0.83, data not shown). Consumption of 1-3 servings of raw 
cruciferous vegetables per month compared to <1 serving per month was inversely 
associated with ACM (HR 0.67, 95% CI 0.46-0.97), but not with CSM. No association was found 
for consumption of more than three servings. Consumption of total fruit, total vegetables 
or individual cooked cruciferous vegetables was not associated with CSM or ACM.
Dietary supplements 
Fourteen dietary supplementation studies in UBC patients were identified (Table 3). In these 
randomized controlled trials, the effects of the retinoids etretinate (13, 32, 35) and fenretinide 
(20, 34), vitamin B6 (pyridoxine)(17, 31), vitamin E (tocopherol)(26), multivitamins (24, 30), 
a Lactobacillus casei preparation (14, 28, 41), and selenium (21) were investigated. Thirteen 
of the 14 studies were performed in NMIBC patients (13, 14, 17, 20, 21, 26, 28, 30-32, 34, 35, 41) 
and one trial was conducted in NMIBC and MIBC patients combined (24).
 Three studies evaluating the effect of the aromatic retinoid etretinate had conflicting 
results (13, 32, 35). One small study (13) in 32 patients found a lower recurrence rate in the 
etretinate group compared to the placebo group, while a study of 96 patients (32) and a 
trial of 79 patients (35) found no differences in recurrence. Nevertheless, in the last study 
the mean interval to the second recurrence was longer in the etretinate group (20.3 versus 
12.7 months, p=0.006), resulting in less transurethral resections of the bladder per 
patient-year (p <0.01). This may suggest that etretinate needs to be taken for a prolonged 
period before an effect becomes evident. Fenretinide did not affect recurrence in 99 
Italian (20) and 137 US (34) patients. 
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Table 1  Observational cohort studies on body mass index and prognosis of bladder cancer.
Source 
(Study location)
Sample (size and key characteristics) Years of 
diagnosis
Median  
follow-up 
Outcome BMI HR (95% CI) Covariates adjustment
NMIBC
Kluth, 2013, US, Germany, 
France, Italy, Canada (5)
892 NMIBC (T1 high grade)
341 recurrence (38%) 
104 progression (12%) 
184 deaths (21%)
 59 UBC deaths (7%)
TURB w/wo IVT (70% IVT)
1996-2007 Median 42.8 mo 
(IQR 14.8-70.8)
Recurrence 
Progression 
ACM 
CSM 
Continuous
25-30 vs. <251
≥30 vs. <251
≥30 vs. <30
Continuous
25-30 vs. <251
≥30 vs. <251
≥30 vs. <30
Continuous
≥30 vs. <30
Continuous
≥30 vs. <30
1.07 (1.04-1.09)
1.05 (0.73-1.51)
2.72 (2.00-3.69)
2.66 (2.12-3.32)
1.08 (1.04-1.12)
0.90 (0.49-1.64)
1.43 (0.86-2.38)
1.49 (1.00-2.21)
1.29 (1.20-1.37)
3.15 (1.74-5.67)
1.06 (1.04-1.09)
1.42 (1.06-1.92)
Gender, concomitant carcinoma in situ, 
tumor size, number of tumors, intravesical 
therapy
Wyszynski, 2014, US (38) 338 NMIBC (Ta, T1 Tis)
In total sample (n=726):
373 recurrence (51%)
In total sample: TURB (75%), TURB with 
immunotherapy (16%), immunotherapy (9%)
1994-2001 Median 6 y (range 
0.25-15)
Recurrence 24.9-29.9 vs. ≤24.9 
≥30 vs. ≤24.9
>24.9 vs. ≤24.9 
Current smokers:
>24.9 vs. ≤24.9 
1.39 (0.96-2.01)
1.22 (0.80-1.87)
1.33 (0.94-1.89)
2.24 (1.15-4.34)
Age, sex, stage, grade, tumor size, 
multiplicity, treatment, smoking
Xu, 2015, China (39) 403 NMIBC (Ta, T1) 
177 recurrence (44%)
30 progression (7.4%)
TURB w/wo intravesical chemotherapy
2006-2014 Median 53 mo 
(range 6-102)
Recurrence
Progression
≥24-<28 vs. <24
≥28 vs. <24
≥24-<28 vs. <24
≥28 vs. <24
1.44 (1.03-2.00)
1.71 (1.12-2.60)
1.36 (0.57-3.23)
3.04 (1.24-7.42)
Prior recurrence, grade, tumor size, tumor 
in trigone, concomitant CIS
NMIBC and MIBC
Maurer, 2009, Germany (6) 390 NMIBC and MIBC 
(% NMIBC N/S)
Radical cystectomy
1986-2004 N/S 5 year survival rate 25-29.9 vs. <25 
 ≥30 vs. <25
No difference2
No difference2
Univariable
Chromecki, 2012, US, 
Austria, Germany, Canada, 
Czech Republic (18)
4118 NMIBC and MIBC (32% NMIBC)
1365 recurrence (33%)
1121 UBC deaths (27%)
Radical cystectomy
1979-2008 Median alive  
at last follow-up 
44 mo
Recurrence
CSM 
ACM 
25.0-29.9 vs. <25  
>30 vs. <25
25.0-29.9 vs. <25  
>30 vs. <25
25.0-29.9 vs. <25  
>30 vs. <25
0.91 (0.76-1.06) 
1.67 (1.46-1.91)
0.80 (0.68-0.95)
1.43 (1.24-1.66)
1.40 (1.23-1.57)
1.81 (1.60-2.05)
Age, sex, pT stage, tumour grade, 
lymphvascular invasion, lymph node 
metastasis, soft tissue surgical margin, 
concomitant carcinoma in situ, adjuvant 
chemotherapy
Bachir, 2014, Canada (16) 847 NMIBC and MIBC 
(% NMIBC N/S)
Radical cystecomy
1998-2008 Median 23.4 mo OS
CSM
Recurrence
Continuous
Continuous
Continuous
0.98 (0.96-1.01)
0.99 (0.96-1.02)
0.98 (0.96-1.00)
Age, grade, pathological stage, lymph 
nodal metastasis, surgical margin status, 
adjuvant chemotherapy
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Table 1  Observational cohort studies on body mass index and prognosis of bladder cancer.
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Median  
follow-up 
Outcome BMI HR (95% CI) Covariates adjustment
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1.06 (1.04-1.09)
1.42 (1.06-1.92)
Gender, concomitant carcinoma in situ, 
tumor size, number of tumors, intravesical 
therapy
Wyszynski, 2014, US (38) 338 NMIBC (Ta, T1 Tis)
In total sample (n=726):
373 recurrence (51%)
In total sample: TURB (75%), TURB with 
immunotherapy (16%), immunotherapy (9%)
1994-2001 Median 6 y (range 
0.25-15)
Recurrence 24.9-29.9 vs. ≤24.9 
≥30 vs. ≤24.9
>24.9 vs. ≤24.9 
Current smokers:
>24.9 vs. ≤24.9 
1.39 (0.96-2.01)
1.22 (0.80-1.87)
1.33 (0.94-1.89)
2.24 (1.15-4.34)
Age, sex, stage, grade, tumor size, 
multiplicity, treatment, smoking
Xu, 2015, China (39) 403 NMIBC (Ta, T1) 
177 recurrence (44%)
30 progression (7.4%)
TURB w/wo intravesical chemotherapy
2006-2014 Median 53 mo 
(range 6-102)
Recurrence
Progression
≥24-<28 vs. <24
≥28 vs. <24
≥24-<28 vs. <24
≥28 vs. <24
1.44 (1.03-2.00)
1.71 (1.12-2.60)
1.36 (0.57-3.23)
3.04 (1.24-7.42)
Prior recurrence, grade, tumor size, tumor 
in trigone, concomitant CIS
NMIBC and MIBC
Maurer, 2009, Germany (6) 390 NMIBC and MIBC 
(% NMIBC N/S)
Radical cystectomy
1986-2004 N/S 5 year survival rate 25-29.9 vs. <25 
 ≥30 vs. <25
No difference2
No difference2
Univariable
Chromecki, 2012, US, 
Austria, Germany, Canada, 
Czech Republic (18)
4118 NMIBC and MIBC (32% NMIBC)
1365 recurrence (33%)
1121 UBC deaths (27%)
Radical cystectomy
1979-2008 Median alive  
at last follow-up 
44 mo
Recurrence
CSM 
ACM 
25.0-29.9 vs. <25  
>30 vs. <25
25.0-29.9 vs. <25  
>30 vs. <25
25.0-29.9 vs. <25  
>30 vs. <25
0.91 (0.76-1.06) 
1.67 (1.46-1.91)
0.80 (0.68-0.95)
1.43 (1.24-1.66)
1.40 (1.23-1.57)
1.81 (1.60-2.05)
Age, sex, pT stage, tumour grade, 
lymphvascular invasion, lymph node 
metastasis, soft tissue surgical margin, 
concomitant carcinoma in situ, adjuvant 
chemotherapy
Bachir, 2014, Canada (16) 847 NMIBC and MIBC 
(% NMIBC N/S)
Radical cystecomy
1998-2008 Median 23.4 mo OS
CSM
Recurrence
Continuous
Continuous
Continuous
0.98 (0.96-1.01)
0.99 (0.96-1.02)
0.98 (0.96-1.00)
Age, grade, pathological stage, lymph 
nodal metastasis, surgical margin status, 
adjuvant chemotherapy
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Table 1  Continued.
Source 
(Study location)
Sample (size and key characteristics) Years of 
diagnosis
Median  
follow-up 
Outcome BMI HR (95% CI) Covariates adjustment
NMIBC and MIBC
Kwon, 2014, Korea (23) 714 NMIBC and MIBC
(% NMIBC N/S)
Radical cystectomy
1990-2012 Median 64.1 mo 
(range 1-231.4)
Recurrence
CSM
23-25 vs. <23
≥25 vs. <23
23-25 vs. <23
≥25 vs. <23
0.66 (0.48-0.90)
0.52 (0.37-0.73)
0.67 (0.48-0.94)
0.41 (0.27-0.62)
Age, sex, performance status, serum 
albumin level, clinical stage, pathological 
T stage, lymph node metastastis, grade, 
lymphovascular invasion, soft tissue 
surgical margin
Psutka, 2015, US (33) 262 NMIBC and MIBC (29% NMIBC) 2000-2008 Median 6.3 y  
(IQR 5.7-9.5)
ACM ≥30 vs. <30 0.79 (0.50-1.26) Age, smoking status, ASA and ECOG score, 
pTN stage
Dabi, 2016, France (19) 701 NMIBC and MIBC (33% NMIBC)
163 recurrence (23%)
127 UBC deaths (18%)
Radical cystectomy and pelvic 
lymphadenectomy
1995-2011 Median 45 mo 
(IQR 23-75)
Recurrence
CSM
25.1-30 vs. 18-25
>30 vs. 18-25
25.1-30 vs. 18-25
>30 vs. 18-25
1.14 (0.78-1.66)
1.58 (1.06-2.34)
1.13 (0.74-1.74)
1.58 (1.01-2.48)
Age, stage, grade, lymphovascular 
invasion, concomitant CIS, lymph node 
metastasis
MIBC
Hafron, 2005, US (22) 288 MIBC
203 deaths (71%)
Radical or partial cystectomy
1990-1993 Median 39 mo 
(range 1-168)
ACM 
CSM
≥30 vs. ≤29.9
≥30 vs. ≤29.9
0.87 (0.71-1.06)
No difference
Age, sex, pathological stage, lymph node 
status, soft tissue margin status, urothelial 
margin, smoking
Leiter, 2016, US, Germany, 
Greece, Taiwan (25)
537 MIBC
417 deaths (77%)
Chemotherapy 
1998-2011 Progression
ACM
18.5-24.99 vs. <18.5
25-29.99 vs. <18.5
≥30 vs. <18.5
18.5-24.99 vs. <18.5
25-29.99 vs. <18.5
≥30 vs. <18.5
1.14 (0.70-1.85)
1.31 (0.80-2.13)
1.23 (0.72-2.11)
0.97 (0.59-1.59)
1.19 (0.73-1.95)
1.08 (0.63-1.87)
ECOG-PS ≥ 1, visceral metastasis 
Xu, 2016, US, Canada (40) 360 MIBC (0.6% NMIBC and 0.6% unknown) N/S N/S ACM ≥31.2 vs <31.2
≥27 vs. 27
0.46 (0.26-0.83)
0.77 (0.51-1.17)
Univariable 
Necchi, 2017, US, Canada, 
Europe, Israel (29)
1020 urothelial cancer (81.2% bladder cancer)
664 deaths (65%)3
Chemotherapy
2006-2011 Median 31.6 mo 
(95% CI 29.4-35.0)
ACM 26.3-29.1 vs. <23.6 0.80 (0.69-0.93) White blood cell count, ECOG-PS,  
lung/liver/bone metastases, ethnicity,  
prior perioperative chemotherapy, age
HR (95% CI) printed in bold means result statistically significant at the p<0.05 level; 1 Data needed for this 
comparison was received from the authors;  2 p value not reported; 3 Percentage of deaths among primary 
bladder cancer patients is not reported.
Abbreviations: ACM: all-cause mortality; BMI: body mass index; CIS: carcinoma in situ; CSM: cancer-specific 
mortality; ECOG-PS: Eastern Cooperation Oncology Group Performance Status; IQR: interquartile range; IVT: 
intravesical therapy ; MIBC: muscle invasive bladder cancer; mo: months; NMIBC: non-muscle-invasive bladder 
cancer; NS: not specified; TURB: transurethral resection of the bladder; y: years.
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Table 1  Continued.
Source 
(Study location)
Sample (size and key characteristics) Years of 
diagnosis
Median  
follow-up 
Outcome BMI HR (95% CI) Covariates adjustment
NMIBC and MIBC
Kwon, 2014, Korea (23) 714 NMIBC and MIBC
(% NMIBC N/S)
Radical cystectomy
1990-2012 Median 64.1 mo 
(range 1-231.4)
Recurrence
CSM
23-25 vs. <23
≥25 vs. <23
23-25 vs. <23
≥25 vs. <23
0.66 (0.48-0.90)
0.52 (0.37-0.73)
0.67 (0.48-0.94)
0.41 (0.27-0.62)
Age, sex, performance status, serum 
albumin level, clinical stage, pathological 
T stage, lymph node metastastis, grade, 
lymphovascular invasion, soft tissue 
surgical margin
Psutka, 2015, US (33) 262 NMIBC and MIBC (29% NMIBC) 2000-2008 Median 6.3 y  
(IQR 5.7-9.5)
ACM ≥30 vs. <30 0.79 (0.50-1.26) Age, smoking status, ASA and ECOG score, 
pTN stage
Dabi, 2016, France (19) 701 NMIBC and MIBC (33% NMIBC)
163 recurrence (23%)
127 UBC deaths (18%)
Radical cystectomy and pelvic 
lymphadenectomy
1995-2011 Median 45 mo 
(IQR 23-75)
Recurrence
CSM
25.1-30 vs. 18-25
>30 vs. 18-25
25.1-30 vs. 18-25
>30 vs. 18-25
1.14 (0.78-1.66)
1.58 (1.06-2.34)
1.13 (0.74-1.74)
1.58 (1.01-2.48)
Age, stage, grade, lymphovascular 
invasion, concomitant CIS, lymph node 
metastasis
MIBC
Hafron, 2005, US (22) 288 MIBC
203 deaths (71%)
Radical or partial cystectomy
1990-1993 Median 39 mo 
(range 1-168)
ACM 
CSM
≥30 vs. ≤29.9
≥30 vs. ≤29.9
0.87 (0.71-1.06)
No difference
Age, sex, pathological stage, lymph node 
status, soft tissue margin status, urothelial 
margin, smoking
Leiter, 2016, US, Germany, 
Greece, Taiwan (25)
537 MIBC
417 deaths (77%)
Chemotherapy 
1998-2011 Progression
ACM
18.5-24.99 vs. <18.5
25-29.99 vs. <18.5
≥30 vs. <18.5
18.5-24.99 vs. <18.5
25-29.99 vs. <18.5
≥30 vs. <18.5
1.14 (0.70-1.85)
1.31 (0.80-2.13)
1.23 (0.72-2.11)
0.97 (0.59-1.59)
1.19 (0.73-1.95)
1.08 (0.63-1.87)
ECOG-PS ≥ 1, visceral metastasis 
Xu, 2016, US, Canada (40) 360 MIBC (0.6% NMIBC and 0.6% unknown) N/S N/S ACM ≥31.2 vs <31.2
≥27 vs. 27
0.46 (0.26-0.83)
0.77 (0.51-1.17)
Univariable 
Necchi, 2017, US, Canada, 
Europe, Israel (29)
1020 urothelial cancer (81.2% bladder cancer)
664 deaths (65%)3
Chemotherapy
2006-2011 Median 31.6 mo 
(95% CI 29.4-35.0)
ACM 26.3-29.1 vs. <23.6 0.80 (0.69-0.93) White blood cell count, ECOG-PS,  
lung/liver/bone metastases, ethnicity,  
prior perioperative chemotherapy, age
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Table 2  Observational studies on dietary factors and prognosis of bladder cancer.
Source 
(Study location)
Sample (size and key characteristics) Years of 
diagnosis
Median follow-up Outcome Dietary Factor HR (95% CI) Covariates adjustment
NMIBC
Michalek, 1987, 
US (27)
102 NMIBC
34 recurrences (33%)
Treatment unknown
1960-1965 N/A Recurrence 
Recurrence rate  
(number of recurrences  
per 1,000 person-months)
Lower 50% vs. upper 
50% of vitamin A 
consumption
Lower 50% vs. upper 
50% of vitamin A 
consumption
OR 1.34 (0.50-3.34)
Rate 1.8 (p=0.02)
Univariable
Age, sex, smoking status
NMIBC and MIBC
Wakai, 1993, Japan 
(37)
258 NMIBC and MIBC (%NMIBC N/S)
81 deaths (31%)
Treatment unknown
1976-1978 Median 29.8 mo 5-year ACM Alcoholic beverages1
Artificial sweetener1
Coffee1
Black tea1
Green tea1
Matcha1
Cola1
 0.46 (0.26-0.79)
1.05 (0.62-1.79
0.88 (0.49-1.59)
0.77 (0.44-1.33)
0.62 (0.22-1.74)
1.36 (0.75-2.44)
1.11 (0.61-2.01)
Age at first consultation, stage, 
histological type and grade, 
distant metastasis
Donat, 2003, US (9) 267 primary and recurrent NMIBC and MIBC 
(90% NMIBC)
123 recurrences (46%)
TURB (unknown %),  
partial cystectomy (7.5%) and/or IVT (65.5%)
N/S Median 2.6 y (range 
0.96-3.77)
Recurrence Average daily fluid 
intake postdiagnosis, 
continuous
RR 1.05 (0.92-1.19) Age, gender, years since initial 
diagnosis, months since last 
tumor, recurrence within 3 
months before study, recurrence 
risk group, persistent positive 
cytology, smoking status
Tang, 2010, US (36) 239 NMIBC and MIBC (% NMIBC N/S)
179 deaths (75%)
101 UBC deaths (56%)
TURB (64.4%), cystectomy (27.6%),  
unknown (7.9%) w/wo IVT 
1980-1998 Median 77 mo (range 
1-301)
CSM Fruits2
Vegetables2
Cruciferous 
vegetables cooked2
Cruciferous 
vegetables raw2
Broccoli raw3
Broccoli cooked3
Cabbage raw3
Cabbage cooked3
Cauliflower raw3
Cauliflower cooked3
Brussels sprout3
Kale, turnip, collard, 
mustard greens3
1.09 (0.66-1.81)
1.06 (0.63-1.78)
0.89 (0.53-1.48)
0.73 (0.44-1.21)
0.43 (0.25-0.74)
0.68 (0.45-1.01)
1.11 (0.74-1.66)
1.15 (0.75-1.77)
1.08 (0.66-1.77)
0.95 (0.63-1.42)
1.37 (0.86-2.18)
1.07 (0.63-1.79)
Age at diagnosis, tumor stage, 
radiation therapy, pack-years of 
smoking, total meat intake
HR (95% CI) printed in bold means result statistically significant at the p<0.05 level; 1 Ever vs. never consumed, 
hazard ratios are for male patients only; 2 Servings per month, highest tertile vs. lowest tertile; 3 Servings per 
month,  ≥1 vs. <1 .
Abbreviations: ACM, all-cause mortality; CSM: cancer-specific mortality; IVT: intravesical therapy ; MIBC: muscle 
invasive bladder cancer; mo: months; NA: not assessed; NMIBC: non-muscle-invasive bladder cancer; NS: not 
specified; TURB: transurethral resection of the bladder; y: years.
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Table 2  Observational studies on dietary factors and prognosis of bladder cancer.
Source 
(Study location)
Sample (size and key characteristics) Years of 
diagnosis
Median follow-up Outcome Dietary Factor HR (95% CI) Covariates adjustment
NMIBC
Michalek, 1987, 
US (27)
102 NMIBC
34 recurrences (33%)
Treatment unknown
1960-1965 N/A Recurrence 
Recurrence rate  
(number of recurrences  
per 1,000 person-months)
Lower 50% vs. upper 
50% of vitamin A 
consumption
Lower 50% vs. upper 
50% of vitamin A 
consumption
OR 1.34 (0.50-3.34)
Rate 1.8 (p=0.02)
Univariable
Age, sex, smoking status
NMIBC and MIBC
Wakai, 1993, Japan 
(37)
258 NMIBC and MIBC (%NMIBC N/S)
81 deaths (31%)
Treatment unknown
1976-1978 Median 29.8 mo 5-year ACM Alcoholic beverages1
Artificial sweetener1
Coffee1
Black tea1
Green tea1
Matcha1
Cola1
 0.46 (0.26-0.79)
1.05 (0.62-1.79
0.88 (0.49-1.59)
0.77 (0.44-1.33)
0.62 (0.22-1.74)
1.36 (0.75-2.44)
1.11 (0.61-2.01)
Age at first consultation, stage, 
histological type and grade, 
distant metastasis
Donat, 2003, US (9) 267 primary and recurrent NMIBC and MIBC 
(90% NMIBC)
123 recurrences (46%)
TURB (unknown %),  
partial cystectomy (7.5%) and/or IVT (65.5%)
N/S Median 2.6 y (range 
0.96-3.77)
Recurrence Average daily fluid 
intake postdiagnosis, 
continuous
RR 1.05 (0.92-1.19) Age, gender, years since initial 
diagnosis, months since last 
tumor, recurrence within 3 
months before study, recurrence 
risk group, persistent positive 
cytology, smoking status
Tang, 2010, US (36) 239 NMIBC and MIBC (% NMIBC N/S)
179 deaths (75%)
101 UBC deaths (56%)
TURB (64.4%), cystectomy (27.6%),  
unknown (7.9%) w/wo IVT 
1980-1998 Median 77 mo (range 
1-301)
CSM Fruits2
Vegetables2
Cruciferous 
vegetables cooked2
Cruciferous 
vegetables raw2
Broccoli raw3
Broccoli cooked3
Cabbage raw3
Cabbage cooked3
Cauliflower raw3
Cauliflower cooked3
Brussels sprout3
Kale, turnip, collard, 
mustard greens3
1.09 (0.66-1.81)
1.06 (0.63-1.78)
0.89 (0.53-1.48)
0.73 (0.44-1.21)
0.43 (0.25-0.74)
0.68 (0.45-1.01)
1.11 (0.74-1.66)
1.15 (0.75-1.77)
1.08 (0.66-1.77)
0.95 (0.63-1.42)
1.37 (0.86-2.18)
1.07 (0.63-1.79)
Age at diagnosis, tumor stage, 
radiation therapy, pack-years of 
smoking, total meat intake
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Table 3  Intervention studies on dietary supplements and prognosis of bladder cancer. 
Source 
(Study location)
Study population Years of 
diagnosis
Follow-up No. of subjects per treatment 
group
Treatment 
duration
Drop-out (n) Outcome and timing of 
measurement 
Effect Covariates 
adjustment
Etretinate
Alfthan, 1983, 
Finland (13)
Recurrent NMIBC diagnosed 
mean 5 (range 1.5-26) y ago
TURB or electrocoagulation 
(unknown %)
N/A 17.6 mo (10-26)1 15 etretinate – 25 mg/day
15 placebo
Range 10-26 mo 2 Recurrence rate 
Timing N/S
60% vs. 87% 
(p<0.02)
N/A
Pedersen, 1984, 
Denmark (32)
NMIBC with at least  
2 recurrences within  
previous 18 mo
N/A Up to 8 months 47 etretinate – 50 mg/day
49 placebo
8 mo 12 etretinate
7 placebo
Recurrence at 8 mo No difference2 N/A
Studer, 1995, 
Switzerland (35)
Primary and recurrent NMIBC
TURB
N/A Control 30 mo
Treatment 33 mo,
37 etretinate – 25 mg/day
42 placebo
Median etretinate 
33.0 mo
Median placebo 
30.0 mo 
15 etretinate
15 placebo
Mean time to first recurrence 13.6 mo vs.13.5 mo N/A
Fenretinide
Decensi, 2000,  
Italy (20)
Primary and recurrent NMIBC
TURB w IVT or diathermy
1993-1994 Up to 36 mo 49 fenretinide – 200 mg/day
50 controls
24 mo, 3 day drug 
free period at the 
end of each mo
12 fenretinide
12 controls
No. of recurrence at end of follow-up 27 vs. 21 in control 
group (p=0.36)
Baseline values 
(N/S) 
Sabichi, 2008,  
US (34)
Primary and recurrent NMIBC
 (with minimum preceding  
12- month disease- free interval)
TURB w/wo IVT (27.7% IVT)
1998-2003 N/A 70 fenretinide – 200 mg/day
67 placebo
12 mo, 3 day drug 
free period every 
28 days
70 (N/S which 
group)
Recurrence at 1 y 31.5% vs. 32.3% 
(p=0.88)
N/A
Pyridoxine
Byar, 1977 (17) Primary and recurrent NMIBC
TURB
1971-1976 31 mo 33 pyridoxine – 25 mg/day
38 intravesical thiotepa3
50 placebo
Mean 30 mo 1 pyridoxine
2 placebo
Mean time to first recurrence
Pyridoxine vs. placebo
Thiotepa vs. placebo
Thiotepa vs. pyridoxine
Recurrence rate per 100 patient months
Pyridoxine vs. placebo
Thiotepa vs. placebo
Thiotepa vs. pyridoxine
Mean time to progression
Pyridoxine vs. placebo
Thiotepa vs. placebo
Thiotepa vs. pyridoxine
No difference2
No difference2 
No difference2 
No difference 2,4
p 0.016
p 0.015
No difference2 
No difference2 
No difference2 
N/A
Newling, 1995, 
England (31)
NMIBC with estimated  
survival >3 y
TURB or fulguration
1979-1981 Mean 3.4 y 147 pyridoxine – 20 mg/day
144 placebo
Duration N/S 6 pyridoxine
6 placebo
Mean time to first recurrence 
Recurrence rate per year
Progression at end of follow-up
Survival at end of follow-up
No difference (p=0.30)
No difference
(p=0.992)
No difference2
No difference (p=0.53)
Recurrence rate 
before entry, 
numbers of 
tumors at entry, 
tryptophan 
metabolite levels
Vitamin E
Mazdak, 2012,  
Iran (26)
NMIBC
TURB
2006-2010 Control 12.1 mo
Treatment 16.2 mo 
21 vitamin E – 400 IU/day
25 placebo
Duration N/S N/S Recurrence at the end of follow-up RR 0.53 (0.11-0.94)
OR 0.42 (p=0.04)
N/A
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Table 3  Intervention studies on dietary supplements and prognosis of bladder cancer. 
Source 
(Study location)
Study population Years of 
diagnosis
Follow-up No. of subjects per treatment 
group
Treatment 
duration
Drop-out (n) Outcome and timing of 
measurement 
Effect Covariates 
adjustment
Etretinate
Alfthan, 1983, 
Finland (13)
Recurrent NMIBC diagnosed 
mean 5 (range 1.5-26) y ago
TURB or electrocoagulation 
(unknown %)
N/A 17.6 mo (10-26)1 15 etretinate – 25 mg/day
15 placebo
Range 10-26 mo 2 Recurrence rate 
Timing N/S
60% vs. 87% 
(p<0.02)
N/A
Pedersen, 1984, 
Denmark (32)
NMIBC with at least  
2 recurrences within  
previous 18 mo
N/A Up to 8 months 47 etretinate – 50 mg/day
49 placebo
8 mo 12 etretinate
7 placebo
Recurrence at 8 mo No difference2 N/A
Studer, 1995, 
Switzerland (35)
Primary and recurrent NMIBC
TURB
N/A Control 30 mo
Treatment 33 mo,
37 etretinate – 25 mg/day
42 placebo
Median etretinate 
33.0 mo
Median placebo 
30.0 mo 
15 etretinate
15 placebo
Mean time to first recurrence 13.6 mo vs.13.5 mo N/A
Fenretinide
Decensi, 2000,  
Italy (20)
Primary and recurrent NMIBC
TURB w IVT or diathermy
1993-1994 Up to 36 mo 49 fenretinide – 200 mg/day
50 controls
24 mo, 3 day drug 
free period at the 
end of each mo
12 fenretinide
12 controls
No. of recurrence at end of follow-up 27 vs. 21 in control 
group (p=0.36)
Baseline values 
(N/S) 
Sabichi, 2008,  
US (34)
Primary and recurrent NMIBC
 (with minimum preceding  
12- month disease- free interval)
TURB w/wo IVT (27.7% IVT)
1998-2003 N/A 70 fenretinide – 200 mg/day
67 placebo
12 mo, 3 day drug 
free period every 
28 days
70 (N/S which 
group)
Recurrence at 1 y 31.5% vs. 32.3% 
(p=0.88)
N/A
Pyridoxine
Byar, 1977 (17) Primary and recurrent NMIBC
TURB
1971-1976 31 mo 33 pyridoxine – 25 mg/day
38 intravesical thiotepa3
50 placebo
Mean 30 mo 1 pyridoxine
2 placebo
Mean time to first recurrence
Pyridoxine vs. placebo
Thiotepa vs. placebo
Thiotepa vs. pyridoxine
Recurrence rate per 100 patient months
Pyridoxine vs. placebo
Thiotepa vs. placebo
Thiotepa vs. pyridoxine
Mean time to progression
Pyridoxine vs. placebo
Thiotepa vs. placebo
Thiotepa vs. pyridoxine
No difference2
No difference2 
No difference2 
No difference 2,4
p 0.016
p 0.015
No difference2 
No difference2 
No difference2 
N/A
Newling, 1995, 
England (31)
NMIBC with estimated  
survival >3 y
TURB or fulguration
1979-1981 Mean 3.4 y 147 pyridoxine – 20 mg/day
144 placebo
Duration N/S 6 pyridoxine
6 placebo
Mean time to first recurrence 
Recurrence rate per year
Progression at end of follow-up
Survival at end of follow-up
No difference (p=0.30)
No difference
(p=0.992)
No difference2
No difference (p=0.53)
Recurrence rate 
before entry, 
numbers of 
tumors at entry, 
tryptophan 
metabolite levels
Vitamin E
Mazdak, 2012,  
Iran (26)
NMIBC
TURB
2006-2010 Control 12.1 mo
Treatment 16.2 mo 
21 vitamin E – 400 IU/day
25 placebo
Duration N/S N/S Recurrence at the end of follow-up RR 0.53 (0.11-0.94)
OR 0.42 (p=0.04)
N/A
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Table 3  Continued. 
Source 
(Study location)
Study population Years of 
diagnosis
Follow-up No. of subjects per treatment 
group
Treatment 
duration
Drop-out (n) Outcome and timing of 
measurement 
Effect Covariates 
adjustment
Multiple vitamins
Lamm, 1994,  
US (24)
NMIBC and MIBC (control 87% 
NMIBC; treatment 88.6% NMIBC)
TURB w IVT
1985-1992 Control 40 mo (6-80)
Treatment 49 (6-81)
30 RDA of multiple  
vitamins/day 
35 RDA plus megadose5 of 
vitamin A, B6, C, E and zinc/day
Duration N/S N/S Recurrence at 1y
Overall recurrence rate
Survival rate
37% vs. 9% 
(p=0.008)
80% vs. 40%  
(p=0.001)
76% vs. 74% (p=N/S) 
N/A
Nepple, 2010,  
US (30)
NMIBC
113 recurrences RDA (33.6%)
118 recurrences megadose 
vitamins (35.3%)
Biopsy or TURB (98.5%) and IVT
1999-2003 Median 24 mo 336 RDA of multiple vitamins
334 megadose vitamins6
Median 24 mo N/S Time to first recurrence HR 1.07 (0.83-1.39) N/A
Lactobacillus casei preparation
Aso, 1992,  
Japan (41)
Primary and recurrent NMIBC
TURB
1988-1989 Control 428 days
Treatment 427 days 
29 Lactobacillus casei 
preparation - 3 g/day
29 placebo
12 mo 2 drop-out 
Lactobacillus 
casei 
preparation
50% recurrence-free interval Treatment 350 d; 
placebo 195 d
HR 2.41 (p=0.028)
Age, grade, 
primary or 
recurrent tumor, 
multiplicity, 
tumor size
Aso, 1995,  
Japan (14)
Primary and recurrent NMIBC
TURB
1990-1991 N/S 68 Lactobacillus casei 
preparation - 3 g/day
70 placebo
12 mo 4 drop-out 
Lactobacillus 
casei 
preparation 
4 drop-out 
placebo
50% recurrence free period all patients
50% recurrence free period  
group A and B7
No difference  
(p=0.325)
Treatment 688 d; 
placebo 543 d
HR 2.58 (p=0.013)
Univariable
Clinical and 
patient 
characteristics 
(N/S)
Naito, 2008,  
Japan (28)
Primary and recurrent NMIBC
26 recurrences Lactobacillus 
casei preparation (26%)
42 recurrences control (41%)
4 progression (1.9%)
5 deaths (2.4%)
2 BC deaths (1%)
TURB and IVT
1999-2002 Median 43.6 mo 
(range 0.2 to 75.0) 
vs. 26.9  
(range 0.6 to 79.9) 
100 Lactobacillus casei 
preparation - 3 g/day
102 control
12 mo N/S Recurrence free survival rate at 3 y  
Progression free survival rate  
(timing N/S)
Overall survival rate (timing N/S)
HR 0.57 (0.35-0.93)
No difference2
No difference2
Multiplicity,  
tumor size, stage
Selenium
Goossens, 2016, 
Belgium (21)
Primary and recurrent NMIBC
43 recurrences selenium (28%)
45 recurrences placebo (32%)
15 progression selenium (10%)
14 progression (10%) placebo
TURB
2009-2013 Median 17.9 mo 
(range 0.1 to 36)  
vs. 17.8  
(range 0.4 to 36)
151 selenium – 200 µg/day
141 placebo
36 mo 41 drop-out 
selenium
35 drop-out 
placebo
Recurrence
Progression free interval
HR 0.88 (0.58-1.35)
HR 0.89 (0.42-1.86)
Age, gender, 
smoking status, 
staging, baseline 
serum selenium 
level, hospital
HR (95% CI) printed in bold means result statistically significant at the p<0.05 level; 1 Excluding one patient in the placebo 
group who died after 6 months; 2 p value not reported; 3 Thiothepa is a cytotoxic, alkylating agent used as chemotherapy; 4 
When patients followed up less than 10 months are excluded p 0.03; 5 Daily dose of patients in megadose group: 40,000 IU 
vitamin A, 100 mg vitamin B6, 2,000 mg vitamin C, 400 IU vitamin E and 90 mg zinc; 6 Daily dose of patients in megadose 
group: 36,000 IU vitamin A, 100 mg vitamin B6, 2,000 mg vitamin C, 1,600 IU vitamin D3, 1.6 mg folate, 400 IU vitamin E and 
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Table 3  Continued. 
Source 
(Study location)
Study population Years of 
diagnosis
Follow-up No. of subjects per treatment 
group
Treatment 
duration
Drop-out (n) Outcome and timing of 
measurement 
Effect Covariates 
adjustment
Multiple vitamins
Lamm, 1994,  
US (24)
NMIBC and MIBC (control 87% 
NMIBC; treatment 88.6% NMIBC)
TURB w IVT
1985-1992 Control 40 mo (6-80)
Treatment 49 (6-81)
30 RDA of multiple  
vitamins/day 
35 RDA plus megadose5 of 
vitamin A, B6, C, E and zinc/day
Duration N/S N/S Recurrence at 1y
Overall recurrence rate
Survival rate
37% vs. 9% 
(p=0.008)
80% vs. 40%  
(p=0.001)
76% vs. 74% (p=N/S) 
N/A
Nepple, 2010,  
US (30)
NMIBC
113 recurrences RDA (33.6%)
118 recurrences megadose 
vitamins (35.3%)
Biopsy or TURB (98.5%) and IVT
1999-2003 Median 24 mo 336 RDA of multiple vitamins
334 megadose vitamins6
Median 24 mo N/S Time to first recurrence HR 1.07 (0.83-1.39) N/A
Lactobacillus casei preparation
Aso, 1992,  
Japan (41)
Primary and recurrent NMIBC
TURB
1988-1989 Control 428 days
Treatment 427 days 
29 Lactobacillus casei 
preparation - 3 g/day
29 placebo
12 mo 2 drop-out 
Lactobacillus 
casei 
preparation
50% recurrence-free interval Treatment 350 d; 
placebo 195 d
HR 2.41 (p=0.028)
Age, grade, 
primary or 
recurrent tumor, 
multiplicity, 
tumor size
Aso, 1995,  
Japan (14)
Primary and recurrent NMIBC
TURB
1990-1991 N/S 68 Lactobacillus casei 
preparation - 3 g/day
70 placebo
12 mo 4 drop-out 
Lactobacillus 
casei 
preparation 
4 drop-out 
placebo
50% recurrence free period all patients
50% recurrence free period  
group A and B7
No difference  
(p=0.325)
Treatment 688 d; 
placebo 543 d
HR 2.58 (p=0.013)
Univariable
Clinical and 
patient 
characteristics 
(N/S)
Naito, 2008,  
Japan (28)
Primary and recurrent NMIBC
26 recurrences Lactobacillus 
casei preparation (26%)
42 recurrences control (41%)
4 progression (1.9%)
5 deaths (2.4%)
2 BC deaths (1%)
TURB and IVT
1999-2002 Median 43.6 mo 
(range 0.2 to 75.0) 
vs. 26.9  
(range 0.6 to 79.9) 
100 Lactobacillus casei 
preparation - 3 g/day
102 control
12 mo N/S Recurrence free survival rate at 3 y  
Progression free survival rate  
(timing N/S)
Overall survival rate (timing N/S)
HR 0.57 (0.35-0.93)
No difference2
No difference2
Multiplicity,  
tumor size, stage
Selenium
Goossens, 2016, 
Belgium (21)
Primary and recurrent NMIBC
43 recurrences selenium (28%)
45 recurrences placebo (32%)
15 progression selenium (10%)
14 progression (10%) placebo
TURB
2009-2013 Median 17.9 mo 
(range 0.1 to 36)  
vs. 17.8  
(range 0.4 to 36)
151 selenium – 200 µg/day
141 placebo
36 mo 41 drop-out 
selenium
35 drop-out 
placebo
Recurrence
Progression free interval
HR 0.88 (0.58-1.35)
HR 0.89 (0.42-1.86)
Age, gender, 
smoking status, 
staging, baseline 
serum selenium 
level, hospital
30.4 mg zinc; 7 Only 78 patients with primary multiple tumors or recurrent single tumors were evaluated (39 Lactobacillus 
casei preparation; 39 placebo).
Abbreviations: d: days; IU: International Unit; IVT: intravesical therapy ; MIBC: muscle invasive bladder cancer; mo: months; 
NMIBC: non-muscle-invasive bladder cancer; NA: not assessed; NS: not specified; RDA: recommended daily allowance; TURB: 
transurethral resection of the bladder; y: years.
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Figure 2  BMI and NMIBC prognosis: (A) Overweight vs. normal weight and risk of 
recurrence; (B) Obesity vs. normal weight and risk of recurrence; (C) Overweight vs. normal 
weight and risk of progressoin; (D) Obesity vs. normal weight and risk of progression.
 
 
 
  
 
 
 
 
A
B
C
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Figure 3  BMI and prognosis in all stages series: (A) Overweight vs. normal weight  
and risk of recurrence; (B) Obesity vs. normal weight and risk of recurrence; (C) Overweight 
vs. normal weight and risk of CSM; (D) Obesity vs. normal weight and risk of CSM.
A
B
C
D
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Supplementation with pyridoxine was found not to affect recurrence or progression in 
121 stage I patients (17). However, when patients with recurrences during the first ten 
months or followed up less than ten months were excluded, recurrence rate was 
significantly lower for pyridoxine compared to placebo. Again, this suggests that a longer 
duration of supplementation is required. A study in 291 patients (31) did not find an effect 
of pyridoxine on risk of recurrence, progression, or ACM.
 A small trial in NMIBC patients in Iran (n=46) reported that daily intake of 400 IU 
vitamin E after diagnosis resulted in a lower risk of recurrence (RR=0.53, 95 CI% 0.11-0.94) 
compared to a control group (26). 
 Two trials tested if supplementation with a megadose of multivitamins had an effect 
on recurrence (24, 30). In 65 NMIBC and MIBC patients, a reduced risk of recurrence was 
found in the experimental group that received a supplement with the recommended 
daily allowance (RDA) plus a megadose of vitamin A, B6, C, E and zinc compared to RDA 
alone (24). In contrast, a large multicenter trial in 670 BCG naïve patients found no difference 
in recurrence-free survival (30).
 Three studies conducted in Japan investigated the effect of 3 gram/day of the orally 
administered probiotic Lactobacillus casei preparation on prognosis (14, 28, 41). A study of 
202 patients receiving standard treatment of intravesical instillations with epi-adryamicin 
randomized to a daily administration of Lactobacillus casei preparation for one year versus 
a control condition (no Lactobacillus casei preparation), reported that the recurrence rate 
was lower in the Lactobacillus casei group compared to the control group (HR 0.57, 95% CI 
0.35-0.93)(28). No effect on progression or ACM was found. A study in 138 patients 
receiving either a Lactobacillus casei preparation or placebo did not find a difference in 
recurrence-free interval when all patients were included in a univariable analysis (14). 
However, when analysis was restricted to78 patients with primary multiple tumors or 
recurrent single tumors, Lactobacillus casei preparation was associated with a longer 
 recurrence-free interval as compared to placebo (688 days versus 543 days; HR 2.58; 
p=0.013). In a study of 58 patients, the recurrence-free survival interval of the group who 
received the Lactobacillus casei preparation was prolonged to 1.8 times the interval of the 
control group (350 days versus 195 days; HR 2.41, p=0.028)(41).
 A study in 292 NMIBC patients conducted in Belgium showed that selenium 
 supplementation did not lower the risk of recurrence compared to placebo (21).
Discussion
This review was conducted to provide a complete overview of available evidence 
regarding the impact of lifestyle factors on the prognosis of patients with UBC. A total of 
31 studies on BMI, diet or dietary supplements were included while studies on physical 
activity were not available. Overweight and obesity compared to normal weight were 
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associated with increased risk of recurrence but not progression in NMIBC. Results of 
studies on BMI in relation to prognosis in NMIBC and MIBC patients combined or restricted 
to MIBC patients were inconsistent and sometimes even opposite. Observational cohort 
studies on diet and dietary supplementation studies found some inverse associations 
with risk of recurrence, CSM, or ACM, but only for single foods and specific supplements.
 The biologic mechanisms underlying the association of lifestyle factors with cancer 
prognosis in general, and UBC prognosis in particular, are not well understood (1). Our 
results that show an increased recurrence risk in overweight or obese NMIBC patients may 
be explained by systemic and local changes induced by obesity, such as altered levels of 
insulin, insulin-like growth factor-1, leptin, adiponectin, steroid hormones, and cytokines 
(42, 43). In NMIBC patients, markers of systemic inflammatory response have indeed been 
associated with increased risk of recurrence and progression (44). Also, potential difficulties 
in performing a high quality (complete) transurethral resection of the bladder may play a 
role, particularly for obese patients (5, 39). For NMIBC patients it therefore seems advisable 
to attain or maintain a healthy body weight. However, it should be kept in mind that 
available evidence is limited to three studies of which only one was adjusted for smoking 
(38). For MIBC patients, results were inconsistent and no recommendations can be made.
 Dietary factors are also likely to be relevant in UBC carcinogenesis and prognosis. 
Several harmful as well as beneficial substances from food are excreted via the urine and 
may directly act on urothelial cells. Bioactive food compounds can be involved in 
numerous pathways, such as inhibition of inflammation (45), inhibition of cell proliferation, 
invasion, angiogenesis, and metastasis and induction of apoptosis (46), and suppression of 
self-renewal of cancer stem cells (45, 47). However, based on the current available evidence, 
no recommendations on diet and UBC prognosis can be made.
Limitations of the studies included 
Studies on BMI and dietary factors conducted to date mostly included a heterogeneous 
study population with different stages and grades of UBC and undergoing different 
treatments. Risk of recurrence, progression and CSM differs by UBC stage and grade (48). 
This should be taken into account when evaluating the association of BMI and dietary 
factors with these disease endpoints. However, none of the studies included in our review 
performed subgroup analyses by tumor stage and grade, possibly masking true 
associations. Also, disease progression was investigated in a minority of the studies and 
several observational studies only investigated the association with CSM or ACM, which 
are not preferable endpoints for NMIBC. Since risk of death from NMIBC is relatively low, 
mortality mainly reflects the general health condition of the participants instead of the 
consequences of bladder cancer. Thus, a possible association of BMI and dietary factors 
with disease outcomes in these heterogeneous UBC populations may have been missed. 
 In several studies, BMI and diet were not the primary factor of interest, and only one 
or a few single dietary factors were studied in relation to UBC prognosis. Since dietary 
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components interact with each other in a complex way, it is preferable to take the entire 
dietary pattern into account instead of single dietary factors. Furthermore, depending on 
dose, dietary supplements can prevent or promote growth of tumor cells or existing (pre)
cancerous lesions. For example, the ATBC study reported an increased instead of expected 
decreased incidence of lung, prostate and stomach cancer in Finnish male smokers 
receiving supplements with supraphysiological doses of β-carotene versus placebo (49). 
In addition, recent mouse experiments showed that antioxidants may protect melanoma 
and lung cancer cells and promote growth and the ability to metastasize (50, 51). UBC 
survivors could be using dietary supplements more frequently than population controls, 
as is observed for prostate cancer survivors (52). Given the lack of evidence for a beneficial 
effect on prognosis in UBC, and reasoning that the same biology may apply for UBC as for 
other neoplasms, urologists may consider to advise UBC survivors against using dietary 
supplements. This advice is in line with the WCRF/AICR cancer prevention recommendation 
not to use dietary supplements to protect against cancer (53).
 The observational studies on BMI were generally based on historical cohorts with 
information retrospectively collected from medical records of consecutive patient series. 
This may have led to selection bias and incomplete retrieval of information. Also, almost 
none of the included studies compared the same BMI categories, and some studies (29, 
40) did not use official BMI categories as defined by the World Health Organization to 
compare patients, possibly explaining the inconsistent results. Furthermore, only one of 
the studies included other measures to assess obesity or body composition, such as 
waist-to-hip ratio or densitometry (33). The observational studies on dietary factors were 
mostly based on follow-up of existing case-control studies, were small, did not report the 
type of questionnaire used, and defined only two broad comparison groups (e.g. ever vs. 
never, > vs. < median, ≥1 vs. <1 servings per month)(27, 36, 37). None of the studies 
investigated post-diagnostic BMI and only one study investigated post-diagnostic diet 
but was restricted to overall fluid intake (9). Post-diagnostic changes in BMI or diet in 
relation to prognosis were not addressed, while the most relevant question for patients is 
whether making lifestyle changes affects their prognosis. Most supplementation studies 
also had a limited sample size and in some of these studies only a few patients experienced 
the outcome(s) of interest, highly limiting the statistical power. Some studies did not 
report whether study participants and investigators were blinded (13, 14, 17, 24, 26, 32, 41) 
and one study was not blinded (28). In addition, for both observational and supplementation 
studies heterogeneity was present in type of exposure, timing of exposure assessment 
and outcomes of interest which makes it difficult to compare studies and to draw 
conclusions. Incomplete reporting of patient characteristics and methods aggravated this 
problem. Also, smoking was only taken into account in some studies. Thus, there is a 
potential risk of bias in individual studies.
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Ongoing challenges and steps to be taken
Taking into account the shortcomings of the studies published to date, there is an urgent 
need for well-designed, prospective cohort studies on the association of dietary and 
other lifestyle factors with UBC prognosis. There are several considerations for the design 
of such studies. First of all, patients newly diagnosed with UBC should be recruited rapidly 
so that data collection can start shortly after diagnosis. Ideally, questionnaires should 
cover the entire diet, and assessment of pre-diagnostic dietary and lifestyle habits should 
be followed by repeated post-diagnosis assessments to capture changes in lifestyle. In this 
way, the most relevant question for the patient can be addressed, i.e. whether lifestyle 
changes are related to UBC prognosis. Furthermore, blood samples should be collected to 
investigate biomarkers of dietary and lifestyle habits. A representative, population-based 
sample of UBC patients should be included to assure generalizability, but NMIBC and 
MIBC patients should be investigated separately and, if possible, by molecular subtype as 
relevant disease outcomes and prognosis are clearly different for these subgroups (54). 
Sample size should be large enough to study associations with sufficient power, and to 
study progression which is a less frequent outcome. Smoking and perhaps antidiabetic 
medication use should be taken into account as the association between lifestyle and 
UBC prognosis may be confounded by these factors, or may be different according to 
subgroups of these factors. Furthermore, physical activity may be a relevant lifestyle factor 
for further investigation as well, since it has been suggested to improve immune system 
functioning and to reduce systemic inflammation, thereby positively influencing the 
course of disease (55, 56).
 Also, studying body composition may be more relevant than BMI, as BMI cannot 
distinguish between fat mass and skeletal muscle mass, and only low muscle mass but not 
fat mass has been associated with increased risk of ACM in MIBC patients (33, 57).
Conclusions
This review suggests that BMI and certain dietary factors and supplements may influence 
bladder cancer prognosis, but no strong conclusions can be drawn. Well-designed prospective 
studies are neededto provide UBC patients with evidence-based lifestyle guidelines to 
improve their prognosis. These studies should include patients shortly after diagnosis, 
need repeated lifestyle measurements and examine appropriate endpoints (recurrence 
and progression in NMIBC, CSM and ACM in MIBC). Until new evidence becomes available, 
UBC patients are advised to follow the World Cancer Research Fund/American Institute for 
Cancer Research recommendations for cancer prevention which are focused on maintaining 
a healthy weight, being physically active and eating a healthy diet.
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Appendix A
PubMed search 
BMI, physical activity, nutrition and bladder cancer recurrence, progression and survival
A
“Urinary bladder neoplasms”[MeSH Terms] OR ((“malignant”[tiab] OR “malignancy”[tiab] 
OR “malignancies”[tiab] OR “neoplasm”[tiab] OR “neoplasms”[tiab] OR “carcinoma”[tiab] OR 
“carcinomas”[tiab] OR “cancer”[tiab] OR “cancers”[tiab] OR “tumor”[tiab] OR “tumors”[tiab] 
OR “tumour”[tiab] OR “tumours”[tiab]) AND (“bladder”[tiab] OR “urothelial”[tiab])) 
B
“Recurrence”[MeSH Terms] OR “Neoplasm Recurrence, Local” OR “Disease Progression”-
[MeSH Terms] OR “Disease-Free Survival”[MeSH Terms] OR “Mortality”[MeSH Terms] OR 
“Mortality”[Subheading] OR “Survival Analysis”[MeSH Terms] OR “recur”[tiab] OR “recurrence”-
[tiab] OR “recurrences”[tiab] OR “relaps”[tiab] OR “relapse”[tiab] OR “relapses”[tiab] OR 
“survivor”[tiab] OR “survivors”[tiab] OR “progression”[tiab] OR “survival”[tiab] OR “mortality”-
[tiab] OR “death”[tiab]
 
C
“Body Weights and Measures”[MeSH Terms] OR “Body Composition”[Mesh Terms] OR 
“Adipose Tissue” [Mesh Terms] OR “weight”[tiab] OR “body weight”[tiab] OR “body mass 
index”[tiab] OR “bmi”[tiab] OR “quetelet index”[tiab] OR “waist circumference”[tiab] OR “hip 
circumference”[tiab] OR “waist hip ratio”[tiab] OR “waist to hip ratio”[tiab] OR “body fat 
distribution”[tiab] OR “body fat”[tiab] OR “overweight”[tiab] OR “obesity”[tiab] OR “weight 
gain”[tiab] OR “weight change”[tiab] OR “body composition”[tiab] OR “adipose tissue” [tiab]
D
“Exercise”[MeSH Terms] OR “Sports”[MeSH] OR “physical activity”[tiab] OR “motor 
activity”[tiab] OR “exercise”[tiab] OR “sports”[tiab] OR “running”[tiab] OR “jogging”[tiab] OR 
“swimming”[tiab] OR “walking”[tiab] 
E
“Diet”[MeSH Terms] OR “diet therapy”[MeSH Terms] OR “food and beverages”[MeSH Terms] 
OR “nutritional sciences”[MeSH Terms] OR “antioxidants”[MeSH Terms] OR “micronutrients”-
[MeSH Terms] OR “antineoplastic agents”[MeSH terms] OR “diet”[tiab] OR “diets”[tiab] OR 
“dietary”[all fields] OR “intake”[tiab] OR “nutrition”[tiab] OR “food”[tiab] OR “antioxidant”-
[tiab] OR “antioxidants”[tiab] OR “micronutrient”[tiab] OR “micronutrients”[tiab] OR 
“vitamin”[tiab] OR “vitamins”[tiab] OR “supplement”[tiab] OR “supplements”[tiab] 
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EMBASE search 
BMI, physical activity, nutrition and bladder cancer recurrence, progression and survival
A
exp bladder tumor/ OR ((malignant OR neoplasm OR neoplasms OR carcinoma OR carcinomas 
OR cancer OR cancers OR tumor OR tumors OR tumour OR tumours) AND (bladder OR 
urothelial)).ti,ab
B
exp recurrent disease/ OR exp disease progression/ OR exp disease-free survival/ OR exp 
mortality/ OR exp cause of death/ OR exp survival/ OR exp survival rate/ OR (recur OR 
recurrence OR recurrences OR relapse OR Disease-Free Survival OR Disease-Free Survivals 
OR Event Free Survival OR Event Free Survivals OR survivor OR survivors OR Progres-
sion-Free Survival OR Progression-Free Survivals OR survival OR survival rate OR remission).
ti,ab
C
exp body height/ OR exp body weight/ OR exp body mass/ OR exp waist circumference/ 
OR exp waist hip ratio/ OR exp adipose tissue/ OR exp obesity/ OR exp body composition/ 
OR (weight OR body weight OR body mass index OR bmi OR quetelet index OR waist 
circumference OR hip circumference OR waist hip ratio OR waist to hip ratio OR body fat 
OR overweight OR obesity OR weight gain OR weight change OR body composition OR 
adipose tissue).ti,ab
D
exp motor activity/ OR exp exercise/ OR exp sport/ OR (physical activity OR motor activity 
OR exercise OR sports OR running OR jogging OR swimming OR walking).ti,ab
E
exp diet/ OR exp diet therapy/ OR exp food/ OR exp nutritional science/ OR exp 
antioxidant/ OR exp trace element/ OR exp antineoplastic agent/ OR (diet OR diets OR 
dietary OR dietary intake OR intake OR nutrition OR food OR antioxidant OR antioxidants 
OR micronutrient OR micronutrients OR vitamin OR vitamins OR supplement* OR dietary 
supplement OR food supplement).ti,ab

Smoking and fluid intake in relation  
to risk of recurrence in non-muscle invasive 
bladder cancer: a prospective cohort study
Ellen Westhoffa, Ellen Kampmana,b, J. Alfred Witjesc, Katja K. Abena,d, Evert L. Koldewijne, 
Lambertus A. Kiemeneya, Alina Vrielinga 
a  Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. 
b  Wageningen University,  Division of Human Nutrition, Wageningen, The Netherlands. 
c  Radboud university medical center, Radboud Institute for Molecular Life Sciences, Department of Urology,  
Nijmegen, The Netherlands. 
d  Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
e  Catharina Hospital, Department of Urology, Eindhoven, The Netherlands.
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Abstract 
Introduction: Smoking has been associated with a higher risk of recurrence in non-mus-
cle-invasive bladder cancer (NMIBC), but evidence is inconsistent. Fluid intake is 
hypothesized to have an effect on bladder cancer risk, but its role in NMIBC prognosis has 
only scarcely been investigated. 
Methods: We studied the association of self-reported smoking status at diagnosis, 
cumulative smoking exposure, time since smoking cessation, and post-diagnostic fluid 
intake with risk of first recurrence in the prospective cohort study UroLife, including 550 
NMIBC patients diagnosed between 2014 and 2016. Patients completed a questionnaire 
on smoking at 6 and 12 weeks after diagnosis and a 4-day diary on fluid intake at 12 weeks 
after diagnosis. Detailed data on tumour characteristics, treatment, and clinical outcomes 
were collected. Hazard ratio’s (HR) and 95% confidence intervals (CI) were calculated with 
multivariable Cox proportional hazards regression analysis, adjusted for age, gender, 
stage, grade, and treatment. 
Results: During a median follow-up of was 19 months, 103 patients (19%) developed at 
least one recurrence. No statistically significant associations with risk of recurrence were 
found for either smoking or fluid intake. Former (HR 1.41; 95% CI 0.79-2.51), but not current 
(HR 0.87; 95% CI 0.44-1.73) smokers had a non-statistically significant increased risk of 
recurrence compared to never smokers. Among ever smokers, the highest versus lowest 
amount of pack-years was associated with a non-statistically significant increased risk of 
recurrence (HR 1.32; 95% CI 0.75-2.33; p-trend=0.14).
Conclusion: In our study, smoking and fluid intake were not markedly associated with risk 
of recurrence in NMIBC patients. However, future analyses with a larger sample size and 
longer follow-up time are needed before definitive conclusions can be drawn. 
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Introduction
Non-muscle-invasive bladder cancer (NMIBC) is a common malignancy which is 
characterized by a high risk of disease recurrence (1). Therefore, patients require frequent 
check-ups with cystoscopies and usually undergo multiple treatments (2), which makes 
bladder cancer one of the most expensive tumours per patient per year (3). Despite 
improvements in treatment such as single postoperative instillations of chemotherapy 
and enhanced cystoscopy, recurrence rates are still high, indicating the need to identify 
additional prognostic factors that may support treatment. 
 Several lifestyle factors have been associated with prognosis in other cancer types 
(4, 5), but evidence for NMIBC is scarce and equivocal. Smoking is the most important risk 
factor for both NMIBC and muscle-invasive bladder cancer and evidence of an association 
with risk or recurrence is increasing (6-8). A meta-analysis of thirteen cohort and two 
case-control studies showed that former and current smokers may be at a more than 20% 
(95% confidence interval 1.05-1.45; I2=56%) higher recurrence risk than never smokers (7). 
Smoking cessation may limit the detrimental effects of smoking, thereby favorably altering 
the course of disease (6, 9, 10). However, evidence from prospective studies is lacking. 
 Fluid intake has also been hypothesized to be associated with urinary bladder cancer 
(UBC) risk (11, 12). The urogenous contact hypothesis suggests that increased fluid 
consumption results in lower concentrations of carcinogens in the urine and a higher 
micturition frequency, reducing urothelial exposure to carcinogens such as those from 
cigarettes (11, 12). However, different types of beverages may exert different effects due to 
their nutrient composition, complicating the investigation of the role of fluid intake (12). 
Studies on fluid intake and UBC risk yield inconsistent results (13), and the association of 
fluid intake with UBC recurrence has only scarcely been investigated (14). 
 Therefore, we aimed to investigate the association of smoking and fluid intake with 
the risk of recurrence risk in a prospective cohort of newly diagnosed NMIBC patients. 
Methods
Study design and patient population
We used data from a population-based, prospective cohort study, which was initiated to 
investigate the association of dietary and lifestyle habits with prognosis and HRQoL in 
NMIBC patients, named the UroLife study (Urothelial cancer: Lifestyle, prognosis and 
health-related quality of Life). Permission was asked from all urologists of the 22 
participating hospitals to identify their eligible patients in the Netherlands Cancer Registry 
(NCR), held by the Netherlands Comprehensive Cancer Organization (IKNL). Dutch 
speaking men and women between 18 and 80 years old with a primary NMIBC tumour 
(stage Ta, T1, Tis) diagnosed between April 1, 2014 and April 25, 2017 were identified 
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approximately 4 weeks after diagnosis and invited on behalf of their urologist to participate 
in this study. Only patients with a histologically confirmed NMIBC tumour that was 
surgically removed with a transurethral resection were invited. Patients were excluded if 
they had a previous cancer diagnosis in the last five years, positive lymph nodes, or distant 
metastases. For the current study, we included patients diagnosed up to March 18, 2016 
for whom clinical data were collected in September 2017. Written informed consent was 
obtained from all participants. The UroLife study received ethical approval from the 
Committee for Human Research region Arnhem-Nijmegen (CMO 2013-494).
Lifestyle data collection – smoking and fluid intake
Patients completed self-reported web-based or paper-and-pencil questionnaires at six 
weeks (T1), twelve weeks (T2), and fifteen months (T3) after diagnosis. Web-based 
questionnaires were collected via the data collection tool of the Patient Reported 
Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) 
registry (15). T1 referred to the situation before diagnosis up to 6 weeks after diagnosis, 
and T2 and T3 to the situation after diagnosis. The questionnaires included questions 
about socio-demographic characteristics (T1 only), smoking, alcohol consumption, body 
mass index (BMI), and other lifestyle and medical factors. At T2 and T3, patients filled out 
a paper-and-pencil four-day fluid and micturition diary as well. Only the T1 and T2 
questionnaires and the T2 diary were used in the current study.
 Smoking status was assessed by asking whether patients smoked at the time of filling 
out the questionnaire or if they had smoked in the past. Patients were categorized into 
never, former and current smokers at diagnosis. Patients who were current or former 
smokers were asked to indicate at what age they started smoking, the age or date they 
quit (when applicable), the average number of cigarettes smoked per day, and the 
duration of cigarette smoking. To evaluate the impact of smoking cessation, patients were 
categorized using both the T1 and T2 questionnaires into never smokers, former smokers 
who quit ≥10 years before diagnosis, former smokers who quit <10 years and ≥1 year 
before diagnosis, former smokers who quit between 1 year before and <3 months after 
diagnosis, and current smokers. For patients with missing data for T2, smoking status was 
only based on data for T1. Pack-years at diagnosis were calculated to describe cumulative 
smoking exposure, by multiplying duration of cigarette smoking in years with the average 
number of cigarettes smoked per day divided by 20. Fluid intake was measured with a 
four-day fluid and micturition diary. Patients filled out how much they drank on that day either 
in mL or in household measures, and average fluid intake in mL per day was calculated.
Lifestyle data collection – potential confounders
Educational level was categorized into low (primary, secondary, vocational education), 
medium (intermediate vocational education, higher general secondary education, 
pre-university education), or high (university of vocational education, university). Status of 
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smoking pipe and/or cigar was assessed by asking whether patients smoked at the time 
of filling out questionnaire T1 or had smoked in the past. Patients were categorized into 
never, former and current pipe/cigar smokers at diagnosis. BMI (kg/m2) was calculated 
based on self-reported weight and height, and patients were classified as normal weight 
(<25 kg/m2), overweight (25-30 kg/m2), and obese (>30 kg/m2) (16). Alcohol consumption 
was assessed by questions about the number of week days and weekend days patients 
usually consumed alcoholic drinks, and the average number of drinks per week day or 
weekend day. The average number of alcoholic drinks per day was calculated. Average 
frequency of micturition was obtained from the four-day fluid and micturition diary in 
which patients filled out how many times per day they urinated. 
Clinical data collection
Detailed clinical data were collected by well-trained data managers from IKNL from 
medical records in August 2017. These included TNM classification, grade, concomitant 
carcinoma in situ (CIS; yes/no), tumour multiplicity (solitary/multiple), immediate 
postoperative instillation of chemotherapy (yes/no), treatment (TURBT only, TURBT with 
intravesical chemotherapy, TURBT with intravesical immunotherapy), recurrence (yes/no), 
vital status, and duration of follow-up. Follow-up started at the date of TURBT for the 
primary tumour, or at the date of re-TURBT for patients who underwent a re-TURBT. 
A recurrence was defined as the clinical or pathological confirmation of a new bladder 
tumour or a tumour in the prostatic urethra of any grade, with at least one tumour- 
negative cystoscopy in between two tumour-positive cystoscopies, or at least three 
months between the primary tumour and the recurrence. Patients who received both 
adjuvant chemotherapy and immunotherapy were categorized according to which 
therapy they received most often. Patients were divided into low-, intermediate- and 
high-risk tumour categories based on the EAU guidelines (2), without taking into account 
the tumour size (not available) and the recurrent nature of the tumour (only primary 
tumours included). 
Statistical analysis
Descriptive statistics were calculated to summarize baseline characteristics in means with 
standard deviations or medians with interquartile ranges for continuous variables, and 
percentages for categorical variables, both for the total study population as well as by 
smoking status and by fluid intake in quartiles. Recurrence free survival (RFS) was defined 
as the time period between the date of TURBT or, if applicable, date of re-TURBT when a 
re-TURBT was performed, and the date of first recurrence, last check-up with clinical 
information, or death, whichever came first. Univariable and multivariable Cox proportional 
hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals 
(95% CI) for the association of smoking status at diagnosis, cumulative smoking exposure 
in pack-years (quartiles and continuous), smoking cessation, and fluid intake (quartiles and 
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continuous per 100 mL/day) with RFS. The proportional hazards assumption was tested by 
modeling time-dependent covariates and using Schoenfeld residuals (17). The assumption 
was fulfilled for all exposures of interest and potential covariates. All multivariable analyses 
were adjusted for age, gender, tumour grade and stage, and treatment modality. Other 
potential confounders did not change the risk estimates by 10% or more when tested in 
the model and were therefore not included in the final model, i.e. level of education, 
concomitant CIS, tumour multiplicity, immediate postoperative instillation of chemotherapy, 
BMI, alcohol consumption (in quartiles), fluid intake (in smoking analyses only), cigarette 
smoking status at diagnosis and micturition frequency (both in fluid intake analyses only). 
Tests for linear trends across quartiles of cumulative smoking exposure and fluid intake 
were conducted by adding the quartiles as ordinal variables to the model. Further, 
a sensitivity analysis was performed using date of initial TURBT as start of the follow-up for 
all patients as this is a more standard procedure. Stratified analyses were conducted for 
patients with a low- or intermediate-risk tumour versus patients with a high-risk tumour, 
and for fluid intake stratified by smoking status. Statistical significance was defined as a 
two-sided p-value of below 0.05. All statistical analyses were performed using IBM SPSS 
Statistics, version 22. 
Results
Of all 1,114 eligible and invited NMIBC patients diagnosed up to March 18, 2016, 582 agreed 
to participate (response rate 52%) (Figure 1). Thereafter, 32 patients were excluded because 
they had a previous cancer diagnosis in the past five years (n=3), clinical data were not yet 
collected (n=11), they had metastases at diagnosis (n=2), a tumour stage >T1 (n=6), did not 
complete their first questionnaire (n=5), had a follow-up of ≤14 days (n=4), or died within 
three months after diagnosis (n=1). In total, 550 (95%) patients were included in the 
analyses on smoking, and 427 (73%) who completed the four-day diary were included in 
the analyses on fluid intake. Descriptive characteristics for the total study population and 
by smoking status at diagnosis are shown in Table 1, and descriptive characteristics by 
quartile of fluid intake are shown in Supplementary Table 1. Median age at diagnosis was 
67 years, 79% of patients were men, and 74% had a Ta tumour. Median follow-up time was 
19 months (range 0 - 37), 25 patients died (5%), and 103 patients (19%) developed at least 
one recurrence (78% pathologically confirmed; 22% coagulation). In 19 patients (3%), 
this concerned progression to a higher stage or grade. Most patients were former (58%) 
or current (26%) smokers. Median average fluid intake was 1840 mL (IQR 1500 – 2215). 
Descriptive characteristics differed slightly by smoking status. Current smokers were 
somewhat younger at diagnosis and less likely to have grade 3 tumours, while former 
smokers were more often obese compared to never smokers. Both current and former 
smokers were lower educated, had a higher alcohol consumption, and were more likely to 
57
Smoking, fluid intake and recurrence
3
have been diagnosed with multiple tumours and to have received a postoperative 
installation of chemotherapy compared to never smokers. 
 Univariable analysis did not show statistically significant associations with RFS for 
smoking status at diagnosis, cumulative smoking exposure, smoking cessation, or fluid 
intake (Table 2). Also, no associations with RFS were found in the multivariable models 
adjusted for age, gender, grade, stage, and treatment (Table 2). Risks of recurrence were 
non-statistically significant increased for former compared to never smokers (HR 1.41; 95% 
CI 0.79-2.51), but they were not increased for current smokers (HR 0.87; 95% CI 0.44-1.73). 
Among ever smokers, the highest compared to lowest cumulative smoking exposure was 
associated with a non-statistically significant increased risk of recurrence (HR 1.32; 95% CI 
Figure 1  Flowchart of patients included in smoking, fluid intake and recurrence analyses.
423 patients included in 
analysis of fluid intake and 
recurrence risk
 
5 patients excluded because of implausible follow-up
(≤14 days, n=4) or death within three months (n=1)  
43 patients dropped out before filling out 
T1 questionnaires  
489 patients actively or passively refused to participate  
127 patients excluded because of missing or
incomplete fluid or micturition diary
 
550 patients included in 
analysis of smoking and 
recurrence risk  
555 patients with questionnaire 
data and clinical data available 
 
582 patients who started filling
out T1 questionnaires  
625 patients with
informed consent 
 
 
1114 eligible bladder cancer 
patients with an incidence 
date before March 18, 2016 
27 patients excluded because of previous cancer 
diagnosis in the past 5 years (n=3), metastases at 
diagnosis (n=2), tumour stage >T1 (n=6), 
incomplete first questionnaire (n=5), or missing  
clinical data (n=11)  
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Table 2  Univariable and multivariable Cox proportional hazards regression  
models for the association of smoking, fluid intake, socio-demographic,  
and tumour characteristics with risk of recurrence in 550 non-muscle-invasive  
bladder cancer patients.
Variable1 n n events 
(%)
Crude HR  
95% CI
Adj. HR2  
95% CI
Smoking status at diagnosis
   Never 88 14 (16%) 1.00 (ref ) 1.00 (ref )
   Former 319 68 (21%) 1.38 (0.78-2.45) 1.41 (0.79-2.51)
   Current 143 21 (15%) 0.88 (0.45-1.73) 0.87 (0.44-1.73)
Cumulative smoking exposure3,4
   >0-10.9 114 22 (19%) 1.00 (ref ) 1.00 (ref )
   10.9-20.0 115 13 (11%) 0.56 (0.28-1.11) 0.57 (0.28-1.13)
   20.0-34.1 113 24 (21%) 1.09 (0.61-1.95) 1.05 (0.58-1.89)
   34.1-98.0 114 28 (25%) 1.34 (0.77-2.35) 1.32 (0.75-2.33)
   p-trend = 0.10 p-trend = 0.14
Cumulative smoking exposure3,5 456 87 (19%) 1.07 (0.95-1.21)
Smoking cessation6
   Never 77 12 (16%) 1.00 (ref ) 1.00 (ref )
   Quit ≥10y before diagnosis 217 44 (20%) 1.32 (0.70-2.50) 1.33 (0.70-2.53)
   Quit <10y-≥1y before diagnosis 57 14 (25%) 1.56 (0.72-3.38) 1.53 (0.71-3.32)
   Quit <1y before-<3m after diagnosis 48 8 (17%) 1.05 (0.43-2.57) 0.97 (0.39-2.40)
   Current 76 11 (14%) 0.84 (0.37-1.90) 0.85 (0.37-1.94)
Average fluid intake (mL/day)4
   694-1500 106 18 (17%) 1.00 (ref ) 1.00 (ref )
   1501-1840 106 15 (14%) 0.77 (0.39-1.53) 0.82 (0.41-1.64)
   1841-2215 106 24 (23%) 1.34 (0.73-2.46) 1.35 (0.73-2.50)
   2216-4131 105 20 (19%) 1.16 (0.61-2.18) 1.19 (0.63-2.27)
   p-trend = 0.33 p-trend = 0.33
Average fluid intake (per 100 mL/day) 423 77 (18%) 1.01 (0.97-1.05) N/A
Age at diagnosis 550 103 (19%) 0.99 (0.97-1.01) N/A
Sex
   Female 116 21 (18%) 1.00 (ref ) N/A
   Male 434 82 (19%) 1.10 (0.68-1.78) N/A
Tumour stage
   Ta 405 71 (18%) 1.00 (ref ) N/A
   T17 145 32 (22%) 1.20 (0.79-1.82) N/A
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0.75-2.33). When calculated for former and current smokers separately, the association was 
stronger in former, but absent in current smokers (Supplementary Table 2). A sensitivity 
analysis using date of initial TURBT as start of follow-up for all patients showed similar results 
(Supplementary Table 3). Results were not different for patients with high-risk tumours 
compared to patients with low- and intermediate-risk tumours (Table 3). The association 
between fluid intake and risk of recurrence did not differ according to smoking status 
(Supplementary Table 4).
Table 2  Continued.
Variable1 n n events 
(%)
Crude HR  
95% CI
Adj. HR2  
95% CI
Tumour grade8
   1 133 22 (17%) 1.00 (ref ) N/A
   2 263 51 (19%) 1.09 (0.66-1.79) N/A
   3 153 30 (20%) 1.09 (0.63-1.89) N/A
Concomitant CIS 
   No 511 92 (18%) 1.00 (ref ) N/A
   Yes 39 11 (28%) 1.73 (0.92-3.23) N/A
Tumour focality
   Solitary 375 61 (16%) 1.00 (ref ) N/A
   Multiple 99 26 (26%) 1.76 (1.11-2.78) N/A
   Unknown 76 16 (21%) 1.33 (0.77-2.30) N/A
Postoperative instillation of chemotherapy
   No 248 50 (20%) 1.00 (ref ) N/A
   Yes 302 53 (18%) 0.82 (0.56-1.21) N/A
Therapy
   TURBT only 272 47 (17%) 1.00 (ref ) N/A
   TURBT with chemotherapy 142 36 (25%) 1.45 (0.94-2.23) N/A
   TURBT with immunotherapy 136 20 (15%) 0.79 (0.47-1.33) N/A
1 Where scores do not total 100% this is due to missing values; 2 HR adjusted for age, gender, stage, grade and treatment; 3 
In pack-years, based on former and current smokers only; 4 In quartiles; 5 Continuous per 10 pack-years; 6 Only available for 
patients who filled in both T1 and T2 questionnaires; 7 T1 including n=19 Tis tumours; 8 WHO 1973. Abbreviations: CIS: 
carcinoma in situ; TURBT: transurethral resection of the bladder tumour.
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Table 3  Multivariable Cox proportional hazards regression models for the association 
of smoking and fluid intake with recurrence among 351 low- and intermediate- risk, and 
199 high-risk Dutch non-muscle-invasive bladder cancer patients
Low- and intermediate-risk High-risk
Variable1 n n  
events
Adj. HR2  
95% CI
n n  
events
Adj. HR2  
95% CI
Smoking status at diagnosis
Never 58 9 1.00 (ref ) 30 5 1.00 (ref )
Former 193 40 1.45 (0.70-2.99) 126 28 1.39 (0.53-3.66)
Current 100 14 0.83 (0.36-1.93) 42 7 0.92 (0.29-2.92)
Cumulative smoking exposure3,4
>0-10.9 71 13 1.00 (ref ) 43 9 1.00 (ref )
10.9-20.0 74 9 0.61 (0.26-1.43) 41 4 0.43 (0.13-1.43)
20.0-34.1 70 14 1.02 (0.48-2.20) 43 10 0.98 (0.38-2.49)
34.1-98.0 75 17 1.23 (0.59-2.58) 39 11 1.44 (0.59-3.50)
   p-trend = 0.35 p-trend = 0.24
Smoking cessation
Never 50 8 1.00 (ref ) 27 4 1.00 (ref )
Quit ≥10y before diagnosis 126 26 1.41 (0.63-3.13) 91 18 1.40 (0.47-4.20)
Quit <10y-≥1y before diagnosis 39 7 1.12 (0.40-3.09) 18 7 3.01 (0.85-10.66)
Quit <1y before-<3m after diagnosis 28 4 0.71 (0.21-2.46) 20 4 1.31 (0.32-5.35)
Current 57 9 0.95 (0.36-2.47) 19 2 0.65 (0.12-3.59)
Average fluid intake in mL/day4
694-1500 73 12 1.00 (ref ) 33 6 1.00 (ref )
1501-1840 64 12 1.13 (0.50-2.53) 42 3 0.43 (0.10-1.79)
1841-2215 69 14 1.27 (0.58-2.78) 37 10 1.74 (0.59-5.14)
2216-4131 62 12 1.19 (0.53-2.66) 43 8 1.35 (0.45-4.06)
   p-trend = 0.62 p-trend = 0.22
1 Where scores do not total 100% this is due to missing values; 2 HR adjusted for age, gender, stage, grade and treatment; 3 
In pack-years, based on former and current smokers only; 4 In quartiles.
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Discussion
This study found no evidence for a marked association of smoking or fluid intake with risk 
of NMIBC recurrence. Neither smoking status at diagnosis, cumulative smoking exposure, 
time since smoking cessation, nor fluid intake were statistically significantly associated 
with risk of recurrence. 
 A systematic review and a meta-analysis based on 13 historical cohort and two 
case-control studies found a 23% higher recurrence risk for current smokers at diagnosis 
and a 22% higher risk for former smokers (7). Risks were statistically significantly increased 
for only 5 and 3 out of the 15 studies, respectively. Our results did not support the hypothesis 
that current smokers have a higher recurrence risk than never smokers. Although results 
were not statistically significant, in our study, former smokers seemed to have a higher 
recurrence risk than never smokers. High vs. low cumulative smoking exposure also 
seemed to be associated with higher recurrence risk in former smokers. The absence of an 
association for current smokers could be explained by the limited statistical power of the 
current study, and larger prospective studies with longer follow-up time are required.  
 In our study, the distribution of low- and intermediate-risk versus high-risk tumours 
did not differ by smoking status, and results were not different according to tumour 
aggressiveness. Previous studies found that (former) smokers present with more aggressive 
tumours at diagnosis and therefore have a worse prognosis (18-20). In recent years, three 
molecular subtypes of NMIBC have been identified, i.e. urobasal, genomically unstable, 
and squamous-cell-carcinoma-like bladder cancer (21-23). The genomically unstable and 
squamous-cell-carcinoma-like subtypes are mostly found in patients with T1 tumours and 
have high risk of progression (22). Also, a study in muscle-invasive bladder cancer patients 
found that former and current versus never smoking was more strongly associated with 
the genomically unstable subtype than with urobasal tumours (24). Therefore, future 
studies should investigate whether molecular subtypes also modify and/or mediate 
associations of smoking and NMIBC prognosis. 
 The lack of association for smoking cessation may support the hypothesis of ‘field 
cancerization’, which offers an explanation for locally recurrent cancer (25, 26). Genetic 
alterations in stem cells caused by exposure to carcinogens, such as tobacco, can result in 
the replacement of fields of normal mucosa with preneoplastic cells eventually leading to 
disease recurrence when only the primary tumour has been removed (25, 26). However, the 
duration of follow-up of the current study may be inadequate to find associations of smoking 
cessation with risk of recurrence that may become apparent only after multiple years.
 We did not find an association of average daily fluid intake with risk of recurrence. 
This was also found in a US study in 267 bladder cancer patients (14). However, the US 
study included patients on average 7 years after diagnosis, and the association of fluid 
intake with the risk of first recurrence could not be investigated. Other studies on fluid 
intake and bladder cancer prognosis are not yet available. Furthermore, it is possible that 
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the (hypothesized) protective or harmful effects of a higher fluid intake on bladder cancer 
risk and prognosis are not caused by the absolute amount of fluids consumed, but rather by 
their composition (27, 28). The types of fluids consumed may influence the concentrations 
of both carcinogenic and anti-carcinogenic substances in the urine, which is further 
determined by the nutritional content of the diet, but also by possible carcinogenic 
byproducts in food, and carcinogens in cigarettes (11, 12). The role of fluid intake is further 
complicated by the frequency of micturition, which could have an influence on both the 
concentration and the transit time of the urine. Although adjustment for micturition 
frequency did not change our results, we could not yet incorporate all these factors in our 
analysis. Therefore, it is recommended to study fluid intake, micturition, diet and smoking 
together to unravel their independent and potentially different effects.  
 Limitations of our study include the limited follow-up time and the low number of 
events, particularly in certain subgroups, which limited the power to detect statistically 
significant associations. Therefore, in particular stratified analyses should be considered 
purely exploratory. Adjuvant treatment with immunotherapy could have an influence on 
patient’s fluid intake and micturition frequency (29). Eleven percent of the patients filled 
out their fluid- and micturition diary during treatment with immunotherapy, however, 
additional adjustment for treatment did not influence our results. Strengths of the current 
study include the population-based nature and the short time between diagnosis and 
inclusion in the study. This decreased the chance of bias with regard to the correct recall 
of smoking history. Also, our study population is comparable to the general NMIBC 
population with regard to stage, age, and gender (30). Further, prospective and extensive 
data collection made it possible to evaluate the effect of smoking cessation after diagnosis, 
and reduced the chance of misclassification with regards to time since smoking cessation. 
However, misclassification due to socially desirable answers cannot be ruled out. 
Information on fluid intake was collected from four-day diaries, which have the advantage 
that no recall is needed of the patients, and that amounts can be quantified. However, 
patients could have changed their habitual fluid intake because of the diary, or could have 
forgotten to write down every consumption. However, consumption is comparable to 
that measured by a food frequency questionnaire in a Dutch population (12). 
 This prospective cohort study with limited sample size and follow-up time did not 
find evidence of differences in risk of recurrence according to smoking status, cumulative 
smoking exposure or fluid intake. Further research is needed in larger prospective studies 
with longer follow-up times, also taking into account molecular subtypes. Bladder cancer 
patients should still be recommended to quit smoking  based on its well-established 
general health benefits.  
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Supplementary Table 2  Multivariable Cox proportional hazards regression models 
for the association of cumulative smoking exposure with risk of recurrence for former 
and current smokers separately compared to never smokers.
Variable1 n n events Adj. HR2 95% CI
Cumulative smoking exposure former smokers3,4
   Never smokers 88 14 1.00 (ref )
   >0-14.4 125 23 1.24 (0.64-2.41)
   14.4-29.2 104 20 1.22 (0.61-2.43)
   29.2-98.0 87 24 2.09 (1.07-4.06)
p-trend = 0.04
Cumulative smoking exposure current smokers3,4
   Never smokers 88 14 1.00 (ref )
   >0-14.4 26 5 1.17 (0.39-3.53)
   14.4-29.2 49 4 0.43 (0.14-1.34)
   29.2-98.0 64 11 0.97 (0.43-2.22)
   p-trend = 0.66
1 Where scores do not total 100% this is due to missing values; 2 HR adjusted for age, gender, stage, grade and 
treatment; 3 In pack-years; 4 Ever smokers in tertiles with never smokers as reference category.
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Supplementary Table 3  Sensitivity analyses of smoking and fluid intake with start of 
follow-up at date of initial TURBT.
Variable1 n n events Adj. HR2 95% CI
Smoking status at diagnosis
   Never 88 14 1.00 (ref )
   Former 319 68 1.39 (0.78-2.48)
   Current 142 21 0.85 (0.43-1.69)
Cumulative smoking exposure3,4
   >0-10.9 114 22 1.00 (ref )
   10.9-20.0 115 13 0.57 (0.28-1.12)
   20.0-34.1 113 24 1.04 (0.58-1.88)
   34.1-98.0 113 28 1.32 (0.75-2.33)
   p-trend = 0.14
Smoking cessation
   Never 77 12 1.00 (ref )
   Quit ≥10y before diagnosis 217 44 1.31 (0.69-2.48)
   Quit <10y-≥1y before diagnosis 57 14 1.52 (0.70-3.29)
   Quit <1y before-<3m after diagnosis 48 8 0.95 (0.38-2.36)
   Current 76 11 0.82 (0.36-1.88)
Average fluid intake in mL/day4
   694-1500 106 18 1.00 (ref )
   1501-1840 106 15 0.83 (0.42-1.66)
   1841-2215 106 24 1.35 (0.73-2.51)
   2216-4131 105 20 1.20 (0.63-2.28)
   p-trend = 0.33
1 Where scores do not total 100% this is due to missing values; 2 HR adjusted for age, gender, stage, grade and 
treatment; 3 In quartiles; 4 In pack-years.
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Abstract
The association of dietary factors with urinary bladder cancer prognosis has scarcely been 
investigated, and results of studies conducted to date are inconsistent. We investigated 
whether empirically derived dietary patterns are associated with risks of recurrence and 
progression in non-muscle invasive bladder cancer patients. Data from 595 newly 
diagnosed non-muscle-invasive bladder cancer patients from an ongoing prospective 
cohort study were used to derive dietary patterns using exploratory factor analysis. Factor 
scores were calculated and then categorized in sex-specific tertiles. Multivariable adjusted 
proportional hazards regression models were used to estimate hazard ratios and 95% 
confidence intervals for the associations between tertiles of adherence to the dietary 
patterns and risks of recurrence and progression. We identified four dietary patterns: 
“fruits and vegetables”, “Western”, “low-fat”, and “Tex-Mex”. Patients in the highest tertile of 
adherence to the Western pattern experienced a 1.48 times higher risk of recurrence (95% 
CI 1.06-2.06) compared to patients in the lowest tertile. No statistically significant 
associations of a Western diet with risk of progression, or of the other dietary patterns with 
risk of recurrence and progression were found.  Overall, we found that adherence to a 
Western diet was associated with a higher risk of recurrence but further studies are needed 
to confirm our findings.
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Introduction
Urinary bladder cancer (UBC) is a common malignancy with an estimated 77,000 new 
cases and over 16,000 deaths occurring in 2016 in the United States (1). In patients with 
non-muscle invasive bladder cancer (NMIBC), approximately 75% of all UBC, frequent 
recurrences that necessitate an intensive follow-up program pose a large burden on 
quality of life and health care budget (2, 3). In clinical practice, tumor characteristics are 
used to predict the risk of recurrence and disease progression but the predictive ability of 
these characteristics is limited (4).
 Diet has been linked to the risk of many malignancies (5), but its role in UBC etiology 
is still inconclusive. A higher fluid intake is hypothesized to be protective in some studies 
(6-8), as are certain fruits and vegetables (9, 10). On the other hand, (barbecued) meat, 
pork, and total fat might be associated with a higher risk of developing UBC (11-14). 
However, a recent comprehensive meta-analysis on UBC only found probable evidence 
that arsenic in drinking water increases risk and limited suggestive evidence that greater 
consumption of fruit and vegetables and tea decreases risk (15).  
 The association of dietary factors with UBC prognosis is largely unknown. Several 
observational studies on diet and intervention studies with dietary supplements have 
been conducted, but they either found no associations (16-21) or had inconsistent results 
(22-25). Most of them had a limited sample size and other methodological shortcomings. 
Thus, more investigation in this area is needed.
 Since diet consists of many components that are correlated and can potentially 
interact with each other in a complex way, it may be better to evaluate dietary patterns 
rather than single factors when estimating diet-disease associations (26). Factor analysis is 
a suitable method to identify dietary patterns which can then be used to predict cancer 
risk and prognosis (27-29). It is a method that tries to reduce a large amount of observed, 
correlated variables (here: food items) to a smaller amount of underlying variables, called 
factors (dietary patterns), that still explain most of the variation in the dataset. However, 
hardly any study made use of factor analysis to explore associations between dietary 
intake patterns and UBC risk (30), and to our knowledge, no studies to date have 
investigated dietary patterns in relation to UBC prognosis. Therefore, we investigated 
whether empirically derived dietary patterns were associated with risk of recurrence and 
progression in a large ongoing prospective study of newly diagnosed NMIBC patients.
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Methods
Subjects
This study included patients enrolled at The University of Texas M.D. Anderson Cancer 
Center and the Scott Department of Urology at Baylor College of Medicine from 1995 
onwards. The procedures for subject recruitment and eligibility criteria have been 
described in detail elsewhere (31). In short, patients had histologically confirmed NMIBC 
and did not undergo previous treatment with chemotherapy or radiotherapy. There were 
no restrictions on age and gender. The study was approved by the M.D. Anderson and 
Baylor College of Medicine Institutional Review Boards. All patients provided written 
informed consent prior to participation in the study.
Exclusions and eligibility
Inclusion and exclusion criteria for this study have been previously described in detail (32). 
We additionally excluded participants with outlying total energy intake by removing men 
(n=21) and women (n=2) with values outside the range between the 25th percentile minus 
1.5 times the interquartile range and the 75th percentile plus 1.5 times the interquartile 
range. Minority participants (n=48) were also excluded from the present study due to 
their limited number, leaving 595 non-Hispanic white patients for inclusion. 
Data collection
Data were collected through a 45-minute structured interview and included demographic 
characteristics, smoking history, family history, occupational history and exposures, and 
medical history. A participant who had never smoked or had smoked less than 100 cigarettes 
in his or her lifetime was defined as a never smoker. A participant who had smoked at least 
100 cigarettes in his or her lifetime but had quit more than 12 months before diagnosis was 
classified as a former smoker. Current smokers were those who were currently smoking or 
had quit less than 12 months before diagnosis. Body mass index (kg/m2) was calculated 
from measured weight and height at diagnosis.
 Data on dietary intake in the year prior to diagnosis were collected through another 
45-minute interview in which a previously validated modified version of the National 
Cancer Institute Health Habits and History Questionnaire was administered (33). This semi 
quantitative food frequency questionnaire (FFQ) consists of questions on frequency and 
portion size of food and beverage items, including ethnic foods frequently consumed in 
the Houston area, and contains an open-ended section regarding dietary behaviors such 
as dining in restaurants and food preparation methods. Total energy intake in calories and 
amount consumed in grams per day were estimated for each food or beverage item using 
the US Department of Agriculture National Nutrient Database for Standard Reference (34). 
Calculations for multi-ingredient food items not included in Standard Reference were bases 
on the US Department of Agriculture Food and Nutrient Database for Dietary Studies (35).
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Study staff obtained tumor characteristics and information on treatment, recurrence and 
progression through detailed chart review of medical records. In this study, recurrence 
was defined as a new bladder tumor following a previous negative follow-up cystoscopy. 
Progression was defined as the transition from NMIBC to muscle-invasive or metastatic 
tumors (31). 
Food grouping and dietary pattern analysis
Among the 181 initial food and beverage items, we excluded 19 that were eaten by less 
than 5% of our study population (sprouts, soy beans, fava beans, rice milk, soy milk, bottled 
sweetened water, vegetarian chili, tofu, meat substitutes, soy nuts and soy snacks, low-fat 
bacon, dairy products made of tofu, bread made with soy flour, bread made with flaxseed, 
Miso soup, tempeh, soy cheese, textured vegetable protein, and metamucil® or psyllium 
seeds). Twenty-seven foods were grouped into seven predefined food groups according 
to current US Department of Agriculture food group guidelines or groups with similar 
nutritional profile. After these steps, there remained 135 single items or food groups 
(measured in gram/day) to be included in the factor analysis.
 We evaluated the correlation matrix of the foods to determine its factorability through 
both visual inspection of the matrix and the statistical Kayser-Meyer-Olkin measure of 
sampling adequacy. In order to obtain an approximately normal distribution, we 
performed a log-transformation of all of the remaining 135 food items or food groups 
after we added 1 gram/day to all items to avoid food intake values of zero. We then 
adjusted all food intakes for energy intake with the residual method (36).
 We subsequently conducted exploratory factor analysis with the FACTOR command 
in STATA 14.0 (StataCorp LP, College Station, Texas) to reduce the number of food items 
and food groups into a small number of factors that explained the maximum proportion 
of variance in the data. We used the orthogonal varimax rotation and the Horst method 
to create uncorrelated and normally distributed factors (37). For the identification of 
factors that best represented the data, we considered the scree plot, eigenvalues and in-
terpretability of the factors. Foods or food groups with absolute loadings greater than 0.30 
on a given factor were considered as contributing to that factor.
 Retained factors were interpreted as dietary patterns and named after the items that 
contributed most to that factor. Dietary pattern factor scores were calculated and then 
categorized in sex-specific tertiles for analysis with recurrence and progression. The first 
tertile of each dietary pattern corresponded to the lowest factor score or level of adherence 
to that dietary pattern. 
Statistical analysis
Baseline characteristics of the participants were presented separately by tertile for each of 
the retained dietary patterns. Proportional hazards regression models were used to 
estimate hazard ratios (HRs) and 95% CI for the associations of tertiles of adherence to the 
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dietary patterns with recurrence and with progression. All models were adjusted for age 
(continuous) and sex. A multivariable model was further adjusted for education (≤12 years; 
13-15 years; ≥16 years), income (<$25,000/year; $25,000-$50,000; ≥$50,000), body mass 
index (continuous), smoking status (never, former, current) and intensity (pack-years, 
continuous), total energy intake (kcal/day, continuous), stage (Ta; T1; Tis), grade (1; 2; 3), 
presence or absence of concomitant carcinoma in situ, tumor multiplicity (1, 2, ≥3), and 
treatment (transurethral resection (TUR) only; TUR + induction Bacillus Calmette-Guerin 
(BCG); TUR + maintenance BCG; other intravesical chemotherapy). Tests for linear trends 
across tertiles of dietary patterns were conducted by adding the tertiles as an ordinal 
variable in the model. A sensitivity analysis was performed excluding all patients who 
experienced an event (e.g. recurrence, progression) within 90 days after diagnosis. 
Results
The Kayser-Meyer-Olkin measure was equal to 0.72, suggesting adequate sample size 
relative to the number of dietary items for conducting factor analysis. Four dietary patterns 
were derived from the factor analysis: “fruits and vegetables”, “Western”, “low-fat”, and 
“Tex-Mex” (Table 1). Names of the patterns were based on the foods that had absolute 
factor loadings of 0.30 or higher on that factor. Together these factors represented 37% of 
the total variance. 
 Participants were followed-up for a median of 65.7 months. During this period, 
317 patients recurred and 120 patients experienced progression to muscle invasive 
bladder cancer or metastatic tumors. Detailed baseline characteristics of all 595 NMIBC 
patients by tertile for the Western dietary pattern are summarized in Table 2. Patients 
adhering most to a Western dietary pattern were older, had a higher body mass index, 
and smoked more pack-years. Also, coronary heart disease and hypertension were more 
frequent in the highest tertile, and patients seemed to be lower educated and in the 
lower and middle income classes. Characteristics by tertile for the other patterns are 
included as a supplement (Supplementary Table 1-3). 
 Age- and sex-adjusted, and multivariable-adjusted results for the association of 
dietary patterns and NMIBC with recurrence and with progression are shown in Table 3. 
No statistically significant associations were observed in the minimally-adjusted model. 
Greater adherence to a Western diet was positively associated with recurrence after 
multivariable adjustment. Patients in the highest tertile of adherence had a 1.48 times 
higher risk of recurrence than patients in the lowest tertile (95% CI 1.06-2.06, P for trend 
0.03). There seems to be a trend towards higher risk of progression as well with a higher 
intake of a Western diet (HR1.56, 95% CI 0.91-2.65, P for trend 0.10). No significant associations 
with risk of recurrence and progression were found for the other dietary patterns.  
81
Dietary patterns and recurrence
4
Ta
bl
e 
1 
 R
ot
at
ed
 fa
ct
or
 p
at
te
rn
 lo
ad
in
gs
a  f
or
 1
35
 fo
od
 it
em
s 
or
 fo
od
 g
ro
up
s 
as
se
ss
ed
 a
t r
ec
ru
itm
en
t i
n 
a 
co
ho
rt
 s
tu
dy
 o
f n
on
-m
us
cl
e 
in
va
si
ve
 b
la
dd
er
 c
an
ce
r p
at
ie
nt
s, 
H
ou
st
on
, T
ex
as
.
Fo
od
 it
em
Fr
ui
ts
 a
nd
 
ve
ge
ta
bl
es
 
pa
tt
er
n 
 
(F
ac
to
r 1
)b
Fo
od
 it
em
W
es
te
rn
 
pa
tt
er
n
(F
ac
to
r 2
)b
Fo
od
 it
em
Lo
w
-f
at
 
pa
tt
er
n
(F
ac
to
r 3
)
Fo
od
 it
em
Te
x-
M
ex
 
pa
tt
er
n 
(F
ac
to
r 4
)
D
ee
p 
ye
llo
w
 
ve
ge
ta
bl
es
0.
56
Co
rn
br
ea
d
0.
48
Li
gh
t s
al
ad
 d
re
ss
in
g
0.
61
M
ex
ic
an
 fo
od
0.
59
Be
rr
ie
s
0.
53
Bl
ac
k 
ey
ed
 p
ea
s
0.
46
Li
gh
t m
ay
on
na
is
e
0.
48
Sa
ls
a
0.
55
C
ru
ci
fe
ro
us
 
ve
ge
ta
bl
es
0.
48
Fr
ie
d 
ch
ic
ke
n
0.
45
Lo
w
 fa
t d
ai
ry
0.
43
Fl
ou
r t
or
til
la
0.
40
Ce
le
ry
0.
47
Fr
ie
d 
fis
h
0.
40
Li
gh
t c
oo
ki
es
0.
43
Sa
lty
 s
na
ck
s 
w
ith
 
di
ps
 o
r t
op
pi
ng
s
0.
39
M
el
on
s
0.
47
O
kr
a
0.
38
Li
gh
t l
un
ch
m
ea
t
0.
42
Ba
rb
ec
ue
0.
38
D
ar
k 
le
af
y 
ve
ge
ta
bl
es
0.
46
G
ra
vy
0.
38
Sa
lty
 s
na
ck
s 
w
ith
ou
t 
di
ps
 o
r t
op
pi
ng
s
0.
39
A
vo
ca
do
0.
37
Pe
ac
he
s
0.
46
Ca
nn
ed
 c
hi
li
0.
38
Li
gh
t h
ot
do
gs
0.
32
Re
fri
ed
 b
ea
ns
0.
34
A
sp
ar
ag
us
0.
46
G
re
en
 b
ea
ns
0.
36
C
hi
ck
en
0.
30
Pi
zz
a
0.
33
St
ra
w
be
rr
ie
s
0.
45
Fr
en
ch
 fr
ie
s 
an
d 
fri
ed
 p
ot
at
oe
s
0.
35
Ba
co
n
-0
.3
1
Co
rn
 to
rt
ill
a
0.
33
A
pp
le
s
0.
40
Ba
co
n
0.
35
So
da
-0
.3
2
Be
ef
0.
30
Le
nt
il,
 p
ea
 a
nd
 
be
an
 s
ou
p
0.
39
Co
rn
0.
34
H
ot
do
gs
-0
.3
3
M
us
hr
oo
m
s
0.
39
H
am
bu
rg
er
s
0.
33
Eg
gs
-0
.3
4
Pi
ne
ap
pl
es
0.
38
Be
ef
 s
te
w
 o
r p
ot
pi
e
0.
33
Lu
nc
hm
ea
t
-0
.3
9
82
Chapter 4
Ta
bl
e 
1 
  C
on
tin
ue
d.
Fo
od
 it
em
Fr
ui
ts
 a
nd
 
ve
ge
ta
bl
es
 
pa
tt
er
n 
 
(F
ac
to
r 1
)b
Fo
od
 it
em
W
es
te
rn
 
pa
tt
er
n
(F
ac
to
r 2
)b
Fo
od
 it
em
Lo
w
-f
at
 
pa
tt
er
n
(F
ac
to
r 3
)
Fo
od
 it
em
Te
x-
M
ex
 
pa
tt
er
n 
(F
ac
to
r 4
)
O
ra
ng
es
0.
38
Po
rk
 a
nd
 h
am
0.
32
M
ay
on
na
is
e
-0
.4
5
Ki
w
is
0.
38
Po
ta
to
es
0.
32
Sa
la
d 
dr
es
si
ng
-0
.4
6
Pe
ar
s
0.
37
Sa
us
ag
es
0.
32
D
ai
ry
-0
.4
8
To
m
at
oe
s
0.
37
W
in
e
-0
.3
9
G
ar
lic
0.
37
Ve
ge
ta
bl
e 
so
up
0.
35
Be
et
s
0.
35
a  T
he
 ta
bl
e 
sh
ow
s 
an
y 
fo
od
 it
em
 o
r f
oo
d 
gr
ou
p 
w
ith
 a
 fa
ct
or
 lo
ad
in
g 
gr
ea
te
r t
ha
n 
0.
30
b  
Fo
r F
ac
to
r 1
 a
nd
 2
, o
nl
y 
th
e 
to
p 
20
 fa
ct
or
 lo
ad
in
gs
 a
re
 d
is
pl
ay
ed
83
Dietary patterns and recurrence
4
Table 2  Baseline Characteristics of 595 NMIBC Patients by Tertiles of Western  
Dietary Patterna
Western Dietary Pattern
Tertile 1 (n=199) Tertile 2 (n=199) Tertile 3 (n=197)
No. % No. % No. %
Ageb, years 62.5 (10.4) 63.3 (12.1) 66.0 (9.4)
Follow upb, months 79.9 (39.0) 70.7 (38.1) 63.2 (40.5)
Sex
   Male 159 79.9 158 79.4 158 80.2
   Female 40 20.1 41 20.6 39 19.8
Body mass indexb,c, 
continuous
27.5 (4.2) 27.9 (4.7) 29.1 (6.1)
Body mass indexd
   Underweight 1 0.5 1 0.5 2 1.0
   Normal weight 54 27.1 53 26.6 43 21.8
   Overweight 97 48.7 85 42.7 82 41.6
   Obese 45 22.6 59 29.7 70 35.5
   Unknown/Missing 2 1.0 1 0.5 0 0.0
Energyb, kcal 2322.9 (1053.0) 2319.8 (975.8) 2354.0 (847.1)
Smoking status
   Never smoker 67 33.7 53 26.6 52 26.5
   Former smoker 98 49.3 106 53.3 91 46.4
   Current smoker 34 17.1 40 20.1 53 27.0
Smokingb, pack years 32.3 (27.3) 38.4 (27.8) 46.8 (33.9)
Education
   ≤12 years 31 15.6 45 22.6 79 40.1
   13-15 years 46 23.1 64 32.2 64 32.5
   ≥16 years 118 59.3 89 44.7 51 25.9
   Unknown/Missing 4 2.0 1 0.5 3 1.5
Incomee
   <25.000 11 5.5 17 8.5 31 15.7
   25.000-50.000 29 14.6 29 14.6 50 25.4
   ≥50.000 127 63.8 114 57.3 79 40.1
   Unknown/Missing 32 16.1 39 19.6 37 18.8
Stage
   Tis 94 47.2 82 41.2 81 41.1
   Ta 9 4.5 11 5.5 13 6.6
   T1 94 47.2 102 51.3 102 51.8
   Unknown/Missing 2 1.0 4 2.0 1 0.5
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Table 2   Continued.
Western Dietary Pattern
Tertile 1 (n=199) Tertile 2 (n=199) Tertile 3 (n=197)
No. % No. % No. %
Grade
   1 7 3.5 6 3.0 5 2.5
   2 65 32.7 62 31.2 66 33.5
   3 120 60.3 118 59.3 121 60.8
   Unknown/Missing 7 3.5 13 6.5 5 2.5
Treatment
   TUR 58 29.2 59 29.7 48 24.4
   TUR + iBCGf 59 29.7 52 26.1 54 27.4
   TUR + mBCGg 47 23.6 53 26.6 53 26.9
   Other 35 17.6 35 17.6 42 21.3
Focality
   One tumor 89 44.7 68 34.2 58 29.4
   Two tumors 18 9.1 19 9.6 18 9.1
   ≥ three tumors 41 20.6 49 24.6 53 26.9
   Unknown/Missing 51 25.6 63 31.7 68 34.5
Concomitant CISh
   Present 72 36.2 69 34.7 59 30.0
   Not present 116 58.3 114 57.3 119 60.4
   Unknown/Missing 11 5.5 16 8.0 19 9.6
Medical historyi
   Coronary heart 
   Disease
28 14.1 33 16.6 48 24.4
   Hypertension 75 37.7 95 47.7 103 52.3
   Diabetes Mellitus 
   type II
17 8.5 30 15.1 44 22.3
   Other comorbiditiesj 69 11.6 61 10.3 96 16.1
a For all patterns, the higher tertiles are indicative of higher intake of that diet; b Mean (SD); c Weight (kg)/height 
(m2); d <18.5=underweight, 18.5-24.9=normal weight, 25-29.9=overweight, ≥30=obese; e Income per year; 
f induction BCG; g maintenance BCG;  h Carcinoma in situ; i number and percentage of patients in whom disease 
is present; j Chronic obstructive pulmonary disease, peptic disease, liver disease, chronic renal failure, renal 
stones, diseases of the central nervous system, diseases of the endocrine system, benign hyperplasia
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A sensitivity analysis excluding all patients who experienced recurrence or progression 
within 90 days after diagnosis did not materially alter these associations (data not shown). 
The association of dietary patterns with risk of recurrence did not differ by tumor grade. 
When the analyses were restricted to BCG-treated patients only, similar associations with 
risk of recurrence and progression were found (Supplementary Table 4).
Discussion
In this study, we observed that adherence to a Western dietary pattern, high in fried food 
and red and processed meat was associated with a higher risk of NMIBC recurrence. No 
statistically significant associations were observed for the fruits and vegetables pattern, 
low-fat pattern, and Tex-Mex pattern. 
 To our knowledge, we are the first to study the association of dietary patterns with 
UBC prognosis. As is the case for all single studies, it is not possible to draw conclusions 
based on our findings only. However, several mechanisms that are known or proposed to 
play a role in cancer prognosis might explain and support our results. Potentially harmful 
substances present in the Western diet, such as N-nitroso-compounds, polycyclic aromatic 
hydrocarbons and heterocyclic aromatic amines in red meat, are excreted in the urine. 
Therefore they come into close contact with the inner lining of the bladder wall and may 
directly exert a carcinogenic effect on urothelial cells (38, 39). Our finding that having a 
Western diet is associated with higher risk of NMIBC recurrence might endorse this theory. 
A recent meta-analysis on dietary patterns and cancer prognosis also showed an 
association of a Western diet with risk of recurrence for colorectal cancer but not for breast 
cancer (40). 
 Likewise, potentially beneficial substances from fruits and vegetables such as 
antioxidants, phenols, flavonoids and phytochemicals may be involved in carcinogenesis 
by acting directly on the bladder epithelium when excreted in the urine (10, 41). 
Furthermore, they may be involved in numerous other carcinogenic pathways, one of 
which is the reduction of oxidative stress and DNA damage caused by free radicals (14). 
Nevertheless, results from factor analysis underpinning these hypotheses are scarce. In 
this study, we did not find an association of a fruits and vegetables pattern with risk of 
recurrence. This is in line with a US study in 239 NMIBC and MIBC patients, which found no 
associations for total fruit and vegetables consumption with cancer-specific mortality, 
except for an inverse association of more than one compared to less than one serving of 
raw broccoli per month (24). Also for other cancers, no associations for a healthy/prudent 
dietary pattern with risk of recurrence were found in a recent meta-analysis of four studies 
conducted in breast, colorectal or head and neck cancer patients (40). 
 The Tex-Mex pattern is based on an American regional cuisine which is quite specific 
for the area where this study was conducted. Except for two studies on renal cancer risk 
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(42) and lung cancer risk (43), no studies reported about this pattern before. The Tex-Mex 
pattern contains potentially beneficial components such as legumes, as well as potentially 
harmful components such as red meat and pizza. The effects of the nutrients in these 
food items might neutralize each other, possibly explaining why we did not find an 
association. 
 Lastly, we found the dietary pattern ‘low-fat’ in our population. Patients adhering 
most to the low-fat pattern do not necessarily eat healthy but always choose for the 
low-fat or diet option. None of the food items contributing most to this pattern are directly 
linked to cancer, which may explain why we did not find an association. However, a dietary 
intervention trial focusing on fat reduction in early-stage breast cancer patients reported 
an improved relapse-free survival in the intervention compared to the control group. This 
finding supports that fat reduction could possibly lower risk of tumor recurrence (44). 
 This study had several strengths. Most importantly, we are the first to study the 
association of dietary patterns with UBC prognosis. Since UBC is a common malignancy 
with a high burden on quality of life and the health care budget, it is important to 
investigate other strategies to manage the disease besides treatment. Also, we made use 
of a validated FFQ that provided detailed information and was able to capture the cultural 
differences in eating habits in the Houston area. Furthermore, we derived dietary patterns 
using exploratory factor analysis, which we think is the right method considering the lack 
of confirmed findings in the field of diet and bladder cancer prognosis. The variation 
explained by the four patterns we derived is relatively low, but not uncommonly so when 
comparing our results with that of other studies with three or four dietary patterns (45). 
Also, the Western and the fruits and vegetables patterns have been consistently identified 
in literature. There was little overlap between patients in the same tertile for different 
dietary patterns, indicating that energy intake did not play a role of major importance in 
the derivation of factors (Supplementary figures 1-4).
 Potential limitations include all weaknesses associated with the use of self-reported 
measurements such as recall bias and the underreporting of energy intake (46). 
Furthermore, food intake was assessed once and shortly after diagnosis, and referred to 
the year before diagnosis. Post diagnostic diet and dietary changes after diagnosis were 
not assessed but may be most relevant with respect to risk of recurrence and progression. 
Since we decided to include only non-Hispanic whites in our analysis, the associations we 
found may not be generalizable to patients from other ethnic backgrounds. Even though 
we had a reasonable sample size of 595 NMIBC patients, statistical power for detecting an 
association with progression was limited. The stratified analyses had limited power as well, 
which may explain why we did not find any differences by tumor grade. Lastly, we cannot 
rule out any residual and unmeasured confounding that may to some extent explain the 
observed associations.
 In summary, the most important finding of this study is that having a more Western 
dietary pattern was associated with a higher risk of NMIBC recurrence. This finding 
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supports the hypothesis that a Western diet plays a role in the etiology and prognosis of 
cancer. Since diet-disease associations are complex and causality cannot be drawn from 
this observational study, further research is needed to confirm our findings and elucidate 
the association of diet with both muscle invasive and non-muscle invasive UBC prognosis.
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Online Supporting Material 
Supplementary table 1  Baseline Characteristics of 595 Non-Muscle Invasive Bladder 
Cancer Patients by Tertiles of Fruits and Vegetables Dietary Patterna
Fruits and Vegetables Pattern
Tertile 1 (n=198) Tertile 2 (n=200) Tertile 3 (n=197)
No. % No. % No. %
Ageb, years 60.5 (11.8) 64.3 (10.1) 66.9 (9.4)
Follow upb, months 73.3 (40.7) 72.2 (40.5) 68.4 (38.0)
Sex
   Male 159 80.3 158 79.0 158 80.2
   Female 39 19.7 42 21.0 39 19.8
Body mass indexb,c, 
continuous
28.4 (5.2) 28.3 (5.4) 27.7 (4.8)
Body mass indexd
   Underweight 1 0.5 2 1.0 1 0.5
   Normal weight 44 22.2 50 25.0 56 28.4
   Overweight 90 45.5 86 43.0 88 44.7
   Obese 61 30.8 61 30.5 52 26.4
   Unknown/Missing 2 1.0 1 0.5 0 0.0
Energyb, kcal 2248.7 (1075.0) 2386.0  (960.3) 2361.4 (831.8)
Smoking status
   Never smoker 52 26.3 54 27.0 66 33.7
   Former smoker 84 42.4 102 51.0 109 55.6
   Current smoker 62 31.3 44 22.0 21 10.7
Smokingb, pack years 44.3 (32.4) 39.6 (31.0) 33.5 (26.3)
Education
   ≤12 years 75 37.9 53 26.5 27 13.7
   13-15 years 54 27.3 63 31.5 57 28.9
   ≥16 years 66 33.3 81 40.5 111 56.4
   Unknown/Missing 3 1.5 3 1.5 2 1.0
Incomee
   <25.000 24 12.1 21 10.5 14 7.1
   25.000-50.000 45 22.7 36 18.0 27 13.7
   ≥50.000 91 46.0 108 54.0 121 61.4
   Unknown/Missing 38 19.2 35 17.5 35 17.8
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Supplementary table 1  Continued.
Fruits and Vegetables Pattern
Tertile 1 (n=198) Tertile 2 (n=200) Tertile 3 (n=197)
No. % No. % No. %
Stage
   Tis 89 45.0 90 45.0 78 39.6
   Ta 11 5.6 13 6.5 9 4.6
   T1 96 48.5 95 47.5 107 54.3
   Unknown/Missing 2 1.0 2 1.0 3 1.5
Grade
   1 7 3.5 5 2.5 6 3.0
   2 63 31.8 69 34.5 61 31.0
   3 118 59.6 121 60.5 120 60.9
   Unknown/Missing 10 5.1 5 2.5 10 5.1
Treatment
   TUR 58 29.3 56 28.0 51 25.9
   TUR + iBCGf 61 30.8 49 24.5 55 27.9
   TUR + mBCGg 43 21.7 60 30.0 50 25.4
   Other 36 18.2 35 17.5 41 20.8
Focality
   One tumor 71 35.9 70 35.0 74 37.6
   Two tumors 14 7.1 21 10.5 20 10.2
   ≥ three tumors 50 25.3 47 23.5 46 23.4
   Unknown/Missing 63 31.8 62 31.0 57 28.9
Concomitant CISh
   Present 64 32.3 63 31.5 73 37.1
   Not present 122 61.6 121 60.5 106 53.8
   Unknown/Missing 12 6.1 16 8.0 18 9.1
Medical historyi
   Coronary heart Disease 35 17.7 40 20.0 34 17.3
   Hypertension 87 43.9 93 46.5 93 47.2
   Diabetes Mellitus type II 32 16.2 31 15.5 28 14.1
   Other comorbiditiesj 76 12.8 77 12.9 73 12.3
a For all patterns, the higher tertiles are indicative of higher intake of that diet; b Mean (SD); c Weight (kg)/height (m2); 
d <18.5=underweight, 18.5-24.9=normal weight, 25-29.9=overweight, ≥30=obese; e Income per year; f induction 
BCG; g maintenance BCG; h Carcinoma in situ; i number and percentage of patients in whom disease is present; 
j Chronic obstructive pulmonary disease, peptic disease, liver disease, chronic renal failure, renal stones, diseases of 
the central nervous system, diseases of the endocrine system, benign hyperplasia
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Supplementary table 2  Baseline Characteristics of 595 Non-Muscle Invasive Bladder  
Cancer Patients by Tertiles of Low-Fat Dietary Patterna
Low-Fat Pattern
Tertile 1 (n=199) Tertile 2 (n=198) Tertile 3 (n=198)
No. % No. % No. %
Ageb, years 62.9 (11.5) 65.5 (10.0) 63.3 (10.8)
Follow upb, months 71.8 (38.4) 69.0 (40.6) 73.2 (40.2)
Sex
   Male 159 79.9 157 79.3 159 159
   Female 40 20.1 41 20.7 39 19.7
Body mass indexb,c, 
continuous
28.1 (5.4) 27.8 (4.6) 28.6 (5.3)
Body mass indexd
   Underweight 3 1.5 0 0.0 1 0.5
   Normal weight 47 23.6 56 28.3 47 23.7
   Overweight 93 46.7 90 45.5 81 40.9
   Obese 55 27.6 52 26.3 67 33.8
   Unknown/Missing 1 0.5 0 0.0 2 1.0
Energyb, kcal 2471.1  (939.6) 2165.2  (957.3) 2359.5 (966.6)
Smoking status
   Never smoker 44 22.1 58 29.4 70 35.4
   Former smoker 92 46.2 98 49.8 105 53.0
   Current smoker 63 31.7 41 20.8 23 11.6
Smokingb, pack years 43.8 (33.5) 39.9 (30.2) 33.3 (25.4)
Education
   ≤12 years 61 30.7 55 27.8 39 19.7
   13-15 years 65 32.7 58 29.3 51 25.8
   ≥16 years 69 34.7 82 41.4 107 54.0
   Unknown/Missing 4 2.0 3 1.5 1 0.5
Incomee
   <25.000 23 11.6 18 9.1 18 9.1
   25.000-50.000 38 19.1 35 17.7 35 17.7
   ≥50.000 102 51.3 105 53.0 113 57.1
   Unknown/Missing 36 18.1 40 20.2 32 16.2
Stage
   Tis 80 40.2 79 39.9 98 49.5
   Ta 12 6.0 13 6.6 8 4.0
   T1 103 51.8 103 52.0 92 46.5
   Unknown/Missing 4 2.0 3 1.5 0 0.0
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Supplementary table 2  Continued.
Low-Fat Pattern
Tertile 1 (n=199) Tertile 2 (n=198) Tertile 3 (n=198)
No. % No. % No. %
Grade
   1 4 2.0 5 2.5 9 4.5
   2 57 28.6 66 33.3 70 35.4
   3 131 65.8 115 58.1 113 57.1
   Unknown/Missing 7 3.5 12 6.1 6 3.0
Treatment
   TUR 60 30.2 55 27.8 50 25.3
   TUR + iBCGf 57 28.6 54 27.3 54 27.3
   TUR + mBCGg 54 27.1 44 22.2 55 27.8
   Other 28 14.1 45 22.7 39 19.7
Focality
   One tumor 75 37.7 77 38.9 63 31.8
   Two tumors 19 9.6 17 8.6 19 9.6
   ≥ three tumors 50 25.1 42 21.2 51 25.8
   Unknown/Missing 55 27.6 62 31.3 65 32.8
Concomitant CISh
   Present 63 31.7 65 32.8 72 36.4
   Not present 117 58.8 117 59.1 115 58.1
   Unknown/Missing 19 9.6 16 8.1 11 5.6
Medical historyi
   Coronary heart disease 32 16.1 37 18.7 40 20.2
   Hypertension 83 41.7 97 49.0 93 47.0
   Diabetes Mellitus type II 21 10.6 33 16.7 37 18.7
   Other comorbiditiesj 81 13.6 73 12.3 72 12.1
a For all patterns, the higher tertiles are indicative of higher intake of that diet; b Mean (SD); c Weight (kg)/height (m2); d 
<18.5=underweight, 18.5-24.9=normal weight, 25-29.9=overweight, ≥30=obese; e Income per year; f induction BCG; g 
maintenance BCG;  h Carcinoma in situ; i number and percentage of patients in whom disease is present; j Chronic 
obstructive pulmonary disease, peptic disease, liver disease, chronic renal failure, renal stones, diseases of the central 
nervous system, diseases of the endocrine system, benign hyperplasia
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Supplementary table 3  Baseline Characteristics of 595 Non-Muscle Invasive Bladder 
Cancer Patients by Tertiles of Tex-Mex Dietary Patterna
Tex-Mex Pattern
Tertile 1 (n=199) Tertile 2 (n=199) Tertile 3 (n=197)
No. % No. % No. %
Ageb, years 67.9 (9.8) 63.3 (9.7) 60.5 (11.5)
Follow upb, months 74.5 (41.4) 75.4 (42.3) 63.9 (34.1)
Sex
   Male 159 79.9 158 79.4 158 80.2
   Female 40 20.1 41 20.6 39 19.8
Body mass indexb,c, 
continuous
27.7 (4.6) 27.7 (4.8) 29.0 (5.8)
Body mass indexd
   Underweight 3 1.5 1 0.5 0 0.0
   Normal weight 52 16.1 56 28.1 42 21.3
   Overweight 81 40.7 89 44.7 94 47.7
   Obese 61 30.7 53 26.6 60 30.5
   Unknown/Missing 2 1.0 0 0.0 1 0.5
Energyb, kcal 2343.1  (983.5) 2244.1  (964.9) 2410.1 (932.1)
Smoking status
   Never smoker 55 27.6 52 26.3 65 33.0
   Former smoker 104 52.3 104 52.5 87 44.2
   Current smoker 40 20.1 42 21.2 45 22.8
Smokingb, pack years 44.0 (33.5) 38.9 (29.1) 34.7 (27.4)
Education
   ≤12 years 73 36.7 49 24.6 33 16.8
   13-15 years 56 28.1 62 31.2 56 28.4
   ≥16 years 66 33.2 85 42.7 107 54.3
   Unknown/Missing 4 2.0 3 1.5 1 0.5
Incomee
   <25.000 32 16.1 18 9.1 9 4.6
   25.000-50.000 45 22.6 41 20.6 22 11.2
   ≥50.000 76 38.2 115 57.8 129 65.5
   Unknown/Missing 46 23.1 25 12.6 37 18.8
Stage
   Tis 95 47.7 70 35.2 92 46.7
   Ta 10 5.0 18 9.1 5 2.5
   T1 92 46.2 110 55.3 96 48.7
   Unknown/Missing 2 1.0 1 0.5 4 2.0
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Supplementary table 3  Continued.
Tex-Mex Pattern
Tertile 1 (n=199) Tertile 2 (n=199) Tertile 3 (n=197)
No. % No. % No. %
Grade
   1 8 4.0 3 1.5 7 3.6
   2 70 35.2 57 28.6 66 33.5
   3 114 58.8 127 63.8 118 59.9
   Unknown/Missing 7 3.5 12 6.0 6 3.0
Treatment
   TUR 52 26.1 54 27.1 59 30.0
   TUR + iBCGf 58 29.2 59 29.7 48 24.4
   TUR + mBCGg 51 25.6 49 24.6 53 26.9
   Other 38 19.1 37 18.6 37 18.8
Focality
   One tumor 66 33.2 81 40.7 68 34.5
   Two tumors 18 9.1 13 6.5 24 12.2
   ≥ three tumors 55 27.6 46 23.1 42 21.3
   Unknown/Missing 60 30.2 59 29.7 63 32.0
Concomitant CISh
   Present 58 29.2 78 39.2 64 32.5
   Not present 124 62.3 109 54.8 116 58.9
   Unknown/Missing 17 8.5 12 6.0 17 8.6
Medical historyi
   Coronary heart disease 56 28.1 28 14.1 25 12.7
   Hypertension 100 50.3 84 42.2 89 45.2
   Diabetes Mellitus type II 34 17.1 22 11.1 35 17.8
   Other comorbiditiesj 91 15.3 61 10.3 74 12.4
a For all patterns, the higher tertiles are indicative of higher intake of that diet; b Mean (SD); c Weight (kg)/height 
(m2); d <18.5=underweight, 18.5-24.9=normal weight, 25-29.9=overweight, ≥30=obese; e Income per year; f 
induction BCG; g maintenance BCG; h Carcinoma in situ; i number and percentage of patients in whom disease is 
present; j Chronic obstructive pulmonary disease, peptic disease, liver disease, chronic renal failure, renal stones, 
diseases of the central nervous system, diseases of the endocrine system, benign hyperplasia
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Supplementary table 4  Adjusted Associations of Dietary Pattern Score (in Tertile) 
with risk of Recurrence and Progression of 318 NMIBC Patients treated with BCG.
Dietary pattern 
and tertile score
Recurrence/Total 
no. of patients
HR (95% CI) a Progression/Total 
no. of patients
HR (95% CI) a
Fruits and vegetables pattern
Tertile 1 (low) 60/104 1 (referent) 29/104 1 (referent)
Tertile 2 50/109 0.83 (0.55-1.25) 26/109 1.07 (0.58-1.95)
Tertile 3 (high) 48/105 0.70 (0.44-1.11) 28/105 1.23 (0.64-2.37)
 P for trend 0.13 0.53
Western pattern
Tertile 1 (low) 51/106 1 (referent) 26/106 1 (referent)
Tertile 2 49/105 0.95 (0.61-1.47) 23/105 0.90 (0.48-1.67)
Tertile 3 (high) 58/107 1.76 (1.11-2.79) 34/107 1.68 (0.88-3.21)
 P for trend 0.02 0.12
Low-fat pattern
Tertile 1 (low) 59/111 1 (referent) 32/111 1 (referent)
Tertile 2 49/98 0.88 (0.58-1.34) 24/98 0.79 (0.43-1.46)
Tertile 3 (high) 50/109 0.75 (0.50-1.11) 27/109 0.81 (0.44-1.49)
 P for trend 0.16 0.51
Tex-Mex pattern
Tertile 1 (low) 54/109 1 (referent) 29/109 1 (referent)
Tertile 2 61/108 1.33 (0.87-2.02) 34/108 1.19 (0.67-2.10)
Tertile 3 (high) 43/101 0.78 (0.50-1.23) 20/101 0.60 (0.30-1.20)
 P for trend 0.30 0.18
a Adjusted for age, sex, education, income, body mass index, smoking status and intensity, total energy intake, 
grade, tumor multiplicity, concomitant carcinoma in situ, and treatment
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Supplementary figure 1  Overlap in patients who are in the first tertile of  
different dietary patterns.
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Supplementary figure 2  Overlap in patients who are in the second tertile of 
 different dietary patterns.
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Supplementary figure 3  Overlap in patients who are in the third tertile of  
different dietary patterns.
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Although food intake was adjusted for energy intake, we evaluated whether energy intake 
played a role of importance in the derivation of the factors by assessing the proportion of 
patients that have been classified into the same tertile for different dietary patterns. If 
energy intake would play a role, you would expect a large amount of overlap. E.g., a patient 
who is a big eater could be in the third tertile for multiple dietary patterns. 
 To investigate the amount of overlap in patients per tertile as well as overlap in 
patients for all tertiles at the same time,we filled out four-circle venn diagrams. All numbers 
mentioned below can be found in supplementary figures 1 to 4 as well. 
Overlap per tertile
For a study of our size (n=595), you would expect an overlap of roughly 200 patients who 
are in at least two different first (or second or third) tertiles of four dietary patterns, yielding 
a percentage of 25%. A percentage that is much higher than 25% would be reason for 
concern. When we look at the tertiles one by one, the number of patients overlapping is 
very close to what you would expect. This can  be seen in supplementary figures 1 to 3. 
Supplementary figure 4  Overlap in patients in all tertiles of different  
dietary patterns simultaneously.
Fruits and 
vegetables
Western
Low-fat Tex-Mex
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176 174 
201 176 
88 75 
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The percentages we found range between 28.5% and 31.3%, which is in our opinion close 
enough to 25% to ensure that we used the right methodology.
· Overlap at least two patterns first tertile: 226/793*100=28.5%
· Overlap at least two patterns second tertile: 248/793*100=31.3%
· Overlap at least two patterns third tertile: 242/793*100=30.5%
Overlap for all tertiles
When we look at the overlap between all tertiles of the combinations of two patterns 
without considering overlap in the other two patterns at the same time, the percentage 
of overlap ranges between 31% and 36%. This is also close to what you would expect by 
chance. These results can be seen in supplementary figure 4.
The percentage of overlap in two patterns expected by chance = (1/3*1/3+1/3*1/3+1/3*1/3)= 
33.3%, and the following is what we observed:  
· Tex-Mex & Western: 187/595*100=31.4%
· Tex-Mex & Low-fat: 200/595*100=33.6%
· Tex-Mex & Fruits and vegetables: 215/595*100=36.1%
· Western & Low-fat: 192/595*100=32.3%
· Western & Fruits and vegetables: 185/595*100=31.1%
· Low-fat & Fruits and vegetables: 197/595*100=33.1%
The percentage of overlap in three patterns expected by chance = (1/3*1/3*1/3+1/3*1/3*
1/3+1/3*1/3*1/3)=11.1%, and the following is what we observed:  
· Tex-Mex & Western & Low-fat: 61/595*100=10.3%
· Tex-Mex & Western & Fruits and vegetables: 69/595*100=11.6%
· Tex-Mex & Fruits and vegetables & Low-fat: 73/595*100=12.3%
· Western & Fruits and vegetables & Low-fat: 58/595*100=9.7%
The percentage of overlap in all four patterns expected by chance = (1/3*1/3*1/3*1/3+1/3
*1/3*1/3*1/3+1/3*1/3*1/3*1/3)=3.7%, and the following is what we observed:  
· 18/595*100=3.0%
Moreover, in our opinion, there is no clusterization by factors as there is no notable 
difference in overlap between any of the patterns.
Taken together, we think that the dietary patterns identified through factor analysis are 
functioning well in separating the patients. 
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Abstract
Background: Non-muscle-invasive bladder cancer (NMIBC) patients have a high risk of 
recurrence, necessitating a burdensome follow-up program which may impact their 
health-related quality of life (HRQoL).
Methods: We studied HRQoL among 541 recently diagnosed NMIBC patients recruited 
for the prospective cohort study UroLife at 6 weeks, 12 weeks, and 15 months after 
diagnosis, and compared this to an age- and sex-matched normative population. HRQoL 
was assessed with the EORTC QLQ-C30 and the EORTC QLQ-NMIBC24. Also, we assessed 
whether HRQoL differed by treatment modality, smoking status, and fluid intake.
Results: NMIBC patients had a statistically significantly worse role, emotional, and social 
functioning, and reported more fatigue, dyspnoea, insomnia, appetite loss, and diarrhea 
compared to a normative population. Differences were of small clinical importance, 
except for diarrhea, which was of medium clinical importance at 12 weeks (mean 
difference (MD) 9.5; 95% CI 7.2-11.7) and 15 months (MD 9.5; 95% CI 7.2-11.9) after diagnosis. 
HRQoL of NMIBC patients improved over time in most domains, but more appetite loss 
and diarrhea was reported at 12 weeks and 15 months after diagnosis as compared to 6 
weeks after diagnosis. Forty percent of the patients still reported one or more urinary 
symptoms, and 24% reported one or more emotional worries at 15 months after diagnosis. 
Patients treated with intravesical chemotherapy or immunotherapy scored worse on 
several of the QLQ-NMIBC-24 subscales compared to patients treated with transurethral 
resection of the bladder tumour only. Smoking and fluid intake did not have a clinically 
relevant impact on HRQoL. 
Conclusion: Caregivers should be alert as specific domains of HRQoL of NMIBC patients 
are worse than that of the general population, and symptoms and emotional worries may 
be present for a longer period. 
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Introduction
About 70% of urinary bladder cancer (UBC) patients are diagnosed with non-muscle- 
invasive bladder cancer (NMIBC) (1), which has a high survival rate, but tends to recur in 
more than 40% of the patients within five years (2). In addition, high grade T1 tumors have 
a 20% 5-year risk of progression, after which prognosis becomes poor (2, 3). To reduce 
the risk of recurrence and progression, initial surgical treatment with transurethral 
resection of the bladder tumor (TURBT) is mostly complemented with intravesical chemo- 
or immunotherapy. Thereafter, NMIBC patients are subjected to frequent follow-up by 
cystoscopy (4). Intravesical immunotherapy, and to a lesser extent intravesical chemotherapy, 
are often accompanied by side-effects, such as cystitis, urge, dysuria, and incontinence 
(5, 6). These side effects in addition to the minimally invasive follow-up method could 
have a large impact on patients’ health-related quality of life (HRQoL). 
 To date, only a limited number of studies investigated HRQoL in NMIBC patients. 
Two studies showed that mental and/or physical health of NMIBC patients were worse 
compared to a normative population (7, 8). Several studies showed that NMIBC patients 
experienced urinary symptoms and future worries, with problems differing according to 
treatment (7-14). However, some of the studies had a cross-sectional design and could not 
evaluate changes in HRQoL over time. 
 A healthy lifestyle has been linked to better HRQoL in survivors of numerous cancers 
(15-24). NMIBC patients are often advised by their urologist to quit smoking and to increase 
their fluid intake because of the hypothesized effect on recurrence, but the effect of 
smoking and fluid intake on HRQoL has not been investigated in NMIBC patients yet. 
Non-smoking has been linked to better overall quality of life and physical functioning in 
survivors of other cancer types (15, 21, 24). In one (25) out of two studies conducted in UBC 
patients (15, 25), smokers reported increased fear of recurrence and psychological distress 
compared to non-smokers. No evidence is available about the association of fluid intake 
with HRQoL. In this study, we investigated HRQoL among newly diagnosed NMIBC 
patients at 6 weeks, 12 weeks, and 15 months after diagnosis and compared this to an 
age- and sex-matched normative population. Also, we assessed whether HRQoL differed 
according to therapy, smoking status, and fluid intake1. We hypothesized that patients 
treated with immunotherapy, current smokers, and patients with a lower fluid intake 
would report worse HRQoL scores at  the different time points. 
1  No other lifestyle factors were investigated yet as this manuscript will not be submitted to a journal in 
this form. In a future version, other lifestyle factors such as body mass index and physical activity will be 
incorporated.
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Methods
Study design and participants
We used data from a population-based, prospective cohort study on the association of 
dietary and lifestyle habits with prognosis and HRQoL in NMIBC patients, named the 
UroLife study (Urothelial cancer: Lifestyle, prognosis and health-related quality of Life). 
Permission was obtained from all urologists of 22 participating hospitals to identify eligible 
patients in the Netherlands Cancer Registry (NCR), held by the Netherlands Comprehensive 
Cancer Organization (IKNL). Patients with newly diagnosed NMIBC (stage Ta, T1, Tis) 
between April 1, 2014 and April 25, 2017, aged 18 to 80 years old were identified in the NCR 
and invited to participate approximately four weeks after diagnosis. Patients were 
excluded if they did not speak Dutch, if the tumor was not histologically confirmed by 
TURBT, if they had a previous cancer diagnosis in the last five years, positive lymph nodes, 
or distant metastases. The UroLife study received ethical approval from the Committee for 
Human Research region Arnhem-Nijmegen (CMO 2013-494). Written informed consent 
was obtained from all participants. For this preliminary analysis, we included patients 
diagnosed up to March 18, 2016 for whom clinical data were collected in September 2017.
Data collection
Self-reported questionnaire data were collected online or on paper at six weeks (T6wk), 
twelve weeks (T12wk), and fifteen months (T15mo) after diagnosis and consisted of 
questions on socio-demographic characteristics (T6wk only), smoking, comorbidities, and 
HRQoL. Web-based questionnaires were collected via the data collection tool of the 
Patient Reported Outcomes Following Initial treatment and Long term Evaluation of 
Survivorship (PROFILES) registry (26). At T12wk and T15mo, patients filled out a four-day 
fluid and micturition diary. 
HRQoL data collection
HRQoL was assessed using the validated EORTC QLQ-C30 and the EORTC QLQ-NMIBC24 
questionnaires (9, 27). The EORTC QLQ-C30 consists of 30 items comprising of a global 
health status scale, five functioning scales (physical, role, cognitive, emotional, and social 
functioning), and three symptom scales (fatigue, pain, and nausea and vomiting) and six 
single items (dyspnoea, insomnia, loss of appetite, constipation, diarrhea, and financial 
impact). The EORTC QLQ-NMIBC24 consists of 24 items and comprises six scales (urinary 
symptoms, malaise, future worries, bloating and flatulence, sexual functioning, and male 
sexual problems) and five single items (intravesical treatment issues, sexual intimacy, risk 
of contaminating partner, sexual enjoyment, female sexual problems). All items were 
scored on a four-point Likert scale ranging from 1 (not at all) to 4 (very much), except 
global health status, which was answered on a seven-point Likert scale ranging from 1 
(very poor) to 7 (excellent). Scores of items were summed and transformed to calculate 
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subscales ranging from 0 to 100. These procedures have been described in detail 
elsewhere (28). High scores on functioning scales and global health status, and low scores 
on symptom scales and items indicate a better QoL. In addition, a summary score of the 
EORTC QLQ-C30 was calculated by averaging the scores of all subscales and items, except 
global health status and financial impact (29). Results on the EORTC QLQ-C30 of our 
population were compared with normative data on all three time points (30). For this, we 
made use of data of the PROFILES registry. Normative population data was obtained from 
CentERpanel, an online household panel that is representative for the Dutch population. 
The process of the annual data collection has been described elsewhere (30). In 2013, the 
questionnaire was sent to 2,848 panel members ≥18 years, and 2,333 questionnaires were 
returned. Panel members with incomplete questionnaires (n=27) or a previous cancer 
diagnosis within 5 years of completing the questionnaire (n = 119) were excluded, and a 
normative sample (n=541) was matched on age and sex.
Lifestyle data collection
Patients were categorized into current or non-smokers at the time of completing the 
questionnaire. Smoking status was assessed by asking whether patients smoked at the 
time of completing the questionnaire (T12wk and T15mo) or if they had ever smoked in 
the past (T6wk). For the T12wk and T15mo measurements patients were asked whether 
they had smoked or quit smoking since they filled out the last questionnaire. Fluid intake 
was measured with a four-day fluid and micturition diary at T12wk and T15mo. Patients 
filled out how much they drank on those days either in mL or in household measures, and 
average fluid intake in mL per day was calculated.
Covariables
Educational level of the patients was categorized into low (primary-, secondary-, vocational 
education), medium (intermediate vocational education, higher general secondary education, 
pre-university education), and high (university of vocational education, university). Information 
on living situation (partner vs. no partner) and employment (paid job vs. no paid job) was 
also collected.
 To assess comorbidities, an adapted version of the Self-administered Comorbidity 
Questionnaire (SCQ) was used (31), which categorized health problems into heart disease, 
stroke, high blood pressure, lung disease, diabetes, ulcer, kidney disease, anemia or other 
blood disease, thyroid condition, depression, osteoarthritis, back pain, rheumatoid arthritis 
and other medical problems. For analysis, other medical problems were excluded. We 
constructed a sum score of the number of comorbidities patients reported and categorized 
this into no comorbidities, one comorbidity, and two or more comorbidities.
 Detailed clinical data were collected by trained data managers from IKNL by consulting 
the medical records and included tumour stage and grade, focality (unifocal, multifocal, 
unknown), immediate postoperative instillation of chemotherapy (yes, no), and treatment 
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(TURBT only, TURBT with intravesical chemotherapy, TURBT with intravesical immunotherapy). 
Patients who received both intravesical chemotherapy and immuno - therapy for their 
primary tumour were categorized according to which therapy was instilled most often. 
Statistical analysis
Sociodemographic characteristics of NMIBC patients were compared with those of the 
age- and sex-matched normative population using Pearson chi-square tests. We assessed 
the internal consistency of the multi-item scales with the Cronbach’s α coefficient, with 
>0.70 considered acceptable. In addition, we reported floor and ceiling effects (i.e. the 
proportion of patients with the lowest and the highest scores, respectively) for all 
multi-item scales and the number of missing item and scale scores. 
 We calculated mean scores and standard deviations for all EORTC QLQ-C30 and 
QLQ-NMIBC24 scales and items at T6wk, T12wk, and T15mo. Comparisons of differences in 
QLQ-C30 scores between the NMIBC patients and the normative population for each time 
point were made using independent t-tests, and using analysis of covariance adjusted for 
educational level and comorbidity. Differences in QLQ-C30 and QLQ-NMIBC24 scores at 
T12wk and T15mo compared to T6wk were tested using paired t-tests. Analysis of covariance 
was used to evaluate whether scores differed according to treatment modality, smoking 
status at the time of filling out the questionnaire, and fluid intake (per 100 mL increase) at 
the time of filling out the questionnaire, adjusted for age and gender. The analyses for 
therapy were additionally adjusted for undergoing treatment at the time of filling out the 
questionnaire, and the analyses for smoking were additionally adjusted for educational 
level and comorbidity. 
 The clinical relevance of differences in QLQ-C30 scores was interpreted using the 
evidence-based guidelines of Cocks et al. (32, 33). They combined systematic review of 
published literature, expert opinions, and meta-analysis to estimate differences of small, 
medium, and large clinical relevance as opposed to no clinical relevance for most domains. 
The Cohen rule of thumb was used for cross-sectional differences in emotional functioning, 
the summary score, and for the QLQ-NMIBC24 scales, since no guideline was available (34). 
Here, a difference in effect size (mean difference divided by pooled standard deviation) 
of 0.2 is regarded as a small, 0.5 as a medium, and 0.8 as a large effect. 
 Frequency of worries and urinary symptoms that were reported by patients as ‘Quite 
a bit’ or ‘Very much’ in the QLQ-NMIBC24 were calculated for all three time points. Logistic 
regression analyses was used to assess whether therapy, smoking versus not smoking, and fluid 
intake per increase of 100 mL per day were associated with the presence of symptoms. 
All regression analyses were adjusted for age and gender, and the analyses for smoking 
were additionally adjusted for educational level and comorbidity. All tests were two-sided 
and a p-value less than 0.05 was considered statistically significant. All data were analysed 
using IBM SPSS Statistics, Version 22. In future analyses, longitudinal analyses will be 
performed using a form of mixed models . 
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Results
Of 1,114 invited NMIBC patients diagnosed up to March 18, 2016, 582 agreed to participate 
(response rate 52%) (Figure 1). Thereafter, 41 patients were excluded because they had a 
previous cancer diagnosis in the past five years (n=3), clinical data were not yet collected 
(n=11), they had metastases at diagnosis (n=2), a tumour stage >T1 (n=6), did not complete 
their first questionnaire (n=5), filled out T12wk prior to or at the same time as T6wk (n=9), or had 
missing HRQoL data (n=5), leaving a total of 541 patients for inclusion in the analyses.
 Median age of NMIBC patients at diagnosis was 67 years, 79% of patients were men, 
and 75% had a Ta tumour (Table 1). Compared to the normative population, NMIBC 
patients were less educated (p<0.001) and had more comorbidities (p<0.001). 
 Cronbach’s α for the multi-item scales were generally higher than 0.7 and thus 
considered acceptable. Exceptions were cognitive functioning (0.62) and nausea and 
vomiting (0.63) in the EORTC QLQ-C30, and bloating and flatulence (0.57) in the EORTC 
QLQ-NMIBC24 (Supplementary Table I). 
 Mean EORTC QLQ-C30 scores for NMIBC patients at T6wk, T12wk, and T15mo and 
for the normative population are shown in Table 2. In general, statistically significantly 
lower functioning scores and higher symptom scores were observed for NMIBC patients 
compared to the normative population. Differences were of small clinical importance 
for role functioning (T6wk), emotional functioning (T6wk and T12wk), social functioning 
(T6wk), insomnia (T6wk), appetite loss (T12wk and T15mo), and the summary score (T6wk 
and T12wk), also after adjustment for educational level and comorbidity (adjusted mean 
differences not shown). For diarrhea, a difference of medium clinical importance was 
observed at T12wk and T15mo. 
 Among NMIBC patients, small clinically important deteriorations over time were seen 
for appetite loss and diarrhea at T12wk and T15mo. On the other hand, a small clinically 
important improvement was observed for insomnia at T15mo (Table 2; Figure 2).
 Mean EORTC QLQ-NMIBC24 scores for NMIBC patients at T6wk, T12wk, and T15mo 
are shown in Table 3. Improvements of small clinical importance as compared to T6wk 
were observed for urinary symptoms (T12wk), future worries (T15mo), sexual functioning 
(T15mo), intravesical treatment issues (T15mo), and risk of contaminating partner (T12wk). 
At T15mo, improvements of medium clinical importance were seen for urinary symptoms 
and female sexual problems.
 With regard to treatment, patients undergoing intravesical immunotherapy had 
more urinary symptoms, future worries, intravesical treatment issues and a higher 
perceived risk of contaminating their partner during sex at T6wk than patients treated 
with TURBT only (Table 4; Figure 3). At T12wk, these differences were similar, except for 
intravesical treatment issues, where no difference was observed. Symptoms reported 
most often at T6wk were pollakiuria (53%; frequent urination during the day), nocturia 
(35%; frequent urination during the night), and urge to reach a toilet (34%) (Table 5). 
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While fewer symptoms were reported at T12wk and T15mo, 40% reported one or more of 
the urinary symptoms at T15mo. Emotional concerns were reported by 18% (repeated 
treatments) to 29% (results from tests and examinations) at T6wk, and frequency (almost) 
halved for all concerns at T15mo, but still 24% reported one or more of the concerns at 
that time. Patients undergoing immunotherapy reported significantly more symptoms 
compared to patients treated with TURBT only for several urinary symptoms (T6wk and/or 
T12wk), sleep disturbance (T12wk), and difficulties leaving home (T6wk and T12wk). 
No significant differences for patients treated with chemotherapy were observed.
Figure 1  Flowchart of patients included in smoking, fluid intake and HRQoL analyses.
43 patients (4%) dropped out before completing
T6wk questionnaires   
541 patients (49%) included in
HRQoL analysis T6wk  
582 patients (52%) who started 
filling out T6wk questionnaires  
 
489 patients (44%) actively or passively 
refused to participate
625 patients (56%) 
with informed consent   
1114 eligible bladder cancer
patients with a date of diagnosis
before March 18, 2016     
41 (4%) patients excluded because of previous 
cancer diagnosis in the past 5 years (n=3)2, 
metastases at diagnosis (n=2)2, tumour stage >T1 
(n=6)2, missing clinical data (n=11)2, incomplete first 
questionnaire (n=5), filling out T2 questionnaire  
prior to or at the same time as T6wk (n=9), missing 
HRQoL data (n=5)
472 patients (42%) included in
HRQoL analysis T12wk 
 
426 patients (38%) included in
HRQoL analysis T15mo  
69 (6%) patients dropped out before completing
T12wk questionnaires  
46 patients (4%) dropped out before completing
T15mo questionnaires  
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Table 1  Sociodemographic characteristics of the NMIBC patients and  
the normative population.
NMIBC patients Normative population
n (%) n = 541 n = 541 p value
Age (years)
>25 - ≤50 26 (5) 26 (5)
>50 - ≤60 116 (21) 116 (21)
>60 - ≤70 212 (39) 212 (39)
>70 - ≤80 183 (34) 174 (32)
>80 - ≤85 4 (1) 13 (2)
Gender
Male 425 (79) 425 (79)
Female 116 (21) 116 (21)
Educational level <0.001
Low 268 (50) 188 (35)
Medium 140 (26) 138 (26)
High 133 (25) 215 (40)
Living situation 0.07
Partner 458 (85) 435 (80)
No partner 83 (15) 106 (20)
Employment 0.19
Paid job 176 (33) 156 (29)
No paid job 365 (68) 385 (71)
Comorbidity
0 87 (16) 154 (29) <0.001
1 136 (25) 178 (33)
≥2 314 (59) 209 (39)
Missing 4 (1) 0 (0)
Tumour stage
Ta 403 (75) n.a.a
T1 120 (22)
Tis 17 (3)
Missing 1 (0.2)
Grade
1 132 (25) n.a.
2 259 (48)
3 148 (28)
Missing 2 (0.4)
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Current smokers had a clinically relevant lower physical functioning (T6wk and T12wk) and 
global health status (T15mo) than non-smokers (Supplementary Table IIa). No differences were 
seen at other time points, nor for other subscales. Fluid intake was not associated with 
the summary score, global health status, or urinary symptoms in a clinically meaningful way 
(data not shown). Smoking and fluid intake at the time of filling out the questionnaire 
were not associated with experiencing symptoms, except that patients with a higher fluid 
intake reported less incontinence at T12wk (Supplementary Table IIb-c).
Table 1  Continued.
NMIBC patients Normative population
n (%) n = 541 n = 541 p value
Focality
Unifocal 365 (68) n.a.
Multifocal 170 (32)
Unknown 6 (1)
Adjuvant therapy
No 271 (50) n.a.
Chemob 138 (26)
BCGb,c 132 (24)
Single instillationd
No 243 (45) n.a.
Yes 298 (55)
a not applicable; b Intravesical; c Bacillus Calmette-Guérin; d Of intravesical chemotherapy.
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Figure 2  Unadjusted mean scores (± 95% CI) of EORTC QLQ-C30 subscales for  
NMIBC patients (light blue) and a normative population (dark blue) at three time points: 
(A) Physical functioning; (B) Role functioning; (C) Emotional  functioning; (D) Cognitive 
functioning; (E) Social functioning; (F) Global health status; (G) Insomnia; (H) Appetite loss;  
(I) Diarrhoea; (J) Summary score. 
* p<0.05 and small clinically important difference, also after adjustment for educational level and comorbidity; 
** p<0.05 and medium clinically important difference, also after adjustment for education level and comorbidity.
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Figure 2   Continued. 
* p<0.05 and small clinically important difference, also after adjustment for educational level and comorbidity; 
** p<0.05 and medium clinically important difference, also after adjustment for education level and comorbidity.
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Table 3  Unadjusted mean scores (± SD) of EORTC QLQ-NMIBC24 subscales for  
NMIBC patients at three time points after diagnosis and mean differencesa compared 
to 6 weeks after diagnosis.
Patient score, mean (SD) Mean difference (95% CI) over time
6 wk 12 wk 15 mo 12 wk vs. 6 wk 15 mo vs. 6 wk
Subscale
Urinary symptoms 28 (21) 22 (19) 18 (16) -5.4 (-6.8, -4.0)b -9.9 (-11.7, -8.1)c
Malaise 3.7 (12) 3.4 (11) 2.5 (9.5) 0.2 (-1.1, 1.4) -0.8 (-1.9, 0.4)
Future worries 34 (24) 30 (23) 25 (21) -4.0 (-5.7, -2.2) -8.5 (-10.4, -6.6)b
Bloating and flatulence 17 (21) 17 (20) 14 (18) 0.0 (-1.5, 1.5) -2.8 (-4.8, -0.7)
Sexual functioning 22 (23) 24 (22) 27 (23) 2.6 (1.0, 4.1) 5.3 (3.4, 7.3)b
Male sexual problems 28 (33) 27 (31) 33 (33) -0.3 (-3.7, 3.0) 4.0 (0.6, 7.4)
Intravesical treatment issues 10 (19) 9.5 (19) 6.2 (16) 0.2 (-1.9, 2.4) -4.0 (-6.2, -1.8)b
Sexual intimacy 14 (22) 10 (20) 10 (19) -4.1 (-7.1, -1.1) -5.7 (-9.4, -1.9)
Risk of contaminating partner 19 (27) 14 (23) 10 (21) -4.7 (-8.5, -1.0)b -11.3 (-16.3, -6.3)b
Sexual enjoyment 55 (30) 57 (26) 58 (29) 3.2 (-0.7, 7.0) 5.3 (0.9, 9.8)
Female sexual problemsd 33 (26) 19 (36) 13 (25) -11.2 (-27.6, 5.4) -23.3 (-43.0, -3.7)c
a Effect sizes interpreted using Cohen’s D (mean difference divided by pooled standard deviation); b p<0.05 and 
small clinically important difference; c p<0.05 and medium clinically important difference; c Only 21, 16, and 21 
women filled out the sexuality questions at T6wk, T12wk, and T15mo, respectively.
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Figure 3  Mean scores (± 95% CI) of EORTC QLQ-C30 and EORTC QLQ-NMIBC24 
subscales at 6 weeks after diagnosis for NMIBC patients by treatment:  
(A) Urinary symptoms; (B) Future worries; (C) Intravesical treatment issues; (D) Risk of 
contaminating partner, adjusted for undergoing treatment at the moment of filling out 
the questionnaire, age and gender. 
* p<0.05 and small clinically relevant difference between intravesical immunotherapy and TURBT only; 
** p<0.05 and medium clinically relevant difference between intravesical immunotherapy and TURBT only.
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Discussion
This study showed that NMIBC patients had a worse self-reported role functioning, 
emotional functioning and social functioning, and reported more fatigue, dyspnoea, 
insomnia, appetite loss, and diarrhea than an age- and sex-matched normative population 
at one or more time points during the fifteen months after diagnosis. Although HRQoL of 
NMIBC patients improved over time in most domains, more appetite loss and diarrhea at 
12 weeks and 15 months compared to 6 weeks after diagnosis were reported, 40% of the 
patients still had urinary symptoms and 24% had one or more emotional concerns at the 
end of follow-up. Patients treated with intravesical immunotherapy scored worse on 
several domains. Smoking and fluid intake did not have a large impact on HRQoL.
NMIBC patients scored worse than a normative population on several HRQoL domains, 
both shortly as well as a longer period after diagnosis. These results are comparable 
to other studies, although the use of different questionnaires hampers the comparison 
(7-9, 14, 35). Among NMIBC patients, differences in HRQoL could possibly be explained by 
treatment, as approximately 50% of the patients in our study underwent intravesical 
chemotherapy or immunotherapy. Although in our study, treatment did not seem to 
have a major impact on domains and symptoms assessed by the QLQ-C30 (data not 
shown), patients undergoing immunotherapy had more urinary symptoms as compared 
to patients treated with TURBT only, as expected (5, 36). Also, patients treated with 
immunotherapy reported more future worries and intravesical treatment issues, which 
may also be partly explained by the fact that they generally have higher risk disease. 
A study in 244 NMIBC patients comparing different treatments using the Bladder Cancer 
Index also found small differences by treatment in subscales only (7). Here, patients treated 
with chemotherapy improved in the sexual domain, and patients treated with immuno- 
therapy improved in the bowel domain at 6 and 12 months after diagnosis, as compared 
to patients treated with TURBT only.  
To our knowledge, increased appetite loss and diarrhea have not been previously reported 
in NMIBC patients, and no association with treatment was found (results not shown). 
The fact that these deteriorations were considered of small or medium clinical importance 
and were still present at T15mo warrants further research into possible determinants. 
Even though the frequency of all reported urinary symptoms decreased from T6wk 
to T15mo, still a substantial part of the patients mentioned suffering from pollakiuria, 
nocturia or urge ‘quite a bit’ or ‘very much’ at T15mo. This was also observed in a study 
from the UK among 410 NMIBC patients who filled out the QLQ-C30 and QLQ-NMIBC24 
four times in the first year after diagnosis (9). Also, the number of patients reporting one 
or more emotional worries was considerable, with almost 40% and 26% at T6wk and 
T12wk, respectively, indicating a potential need for psychological support. 
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We found little evidence for an association of smoking with HRQoL, apart from a lower 
physical functioning at T6wk and T12wk, and lower global health status at T15mo.  Results 
of other studies are conflicting (15, 25). One study from the US in 586 bladder cancer 
patients did not find an association of smoking with global health at 2, 5 or 10 years after 
diagnosis (15), but a small study from the US in 109 NMIBC survivors reported increased 
fear of recurrence and more psychological distress among current versus non-smokers at 
approximately 2 years after diagnosis (25). To our knowledge, we are the first to study the 
association of fluid intake with HRQoL in NMIBC patients. As most symptoms of NMIBC 
patients are probably related to the urinary domain, an association with fluid intake is 
plausible.. Other lifestyle factors, such as physical activity may be more important to 
improve HRQoL and will be incorporated in our analyses in the future (15, 37, 38). Overall, 
there is not enough evidence to draw conclusions if, and if so, to what extent smoking and 
fluid intake are associated with HRQoL in NMIBC patients. 
Due to the growing number of cancer survivors, patient-reported outcomes such as 
HRQoL become increasingly important. The integration of statistical significance and 
clinical relevance is a complicated, but necessary next step in the interpretation of HRQoL 
data (39-41). Small differences within or between patients can become statistically 
significant when sample size is sufficiently large, but the important question whether 
these differences are relevant for patients and clinicians often remains unanswered. Also, 
the use of different HRQoL indices with corresponding guidelines complicates the 
comparison with other studies (10). We also used Cohen’s d as a more uniform measure of 
effect size (34). When a guideline was present to determine whether a difference was 
clinically meaningful, the results were generally in line with the effect sizes as measured 
with Cohen’s d. However, (subtle) differences exist, both between the calculation of 
Cohen’s d in different studies (42) as well as between Cohen’s d and the guidelines. 
Therefore, more effort in a uniform interpretation of HRQoL measures is necessary. 
As with all prospective studies, limitations of this study were mainly related to loss to 
follow-up and missing data. It is possible that patients who had a better health and HRQoL 
were more likely to participate in the measurements at 12 weeks and 15 months, causing 
an overestimation of the HRQoL improvement after diagnosis. Indeed, patients in our 
study who did not complete the second and/or third questionnaires were more likely to 
have lower scores on some of the HRQoL scales and items at 6 weeks after diagnosis. 
However, these differences were not considered clinically relevant. Missing data in the 
HRQoL questionnaires were mainly in the sexuality scales and items, which was not 
unexpected (9, 12). Further, the Dutch version of the QLQ-NMIBC24 is not yet validated, 
and no normative data were available. However, validation studies have been performed 
in Korea and the UK which demonstrated the reliability and validity of the instrument (9, 13). 
As it is reasonable that the complaints that influence HRQoL of NMIBC patients are mainly 
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disease-specific, comparison with normative QLQ-NMIBC24 values is recommended. 
As can be seen in Supplementary Table I, quite some floor and ceiling effects were present, 
and data were seriously skewed, asking for advanced statistical methods (43). However, 
there is no consensus yet about which techniques to use. For these preliminary and mainly 
descriptive analyses of our yet incomplete data, we chose to use t-tests, analysis of 
covariance and logistic regression. For future analyses, longitudinal analyses using a form 
of mixed models will be performed. Mixed models have the advantage to be more flexible 
with regard to non-normally distributed data and are able to handle missing values, 
instead of leaving all missing values out of the analyses. Lastly, even though we had a 
reasonable sample size of 541 NMIBC patients, statistical power to detect differences 
between treatment groups was limited. 
Strengths of the current study include the population-based nature, repeated measurements, 
and the use of a NMIBC-specific module to capture symptoms that may remain unnoticed 
when only using a broader cancer-specific questionnaire. Also, we made use of Dutch 
normative data, validated questionnaires, and guidelines to indicate whether differences 
are considered clinically relevant. High Cronbach’s alpha’s were observed for most multi- 
item scales indicating a high internal consistency also in our study. 
In conclusion, specific domains of HRQoL of NMIBC patients were worse than that of the 
general population but generally improved over time. As several symptoms and emotional 
worries persist for a longer period, caregivers should stay alert. Further research is needed 
into a more uniform analysis and interpretation of the diverse HRQoL measures that are 
available, and into the role of lifestyle in HRQoL.   
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Supplementary Table I  Missing items, floor effects, ceiling effects, and internal 
consistency of scales of the EORTC QLQ-C30 and QLQ-NMIBC24 at six weeks.
n (%)
Missing items Floor effecta Ceiling effectb Cronbach’s α
EORTC QLQ-C30
Functioning scales
Physical 1 (0.2) 0 (0) 225 (42) 0.77
Role 0 (0) 14 (3) 283 (52) 0.89
Emotional 0 (0) 1 (0.2) 185 (34) 0.86
Cognitive 0 (0) 0 (0) 333 (62) 0.62
Social 0 (0) 2 (0.4) 306 (57) 0.77
Global health status 1 (0.2) 1 (0.2) 84 (16) 0.91
Symptom scales
Fatigue 0 (0) 177 (33) 1 (0.2) 0.81
Nausea/vomiting 0 (0) 489 (90) 2 (0.4) 0.63
Pain 0 (0) 309 (57) 3 (0.6) 0.76
Single items
Dyspnoea 0 (0) 379 (70) 10 (2) -
Insomnia 0 (0) 324 (60) 15 (3) -
Appetite loss 0 (0) 477 (88) 4 (0.7) -
Constipation 2 (0.4) 450 (83) 4 (0.7) -
Diarrhoea 1 (0.2) 474 (88) 1 (0.2) -
Financial difficulties 0 (0) 478 (88) 10 (2) -
Summary Score 3 (0) 0 (0) 51 (9) 0.92
EORTC QLQ-NMIBC24
Scales
Urinary symptoms 1 (0.2) 52 (10) 0 (0) 0.85
Malaise 0 (0) 471 (0) 3 (0.6) 0.72
Future worries 1 (0.2) 78 (14) 10 (2) 0.90
Bloating and flatulence 0 (0) 249 (46) 3 (0.6) 0.59
Sexual functioning 42 (8) 202 (37) 3 (0.6) 0.83
Male sexual problems 43 (10)c 163 (38) 32 (8) 0.77
Single items
Intravesical treatment issues 42 (8) 374 (69) 2 (0.4) -
Sexual intimacy 301 (56) 164 (30) 2 (0.4) -
Risk of contaminating partner 303 (56) 139 (26) 10 (2) -
Sexual enjoyment 303 (56) 41 (8) 26 (5) -
Female sexual problems 95 (82)d 5 (4) 1 (0.9) -
a The proportion of patients with the lowest possible response; b The proportion of patients with the highest 
possible response; c 43 out of 425 men; d 95 out of 116 women.
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Supplementary Table IIa  Unadjusted mean scores (± SD) of a selection of EORTC 
QLQ-C30 and EORTC QLQ-NMIBC24 subscales for NMIBC patients at three time points 
after diagnosis according to smoking status.
Non 
smokersa,b
Current 
smokersa
Mean difference (95% CI) 
Current vs. non smokersa
Subscales
Physical functioning, 6 wk 88 (1.4) 83 (2.0) -5.4 (-9.1, -1.7)c
Physical functioning, 12 wk 87 (1.5) 81 (2.2) -5.8 (-9.9, -1.6)c
Physical functioning, 15 mo 86 (1.5) 82 (2.3) -3.4 (-7.9, 1.1)
Global health status, 6 wk 75 (1.7) 72 (2.4) -2.9 (-7.3, 1.4)
Global health status, 12 wk 75 (1.6) 71 (2.4) -4.6 (-9.2, 0.1)
Global health status, 15 mo 78 (1.7) 71 (2.6) -7.7 (-12.8, -2.5)c
Summary score, 6 wk 87 (1.0) 84 (1.5) -2.7 (-5.4, -0.1)
Summary score, 12 wk 86 (1.2) 83 (1.8) -3.4 (-6.9, 0.1)
Summary score, 15 mo 87 (1.2) 86 (1.9) -0.9 (-4.8, 2.8)
Urinary symptoms, 6 wk 26 (1.8) 25 (2.6) -0.7 (-5.4, 3.9)
Urinary symptoms, 12 wk 19 (1.7) 21 (2.5) 2.0 (-2.9, 6.8)
Urinary symptoms, 15 mo 16 (1.4) 16 (2.2) 0.3 (-4.1, 4.6)
Future worries, 6 wk 40 (2.0) 37 (2.9) -2.9 (-8.2, 2.4)
Future worries, 12 wk 32 (2.0) 35 (2.9) 2.8 (-2.9, 8.5)
Future worries, 15 mo 26 (1.9) 27 (2.9) 1.6 (-4.2, 7.4)
Male sexual problems, 6 wk 24 (2.6) 25 (4.4) 0.9 (-8.0, 9.7)
Male sexual problems, 12 wk 24 (2.6) 28 (4.9) 3.5 (-6.4, 13.4)
Male sexual problems, 15 mo 29 (2.7) 37 (5.7) 7.3 (-4.4, 19.0)
a Smoking status at the time of filling out the questionnaire; b Including former smokers; c p<0.05 and small 
clinically important difference, also after adjustment for age, gender, educational level and comorbidities.
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Supplementary Table IIb  The association of smoking with frequency of urinary 
symptomsa of NMIBC patients during fifteen months after diagnosis.
Time after diagnosis OR (95% CI) for current smokers vs. non-smokersb
6 wk 12 wk 15 mo
Pollakiuria 0.95 (0.61, 1.48) 1.06 (0.64, 1.76) 1.12 (0.63, 1.97)
Nocturia 1.04 (0.65, 1.66) 1.32 (0.76, 2.28) 0.91 (0.47, 1.78)
Urge 0.99 (0.62, 1.59) 1.30 (0.74, 2.27) 0.73 (0.34, 1.56)
Dysuria 0.84 (0.47, 1.48) 1.33 (0.60, 2.94) 0.77 (0.22, 2.73)
Sleep disturbancec 1.13 (0.63, 2.02) 1.68 (0.82, 3.46) 0.69 (0.23, 2.10)
Difficulties in leaving homec 1.02 (0.52, 1.98) 1.43 (0.61, 3.31) 0.96 (0.30, 3.10)
Incontinence 0.78 (0.22, 2.80) 2.00 (0.82, 4.89) 1.55 (0.45, 5.37)
a Patients answering ‘Quite a bit’ or ‘Very much’; b Odds ratio (OR) for smoking vs. not smoking at time of filling 
out the questionnaire, adjusted for age, gender, education, and comorbidities using logistic regression;  c 
Because of voiding problems.
Supplementary Table IIc  The association of fluid intake with frequency of urinary 
symptomsa of NMIBC patients at 12 weeks and 15 months after diagnosis.
Time after diagnosis OR (95% CI) for 100 ml increase in fluid intakeb
12 wk 15 mo
Pollakiuria 0.99 (0.95, 1.03) 0.99 (0.94, 1.03)
Nocturia 1.00 (0.96, 1.05) 0.99 (0.95, 1.04)
Urge 1.00 (0.96, 1.05) 1.01 (0.95, 1.07)
Dysuria 0.98 (0.92, 1.05) 0.98 (0.88, 1.08)
Sleep disturbancec 1.00 (0.94, 1.06) 0.96 (0.88, 1.05)
Difficulties in leaving homed 1.00 (0.93, 1.08) 1.10 (1.01, 1.20)d
Incontinence 0.86 (0.76, 0.97)d 0.94 (0.84, 1.05)
a Patients answering ‘Quite a bit’ or ‘Very much’; b Odds ratio (OR) per 100 mL increase at time of filling out the 
questionnaire, adjusted for age and gender using logistic regression; c Because of voiding problems; d Significant 
at the p<0.05 level.
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Abstract 
Background: Data on urinary bladder cancer (UBC) patients’ perceptions about causes of 
bladder cancer is limited, while this may be important knowledge for health prevention 
and education. We evaluated self-reported perceptions and beliefs about the causes of 
bladder cancer among UBC survivors in the Netherlands.
Methods: UBC survivors identified through the Netherlands Cancer Registry from 2007 
to 2012 were invited to participate. Patients who consented were asked to fill out a 
questionnaire, including questions on lifestyle characteristics, occupational and medical 
history, and family history of cancer. The final question was ‘You have been diagnosed 
with bladder cancer. Do you have any idea what may have been the cause of your cancer?’. 
Results: Of 1793 UBC survivors included, 366 (20%) reported a possible cause for their 
bladder cancer. The most frequently reported suspected causes were smoking (10%), 
occupational exposure (5%), and heredity (2%). Smoking, occupational exposure and 
heredity were mentioned only slightly more frequently by participants with these risk 
factors (11%, 8%, 5%, respectively) compared to the total population.  
Conclusions: Most UBC survivors did not suspect any cause that might have contributed 
to the development of their cancer. Even among participants with established risk factors 
for bladder cancer, these risk factors were not commonly perceived. This finding probably 
reflects the superficial knowledge of risk factors for bladder cancer in the population and 
highlights the importance of effective education on cancer prevention.
Keywords: Urinary Bladder Neoplasms; Survivors; Risk Factors; Qualitative Research; 
Perception; Questionnaires 
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Introduction
Urinary bladder cancer (UBC) is the ninth most frequently diagnosed malignancy in the 
world (1). Due to intensive follow-up and treatment, it has the highest lifetime treatment 
costs per patient of all cancers (2, 3). Cigarette smoking is the best-established risk factor 
in the development of UBC and is involved in the etiology of approximately 50% of all 
cases (4, 5). Other risk factors associated with UBC are occupational exposure to carcinogens 
like aromatic amines and polycyclic aromatic hydrocarbons, chronic urinary tract infection, 
schistosomiasis infection, pelvic radiation, cyclophosphamide treatment, family history 
and specific low-penetrance germline genetic susceptibility (4). Although some studies 
showed that fluid intake and fruit and vegetable consumption may also influence UBC 
risk, evidence is inconsistent (6-8). 
 Knowledge of what cancer survivors perceive as causes of their cancer may provide 
valuable information for health education and prevention initiatives, especially with 
regards to modifiable risk factors that are under the control of patients. Awareness of the 
association between such a risk factor and the disease can enhance the motivation to 
change it (9). For example, patients’ knowledge that tobacco use contributed to their 
disease can help in their motivation to quit smoking (and advise others to do the same). 
This information is important, since risk factors for cancer development may also be 
associated with prognosis (10). Continuation of smoking after diagnosis, for instance, may 
be related to higher rates of recurrence and increased risk of morbidity and mortality (11, 
12), although the literature on this topic is inconsistent (13). 
 Despite the importance of knowledge on this topic, the literature is sparse. Five 
previous studies suggested poor knowledge regarding smoking as a risk factor for UBC 
among urological (9, 14) and, more specific, UBC (9, 15-17) patients. In this study, we 
evaluated self-reported perceptions and beliefs about the causes of bladder cancer 
among UBC survivors in the Netherlands. We took a different approach from most of the 
previous studies and did not ask about knowledge of bladder cancer risk factors in general. 
Instead we inquired about factors that might have led to the patients’ own disease and 
investigated whether the answers differed according to their reported risk factors.    
Materials and methods
Self-reported causes of bladder cancer were evaluated among Dutch UBC survivors. Data 
from the Nijmegen Bladder Cancer Study (NBCS) were used (18). The population consisted 
of men and women diagnosed with UBC in one of seven hospitals in the eastern part of 
the Netherlands between 1995 and 2011 and recruited for the study between 2007 and 
2012. Participants had to be younger than 75 years at diagnosis. Patients were identified 
through the Netherlands Cancer Registry (NCR) held by the Netherlands Comprehensive 
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Cancer Organisation (IKNL). All eligible UBC survivors received an invitation letter and 
information brochure. The information brochure highlighted the need for etiological 
research into risk factors for UBC. Lifestyle factors (e.g. nutrition), smoking and heredity 
were mentioned as established or probable risk factors for UBC in this information 
brochure. The response rate to the questionnaire was 65%. The questionnaire included 
questions on socio-demographic and lifestyle characteristics, physical activity, occupational 
history, medical history, use of medicines, and family history of cancer. The final question: 
‘You have been diagnosed with bladder cancer. Do you have any idea what may have 
been the cause of your cancer?’ (No/ Yes, namely…) was evaluated in this study. 
 Categories of perceived causes were based on answers given by the participants and 
were presented as groups of risk factors (smoking; passive smoking; environmental and 
chemical exposure; occupational exposure; heredity; history of bladder polyps; bladder 
infections; other medical condition/intervention; medication; lifestyle; micturition/fluid 
intake; stress; treatment delay; don’t know/other). Participants were allowed to give 
multiple answers to the final question. We also stratified the answers by smoking status, 
family history of UBC, and occupational exposure status to verify whether patients who 
were ‘exposed’ to these risk factors acknowledged these as potential causes. We further 
stratified for sex, age, education and marital status.
 The institutional review board approved the NBCS and all participants provided 
written informed consent. The Statistical Package for Social Sciences (SPSS, version 20.0) 
was used to create the tables and compare groups using Pearson chi-square test. P-values 
of less than 0.05 were considered statistically significant.
Results
In this study, 1793 UBC survivors were included and only 366 (20%) participants reported 
one or more possible causes for their cancer. Table 1 summarizes the sociodemographic 
and clinical characteristics of the total study population and of patients who did and did 
not report a suspected cause, separately. The majority of the participants was male 
(n=1448, 81%) and the median age at completion of the questionnaire was 68 years 
(interquartile range: 61-74 years). Most of the participants were married (n=1439; 80%), and 
had a low educational level (n=1388; 77%). Almost two-thirds of the participants were 
former smokers (n=1164; 65%), 23% (n=417) were current smokers and 12% (n=211) never 
smoked. Self-reported positive family history of UBC was present in 6% (n=103) and 963 
(54%) reported occupational exposure. Comparing participants who did and did not 
report a causal explanation, those with a causal explanation were younger (median age 
64 vs. 69 years) and more likely to have a high educational level (32% vs. 19%). Also, those 
who reported a causal explanation were more likely to have had occupational exposure 
(61% vs. 52%). 
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Table 1  Sociodemographic and clinical characteristics of Dutch bladder cancer 
survivors included in the study.
All bladder cancer 
survivors
N=1793
Participants 
who reported a 
suspected cause
N=366
Participants who 
did not report a 
suspected cause 
N=1427
Age at diagnosis (years)1 63 (56-70) 60 (53-66) 64 (57-70)
Age at completion of 
questionnaire (years)1
68 (61-74) 64 (58-71) 69 (62-74)
Time between diagnosis and 
completion of questionnaire 
(years)1
2 (1-6) 3 (1-7) 2 (1-6)
Body mass index (kg/m2)1,2 25.3 (23.7-27.2) 24.7 (23.2-26.3) 25.4 (23.8-27.5)
Gender
Female
Male
345 (19%)
1448 (81%)
78 (21%)
288 (79%)
267 (19%)
1160 (81%)
Marital status (%)
Married
Living alone
Living together3
1439 (80%)
274 (15%)
80 (5%)
290 (79%)
51 (14%)
25 (7%)
1149 (81%)
223 (16%)
55 (4%)
Educational level (%)4
Low
High
Unknown
1388 (77%)
391 (22%)
14 (1%)
244 (67%)
117 (32%)
5 (1%)
1144 (80%)
274 (19%)
9 (1%)
Currently employed (%)
Yes
No
387 (22 %)
1406 (78%)
115 (31%)
251 (69%)
272 (19%)
1155 (81%)
Smoking status5
   Never smoked
   Former smoker
   Current smoker
211 (12%)
1164 (65%)
417 (23%)
44 (12%)
254 (69%)
68 (19%)
167 (12%)
910 (64%)
349 (24%)
Occupational exposure6 (%)
Yes
No
963 (54%)
830 (46%)
223 (61%)
143 (39%)
740 (52%)
687 (48%)
Positive family history of 
bladder cancer7 (%) 103 (6%) 24 (7%) 79 (6%)
1 Median and interquartile range; 2 Self-reported average BMI (kg/m2) during adult life; 3 Cohabiting or living with 
children; 4 Low (primary education, secondary education and vocational education), high (university and 
university of applied sciences) or unknown; 5 At the  time of filling out the questionnaire; 6 Based on questions 
regarding regular, current or past exposure to chemicals, radiation, and vapors/gases; 7 At least one reported 
first-degree family member with UBC.
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Table 2 summarizes the categories of causal explanations among the total study 
population. Smoking (n=184; 10%), occupational exposure (n=85; 5%) and heredity (n=29; 
2%) were the three most reported causal explanations among all participants. 
Environmental and chemical exposure was cited by 2% (n=28) and stress, other medical 
condition/intervention, medication, lifestyle and micturition/fluid intake were each 
mentioned by approximately 1% of the participants. Medical condition/intervention 
comprises answers such as ‘The bladder tumors are caused by tumor in one kidney’, 
‘Late-effects of radiotherapy for rectal cancer?’. Lifestyle encompassed answers related to 
alcohol and food intake as well as physical activity (e.g. ‘overuse of coffee’, regular alcohol 
user/often chips eater’, ‘lack of exercise’). Other causes that were reported by 0.6% or less 
of the participants are passive smoking, bladder infections, history of polyps, treatment 
delay, and don’t know/other. The category don’t know/other contained a variety of 
answers that could not be placed in other categories, e.g. ‘coincidence’, ‘burns accident at 
age 3.5’ and answers of participants that they did not understand what caused their 
disease since they lived a healthy life. All answers are included in Appendix I.
Table 2  Categories of perceived causes of bladder cancer among all included Dutch 
bladder cancer survivors and among those who reported a suspected cause.
Total of participants
No. giving 
explanation
% of all 
participants
 (n=1793) 
% of participants 
who reported a 
suspected cause 
(n=366)
Smoking 184 10% 50%
Occupational exposure 85 5% 23%
Heredity 29 2% 8%
Stress 26 1% 7%
Bladder infections 8 0.4% 2%
History of polyps 4 0.2% 1%
Environmental and chemical exposure 28 2% 7%
Medication 22 1% 6%
Other medical condition/ intervention 25 1% 7%
Lifestyle 22 1% 6%
Micturition/Fluid intake 20 1% 6%
Passive smoking 9 0.5% 3%
Don’t know/other 11 0.6% 3%
Treatment delay 3 0.2% 1%
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Table 3 summarizes the three most cited categories of causal explanations among the 
total study population, stratified by smoking status, family history of UBC and occupational 
exposure. Former smokers seemed slightly more likely to suggest smoking (143 out of 
1164; 12%) as a cause than current smokers (41 out of 417; 10%) (p=0.18). Among all 
participants who had occupational exposure (n=963), 83 participants (9%) reported 
occupational exposure as a cause of their disease. Two participants who reported 
occupational exposure did not have any occupational exposure according to the 
questionnaire. Lastly, participants with a positive family history for UBC were more likely to 
mention heredity as a causal explanation (5 out of 103; 5%) compared to participants with 
a negative family history (24 out of 1690; 1%) (p=0.02). We also stratified these causal 
explanations by sex, age (≤67 vs. ≥68), education and marital status (data not shown, all 
p-values <0.05). Smoking was more often mentioned as a possible cause by younger 
participants, higher educated participants, and by participants who were living together. 
Occupational exposure was more frequently mentioned by men and younger participants, 
and heredity by higher educated participants.
Table 4 presents examples of reported causes divided into three categories, ‘established 
risk factors for bladder cancer’, ‘unknown or unidentified effect on bladder cancer risk’ and 
‘unlikely to have an effect on bladder cancer risk’. 
Table 3  Perceived established causes of bladder cancer among Dutch bladder cancer 
survivors stratified by presence of these causes.
Stratification Total of 
participants
Participants giving the risk factor as 
a causal explanation (%)
Smoking
Never
Former
Current
1792
211
1164
417
184 (10%)
0 (0%)
143 (12%)
41 (10%)
Occupational exposure
Yes
No
1793
963
830
85 (5%)
83 (9%)
2 (0.2%)
Family history of bladder cancer
Positive
Negative
1793
103
1690
   29 (2%)
5 (5%)
24 (1%)
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Table 4  Selection of examples of perceived causes of bladder cancer of Dutch 
bladder cancer survivors.
Perceived causes Examples of perceived causes given by the participants
Established or  
probable risk factors for 
bladder cancer
Smoking
According to physician due to smoking
Genetically determined
I think because of many bladder infections
Pipe smoking
Late-effects of radiotherapy for rectal cancer
Worked with paint for car spraying for 32 years
Paint spraying
Industrial fabrics
exhaust fumes, maybe paints/dyes
During my work in the clothing industry, I came into contact with 
chemical washing products
Bad luck
Coincidence
Because of prolonged use of first an indwelling catheter and then a 
suprapubic catheter
Unknown or  
unidentified effect on 
bladder cancer risk
Hair dye; Working with pesticides
Working with silkscreen printers, cleaning products, thinners/ink
Cleaning up asbestos
Lots of contact with asbestos
As a child exposed to “passive smoking” a lot
Use of immunosuppressive medication
Use of hormones for half a year during menopause transition
Stress
Use of Selsun shampoo against head lice
Used to prepare tics unprotected
Worked in roofing
Perhaps holding in urine for too long
Fears / anxieties
Benign polyp
Little drinking and urination
Prolonged use of medication against bladder spasms
As a painter, worked extensively with dilutions especially methylene
Laboratory work with the use of many kinds of solvents, e.g. benzene, 
chloroform, acetone, etc.
Spend a lot of time in traffic (20 years)
Frequent antibiotics due to inflammations
Lifestyle nutrition-related
Food
Often French fries eater
Can the chickenpox virus have had an effect?
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Discussion
In this study, we evaluated self-reported causes of bladder cancer among UBC survivors. 
Only 20% reported at least one causal explanation for their cancer. The most common 
causal explanations reported among all participants were smoking (10%), occupational 
exposure (5%) and heredity (2%), all established risk factors for UBC. Most patients who 
were exposed to these risk factors failed to report these factors as potential causes of their 
disease. This is even more striking given the fact that these risk factors were named in the 
invitation brochure as established risk factors.   
 Five studies investigated awareness of smoking as a risk factor for UBC among 
urological (9, 14) and UBC (9, 15-17) patients (Table 5). All studies used a closed question 
and asked about bladder cancer in general, except for one study (16) that only asked 
about the patient’s own disease. Two studies (9, 15) additionally asked about believes 
regarding their own bladder cancer. In a study with 280 urological patients (14), the 
participants were asked to indicate whether smoking, as well as other factors, increased 
the risk of UBC. Only 36% reported smoking as a risk factor for UBC. In a study with 202 
urological patients (9), 118 (58%) of them were aware of the relation between smoking and 
bladder cancer, and 22 of 39 (56%) of currently smoking UBC patients believed that 
smoking was related to their disease. In both studies, no difference by smoking status of 
the patients was observed. Three studies were conducted exclusively among UBC patients 
(15-17). In a study with 78 participants, 12 of 55 ever smokers (22%) were aware of smoking 
as a risk factor for their disease (16). A study with 71 participants reported that 85% was 
aware of smoking as a risk factor for UBC (17). Lastly, a larger study (n=790) showed that 
68% of the patients cited tobacco use as a risk factor for UBC in general (90%, 64% and 61% 
for current, former, and never smokers, respectively) (15). Regarding perceived causes of 
their own disease, tobacco was mentioned by 84% of the current smokers, 48% of the 
Table 4  Continued.
Perceived causes Examples of perceived causes given by the participants
Unlikely to have  
an effect on  
bladder cancer risk
Damage of urethra after prostate surgery
Coffee
Sedatives (Diazepam)
Always worked in a cooling compartment
Heart surgery Geneva, where inner penis was damaged. Thereafter 
several surgeries on penis
Too much Erythrocytes/proteins in urine
Sunburn
Drank a lot of diet sodas with aspartame
Sweeteners.
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Table 5  Overview of literature on perceived causes of bladder cancer in urological  
and bladder cancer patients.
Author (year), 
country
Study sample Bladder cancer  
in general  
or own cancer
Open  
or closed 
question
Question1 Main results
Dearing (2005), 
United Kingdom
55 smoking non-muscle invasive bladder 
cancer patients, year(s) of diagnosis 
unknown
Own bladder cancer Closed Are you aware of smoking as a risk factor for development of 
your disease?
Are you aware that continued smoking could worsen prognosis?
Answered yes:
22%
13%
Nieder (2006),  
USA
280 urological patients presenting in the 
clinic in 2005
Bladder cancer  
in general
Closed Which of the following factors can increase the risk of bladder 
cancer? Increasing age, a high fat diet, a low fiber diet, smoking, 
family history, multiple sex partners, none of these factors and  
do not know.
Perceived smoking as a risk factor:
Bladder: 36%
Anastasiou (2010), 
Greece
202 urological patients of whom 39 
currently smoking bladder cancer 
patients, year(s) of diagnosis unknown
Total population: 
bladder cancer  
in general
Smokers: own bladder 
cancer
Closed All patients:
Are you aware of relation between smoking and… 
… bladder cancer?
Smoking bladder cancer patients:
Do you believe smoking is related to your present problem?
Answered yes:
55% 
56%
Guzzo (2012),  
USA
71 bladder cancer patients diagnosed 
2008-2009
Bladder cancer  
in general
Closed 
Smoking is risk factor for bladder cancer.
Smoking is leading cause of bladder cancer in the United States.
Answered true:
85%
51%
Bassett (2014),  
USA
790 non-muscle invasive bladder cancer 
patients diagnosed 2006-2009
Bladder cancer  
in general and own 
bladder cancer
Closed Based on what you know or believe, can any of the following 
cause bladder cancer in anyone?
Based on what you know or believe, did any of the following 
cause your bladder cancer?
Answered yes2:
Tobacco use: 68%
Chemicals: 54%
Age: 45%
Alcohol: 25%
Holding urine: 20%
Sexual activity: 12%
Answered yes to tobacco use2,3:
Active smokers: 93%
Former smokers: 48%
Never smokers: 8%
Current study,  
The Netherlands
1793 Bladder cancer patients diagnosed 
1995-2011
Own bladder cancer Open You have been diagnosed with bladder cancer. 
Do you have any idea what may have been the cause of  
your cancer?
Smoking: 10%
Occupational exposure: 5%
Heredity: 2%
Environmental and chemical exposure: 2%
Stress: 1%
Medication: 1%
Other medical condition/
intervention: 1%
Lifestyle: 1%
Micturition/fluid  
intake: 1%
1 When exact question was not specified in the article, we formulated a question as accurately as possible based 
on the information provided; 
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Table 5  Overview of literature on perceived causes of bladder cancer in urological  
and bladder cancer patients.
Author (year), 
country
Study sample Bladder cancer  
in general  
or own cancer
Open  
or closed 
question
Question1 Main results
Dearing (2005), 
United Kingdom
55 smoking non-muscle invasive bladder 
cancer patients, year(s) of diagnosis 
unknown
Own bladder cancer Closed Are you aware of smoking as a risk factor for development of 
your disease?
Are you aware that continued smoking could worsen prognosis?
Answered yes:
22%
13%
Nieder (2006),  
USA
280 urological patients presenting in the 
clinic in 2005
Bladder cancer  
in general
Closed Which of the following factors can increase the risk of bladder 
cancer? Increasing age, a high fat diet, a low fiber diet, smoking, 
family history, multiple sex partners, none of these factors and  
do not know.
Perceived smoking as a risk factor:
Bladder: 36%
Anastasiou (2010), 
Greece
202 urological patients of whom 39 
currently smoking bladder cancer 
patients, year(s) of diagnosis unknown
Total population: 
bladder cancer  
in general
Smokers: own bladder 
cancer
Closed All patients:
Are you aware of relation between smoking and… 
… bladder cancer?
Smoking bladder cancer patients:
Do you believe smoking is related to your present problem?
Answered yes:
55% 
56%
Guzzo (2012),  
USA
71 bladder cancer patients diagnosed 
2008-2009
Bladder cancer  
in general
Closed 
Smoking is risk factor for bladder cancer.
Smoking is leading cause of bladder cancer in the United States.
Answered true:
85%
51%
Bassett (2014),  
USA
790 non-muscle invasive bladder cancer 
patients diagnosed 2006-2009
Bladder cancer  
in general and own 
bladder cancer
Closed Based on what you know or believe, can any of the following 
cause bladder cancer in anyone?
Based on what you know or believe, did any of the following 
cause your bladder cancer?
Answered yes2:
Tobacco use: 68%
Chemicals: 54%
Age: 45%
Alcohol: 25%
Holding urine: 20%
Sexual activity: 12%
Answered yes to tobacco use2,3:
Active smokers: 93%
Former smokers: 48%
Never smokers: 8%
Current study,  
The Netherlands
1793 Bladder cancer patients diagnosed 
1995-2011
Own bladder cancer Open You have been diagnosed with bladder cancer. 
Do you have any idea what may have been the cause of  
your cancer?
Smoking: 10%
Occupational exposure: 5%
Heredity: 2%
Environmental and chemical exposure: 2%
Stress: 1%
Medication: 1%
Other medical condition/
intervention: 1%
Lifestyle: 1%
Micturition/fluid  
intake: 1%
2 Answer options for both questions: age, family history, alcohol, diet, tobacco use, “holding” urine, chemical 
exposure, bladder infections or stones, sexually transmitted diseases. No information available for risk factors not 
mentioned in the table; 3 Information only available stratified for smoking status (never, former, active)
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former smokers, and 8% of the never smokers. In our study, we found that a strikingly low 
percentage of both former and current smokers reported smoking as a causal explanation 
for their own cancer (12% vs. 9%, respectively). This suggests that the association between 
smoking and bladder cancer is largely unknown. The open-ended format of the question 
used in our study might have played a role, as well as the choice of answering ‘no’, possibly 
giving participants an easy opportunity to avoid thinking about an explanation. 
Furthermore, ignoring risk factors that might have been within the patients’ control may 
be a strategy to shield themselves against negative emotions such as self-blame (19). 
 To date, only two studies examined perceived causes of UBC among urological or 
UBC patients covering causal explanations other than tobacco (14, 15). Unfortunately, one 
of these studies did not report these results (14). In the other study (15), tobacco was the 
most cited risk factor (68%), followed by chemicals (54%) and age (45%). In our study, only 
7% of all participants believed chemical or occupational exposure might have caused 
their disease, and a mere 8% of occupationally exposed participants mentioned this as a 
cause, even though certain types of occupational exposure are established risk factors. 
Surprisingly, none of our participants mentioned age or aging even though this is an 
established risk factor for cancer in general (20). An explanation may be that only patients 
younger than 75 were recruited. The large difference with the Basset study (15) might be 
explained by the type of question used (true/false question as opposed to our open 
question) or the level of education (higher educated as opposed to the low educational 
level of our study population). Ageing has been reported to be an unknown risk factor in 
patients with other types of cancer as well, e.g. in only two of 22 studies on breast cancer 
participants mentioned age as a risk factor (21). 
 With 2%, heredity was the third most cited explanation, indicating that the role of 
genetics in bladder cancer etiology is not very well known among UBC survivors either. As 
expected, the percentage of participants who reported heredity was higher among 
survivors with a positive family history (5%) compared with participants with a negative 
family history (1%). Still, 5% is almost negligible. In a similar study that we performed 
among patients with prostate cancer, the percentage of patients with a positive family 
history that mentioned heredity was four times higher (19%). In a study that described 
survivors’ beliefs about the causes of prostate, colorectal and breast cancer in general, 
awareness of heredity was much higher than in our study (>75%) (10). This might be 
explained by the role of heredity in these types of cancer being more generally known 
but, again, also by the use of a true/false instead of open question. 
 For some of the causes mentioned by the participants, there is no or inconsistent 
evidence for an association with UBC, or an association is unlikely (table 4). An explanation 
for this might be that the mentioned cause is a well-known risk factor for other cancers or 
is frequently suggested to be a risk factor for cancer by the media, leading patients to 
believe that there is a link with UBC as well. This was also found by previous studies on 
other cancers (10, 22-24). It may be important to proactively address the lack of evidence 
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for these factors as certain beliefs may prevent patients from changing real risk behaviors 
(22). 
 Even though a strikingly low percentage of our participants mentioned a possible 
cause for their UBC, this is not an unusual finding. In a systematic review on perceived 
causes of breast cancer among breast cancer survivors (21), the percentage of perceived 
causes mentioned in the different studies varied greatly, even for well established risk 
factors. For example, heredity was reported as possible cause by only 4% in one study, 
while 71% cited it in another study. Comparing two studies on melanoma also reveals a 
large difference in perceived causes (22, 25). One study. (25) found that only about 
one-third of the participants thought sun exposure could have caused their melanoma, 
while in the other study (22) 80% mentioned this as a possible cause. These differences in 
knowledge may be partly explained by factors such as age, education and country of 
origin.
 In conclusion, the results of this study show that most UBC survivors were not aware 
of any causal explanation for the development of their cancer. Even among participants 
with established risk factors for bladder cancer, these established risk factors were not 
commonly perceived. This finding might reflect the superficial knowledge on risk factors 
for bladder cancer in the population and highlights the importance of effective education 
on bladder cancer risk factors.
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nt
 th
in
ne
rs
, p
ai
nt
 re
m
ov
er
s u
se
d 
as
 a
 p
ai
nt
er
’, ‘I
 th
in
k 
th
e 
re
as
on
 
fo
r t
hi
s 
lie
s 
in
 th
e 
pe
rio
d 
of
 1
98
1-
19
85
 (w
or
k)
’, ‘D
ur
in
g 
th
e 
pe
rio
d 
(1
95
5-
19
67
) I
 w
or
ke
d 
in
 a
 g
ra
ph
ic
s 
co
m
pa
ny
 a
nd
 w
or
ke
d 
a 
lo
t w
ith
 
pr
in
tin
g 
in
ks
 st
ai
ne
d-
so
lv
en
ts
 su
ch
 a
s g
as
ol
in
e,
 d
ie
se
l a
nd
 k
er
os
en
e’,
 ‘S
m
ok
in
g 
so
lv
en
ts
. I
 sp
en
t 1
5 
ye
ar
s o
n 
av
er
ag
e 
8 
ho
ur
s p
er
 m
on
th
 
m
ak
in
g 
pr
in
ts
 in
 a
 p
oo
rly
 v
en
til
at
ed
 a
re
a’,
 ‘T
he
 u
se
 o
f p
es
tic
id
es
’, ‘D
ur
in
g 
ho
m
e 
fu
rn
is
hi
ng
 I 
w
or
ke
d 
w
ith
 N
ov
ilo
n 
ca
rp
et
. 
W
hi
ch
 c
on
ta
in
ed
 a
sb
es
to
s 
an
d 
th
e 
ha
nd
lin
g 
of
 g
lu
e’,
 ‘A
t t
he
 a
ge
 o
f 1
6,
 w
or
ke
d 
ne
ar
 a
 p
ai
nt
 s
ho
p 
fo
r 6
 m
on
th
s.’,
 ‘O
cc
up
at
io
na
l d
is
ea
se
 
th
ro
ug
h 
w
or
k’,
 ‘D
ue
 t
o 
au
to
ge
no
us
 a
nd
 e
le
ct
ric
 w
el
di
ng
 w
or
k,
 n
ot
 t
he
 r
ig
ht
 s
af
et
y 
m
ea
su
re
m
en
ts
 t
ak
en
 (
un
sa
fe
, l
ow
 v
en
til
at
io
n)
’, 
‘B
ec
au
se
 o
f 
m
y 
jo
b,
 d
ai
ly
 c
on
ta
ct
 w
ith
 f
ue
ls
 a
nd
 a
ut
o 
ga
s’,
 ‘A
lw
ay
s 
w
or
ke
d 
in
 a
 c
oo
lin
g 
co
m
pa
rt
m
en
t’, 
‘P
re
pa
ra
tio
ns
 c
yt
os
ta
tic
 f
or
 
ch
em
ot
he
ra
py
’, ‘
U
se
 o
f t
ox
ic
 s
ub
st
an
ce
s’,
 ‘U
si
ng
 g
un
 o
il 
PX
10
 d
ur
in
g 
pe
rio
d 
19
65
-1
99
5’,
 ‘E
xp
os
ed
 t
o 
tr
ic
hl
or
oe
th
yl
en
e,
 fi
ne
 a
sb
es
to
s 
du
st
, m
an
y 
ot
he
r 
so
lv
en
ts
’, ‘
W
or
ki
ng
 w
ith
 s
ilk
sc
re
en
s 
pr
in
te
rs
, c
le
an
in
g 
pr
od
uc
ts
, t
hi
nn
er
s/
in
k’,
 ‘R
oo
fin
g/
ro
of
 c
ov
er
in
g’
, ‘
Pr
oc
es
se
d 
as
be
st
os
. S
aw
in
g 
in
 th
e 
ye
ar
s 
19
69
-1
97
0.
 S
hi
el
di
ng
 h
ea
te
rs
’, ‘P
re
pa
ra
tio
n 
an
d 
di
st
rib
ut
in
g 
cy
to
st
at
ic
’, ‘M
ay
be
 p
ai
nt
s/
dy
es
’, ‘W
or
ke
d 
w
ith
 
pa
in
t 
fo
r 
ca
r 
sp
ra
yi
ng
 fo
r 
32
 y
ea
rs
’, ‘
W
or
ke
d 
w
ith
 h
az
ar
do
us
 s
ub
st
an
ce
s 
(A
rg
on
, E
ld
rin
 e
tc
.)’,
  
 ‘T
he
 u
se
 o
f 
pe
st
ic
id
es
’, ‘
W
or
ki
ng
 w
ith
 
pe
st
ic
id
es
’, ‘
Su
gg
es
te
d 
th
at
 t
hi
s 
m
ay
 b
e 
re
la
te
d 
to
 e
xp
os
ur
e 
to
 c
he
m
ic
al
s 
in
 t
he
 la
bo
ra
to
ry
 (f
or
m
al
de
hy
de
, e
tc
.).
 T
w
o 
co
lle
ag
ue
s 
at
 
th
e 
la
b 
ha
ve
 b
ee
n 
di
ag
no
se
d 
w
ith
 b
la
dd
er
 c
an
ce
r’, 
‘P
ai
nt
 (p
ai
nt
in
g)
’, ‘R
ad
ia
tio
n,
 u
se
d 
to
 p
re
pa
re
 c
yt
os
ta
tic
 u
np
ro
te
ct
ed
’, ‘
W
or
ke
d 
w
ith
 
ep
ox
y 
re
si
n,
 P
er
sp
ex
 a
dh
es
iv
es
, p
ro
ce
ss
in
g 
Pe
rs
pe
x,
 s
ol
ve
nt
s 
(t
hi
nn
er
, t
ol
ue
ne
, t
ur
pe
nt
in
e)
, p
ol
ys
ty
re
ne
, a
cr
yl
ic
’, ‘S
pr
ay
in
g 
ca
rs
 w
ith
ou
t 
pr
op
er
 p
ro
te
ct
io
n’,
 ‘P
ai
nt
 s
pr
ay
in
g 
(la
cq
ue
r)’
, ‘H
an
dl
in
g 
X-
ra
ys
 in
 m
y 
pr
of
es
si
on
, h
an
dl
in
g 
ch
lo
ra
la
ct
ofi
no
l i
n 
m
y 
pr
of
es
si
on
’, ‘
W
or
ke
d 
in
 a
 la
bo
ra
to
ry
 fr
om
 t
he
 a
ge
 o
f 1
6 
to
 2
6’,
 ‘W
or
ki
ng
 w
ith
 a
sb
es
to
s 
(w
hi
ch
 w
as
 fo
rm
er
ly
 u
se
d 
in
 b
ra
ke
 li
ni
ng
)’, 
‘P
er
ha
ps
 d
ye
s/
co
lo
ra
nt
s 
(p
ai
nt
er
)’, 
‘P
es
tic
id
es
 o
r 
di
si
nf
ec
ta
nt
s’,
 ‘U
se
 o
f 
sp
ra
y 
bo
tt
le
 w
he
n 
iro
ni
ng
’, ‘
In
ha
lin
g 
so
lv
en
ts
 fo
r 
in
k’,
  
 ‘C
he
m
ic
al
s 
du
rin
g 
w
or
k’,
 ‘P
la
st
ic
 
pr
oc
es
si
ng
 v
ap
or
s 
(s
ty
re
ne
)’, 
‘W
or
ki
ng
 w
ith
 p
ho
to
 p
ro
ce
ss
in
g 
ch
em
ic
al
s, 
in
ha
la
tio
n 
of
 le
ad
-c
on
ta
in
in
g 
su
bs
ta
nc
es
/g
as
es
 d
ur
in
g 
th
e 
fir
in
g 
of
 a
m
m
o’,
 ‘P
rin
tin
g’
, ‘A
sb
es
to
s’,
 ‘D
ue
 to
 p
ro
fe
ss
io
n’,
 ‘C
he
m
ic
al
s 
du
e 
to
 s
pr
ay
in
g 
an
d 
w
el
di
ng
’, ‘
Te
m
po
ra
ril
y 
ha
nd
lin
g 
ph
ot
og
ra
ph
ic
 
ch
em
ic
al
s 
in
 p
oo
rly
 v
en
til
at
ed
 a
re
as
’, ‘W
or
ke
d 
w
ith
 s
om
e 
re
gu
la
rit
y 
w
ith
 d
up
lic
at
or
 d
ur
in
g 
th
e 
jo
b’,
 ‘C
ar
el
es
sl
y 
w
or
ki
ng
 w
ith
 c
he
m
ic
al
s’,
 
‘U
ra
ni
um
 in
 m
is
si
on
 a
re
a’,
 ‘P
ro
lo
ng
ed
 c
on
ta
ct
 w
ith
 p
rin
tin
g 
in
ks
, a
dh
es
iv
es
 b
oo
kb
in
di
ng
’, ‘
In
ha
le
d 
fo
rm
al
de
hy
de
 v
ap
or
s 
fo
r 8
 y
ea
rs
?’,
 
‘E
le
ct
ro
m
ag
ne
tic
 r
ad
ia
tio
n 
(ra
da
r 
eq
ui
pm
en
t)
’, ‘
La
bo
ra
to
ry
 w
or
k 
w
ith
 t
he
 u
se
 o
f 
m
an
y 
ki
nd
s 
of
 s
ol
ve
nt
s, 
eg
. B
en
ze
ne
, c
hl
or
of
or
m
, 
ac
et
on
e 
et
c’,
 ‘W
or
k’,
 ‘C
le
an
in
g 
up
 a
sb
es
to
s’,
 ‘P
ai
nt
 c
he
m
is
tr
y 
(c
om
po
ne
nt
s)
, i
nd
us
tr
ia
l 
fa
br
ic
s’,
 ‘E
xp
os
ur
e 
to
 h
az
ar
do
us
 s
ub
st
an
ce
s’,
 
‘P
os
si
bl
e 
ca
us
e 
th
at
 I 
do
 n
ot
 ru
le
 o
ut
: s
an
di
ng
 p
la
te
 w
ith
 a
sb
es
to
s’,
  ‘W
el
di
ng
 fu
m
es
’,  
‘L
ab
or
at
or
y 
ac
tiv
iti
es
’.  
 
Pa
ss
iv
e 
sm
ok
in
g
‘A
s 
a 
ch
ild
 e
xp
os
ed
 to
 “p
as
si
ve
 s
m
ok
in
g”
 a
 lo
t’, 
‘S
ec
on
d-
ha
nd
 s
m
ok
in
g,
 w
he
n 
st
ay
in
g 
in
 s
m
ok
y 
en
vi
ro
nm
en
ts
 (f
re
qu
en
tly
) i
t s
ee
m
s 
th
at
 
th
e 
po
ly
ps
 c
om
e 
ba
ck
’, ‘S
ec
on
d-
ha
nd
 s
m
ok
in
g 
fo
r m
an
y 
ye
ar
s’,
 ‘D
ur
in
g 
w
or
k 
I w
as
 a
lw
ay
s 
su
rr
ou
nd
ed
 b
y 
sm
ok
er
s, 
ev
en
 a
ft
er
 I 
ha
d 
qu
it 
m
ys
el
f’, 
‘S
ec
on
d-
ha
nd
 s
m
ok
in
g’
, ‘A
lw
ay
s 
sm
ok
ed
 p
as
si
ve
ly
’, ‘
Fa
th
er
 w
as
 a
 s
m
ok
er
. B
ee
n 
ex
po
se
d 
to
 s
m
ok
e 
a 
lo
t 
vi
a 
pa
ss
iv
e 
sm
ok
in
g’
, 
‘P
as
si
ve
 s
m
ok
in
g 
in
 th
e 
offi
ce
’, ‘S
m
ok
ed
 p
as
si
ve
ly
 fo
r 2
0 
ye
ar
s’.
En
vi
ro
nm
en
ta
l a
nd
 
ch
em
ic
al
 e
xp
os
ur
e
‘N
uc
le
ar
 te
st
in
g 
in
 th
e 
ye
ar
s 
19
45
-1
98
0 
an
d 
sp
ra
yi
ng
 p
es
tic
id
es
’, ‘U
se
d 
to
 g
o 
sw
im
m
in
g 
fre
qu
en
tly
 in
 th
e 
IJs
se
lm
ee
r n
ea
r i
ro
n 
fo
un
dr
y,
 
a 
lo
t 
of
 ir
on
 in
 w
at
er
’, ‘
C
he
rn
ob
yl
 (r
ad
ia
tio
n)
, c
ow
s 
ha
d 
to
 g
o 
in
si
de
, w
as
 n
ot
 n
ec
es
sa
ry
 fo
r u
s 
an
d 
ou
r c
hi
ld
re
n.
 O
r p
es
tic
id
es
’, ‘
I h
av
e 
liv
ed
 o
n 
th
e 
si
te
 o
f a
 p
ai
nt
 fa
ct
or
y 
fro
m
 b
irt
h 
un
til
 th
e 
ag
e 
of
 1
6’,
 ‘P
er
ha
ps
 z
in
c 
pl
an
t i
n 
Bu
de
l?
’, ‘I
 li
ve
d 
in
 a
 h
ou
se
 a
t t
he
 S
ch
aa
ps
dr
ift
 
in
 A
rn
he
m
 fo
r 3
6 
ye
ar
s. 
Th
e 
so
il 
or
 g
ro
un
d 
w
at
er
 w
as
 c
on
ta
m
in
at
ed
’, ‘L
iv
ed
 in
 H
ev
ea
do
rp
 fr
om
 b
irt
h 
til
l t
he
 a
ge
 o
f 2
1.
 W
e 
liv
ed
 n
ea
r a
 
ru
bb
er
 fa
ct
or
y,
 w
he
re
 I 
us
ed
 to
 p
la
y 
as
 a
 c
hi
ld
’, ‘I
s 
dr
in
ki
ng
 w
at
er
 n
ot
 th
e 
ca
us
e?
’, ‘E
xh
au
st
 fu
m
es
’, ‘E
xh
au
st
 a
nd
 g
as
ol
in
e 
fu
m
es
’, ‘ 
Cy
cl
ed
 
to
 a
nd
 fr
om
 w
or
k 
fo
r 2
0 
ye
ar
s 
(1
4 
km
 t
he
re
 a
nd
 1
4k
m
 b
ac
k)
 a
lo
ng
 c
ar
s, 
tr
affi
c 
ja
m
s 
an
d 
in
du
st
ria
l a
re
as
 (A
KZ
O
, B
A
SF
, B
ill
ito
n)
.  
U
se
d 
ex
tr
a 
eff
or
t 
rig
ht
 a
t 
th
e 
pl
ac
e 
th
at
 c
on
ta
in
ed
 a
 lo
t 
of
 h
ar
m
fu
l d
us
t’, 
‘A
ir 
po
llu
tio
n,
 e
nv
iro
nm
en
ta
l p
ol
lu
tio
n’,
 ‘P
ro
lo
ng
ed
 e
xp
os
ur
e 
to
 
ex
ha
us
t f
um
es
’, ‘A
sp
ha
lt 
pl
an
t i
n 
th
e 
im
m
ed
ia
te
 s
ur
ro
un
di
ng
s’,
 ‘In
ha
le
d 
fir
ep
la
ce
 fu
m
es
 fo
r 2
0 
ye
ar
s’,
 ‘E
xh
au
st
 fu
m
es
’, ‘P
ar
tic
ul
at
e 
m
at
te
r 
(h
ig
hw
ay
/p
ow
er
 p
la
nt
)’, 
‘M
ot
or
/a
ir 
po
llu
tio
n 
in
 H
on
g 
Ko
ng
. I
 h
av
e 
liv
ed
 in
 H
on
g 
Ko
ng
 fo
r f
ou
r y
ea
rs
’, ‘T
he
 u
se
 o
f c
he
m
ic
al
s i
n 
fo
od
 su
ch
 
as
 g
ro
w
th
 h
or
m
on
es
, e
tc
’, ‘P
os
si
bl
y:
 h
av
e 
be
en
 d
rin
ki
ng
 w
at
er
 (d
ur
in
g 
sp
or
ts
) f
ro
m
 a
 d
is
po
sa
bl
e 
pl
as
tic
 b
ot
tle
, w
hi
ch
 w
as
 m
el
te
d 
in
 
th
e 
sa
un
a,
 fo
r a
 lo
ng
 t
im
e 
(y
ea
r)’
, ‘C
he
m
ic
al
 s
tu
ff
’, ‘
C
he
m
ic
al
s’,
 ‘C
he
m
ic
al
s 
da
rk
ro
om
’, ‘
H
ai
r d
ye
 (h
ai
rd
re
ss
er
 d
en
ie
d 
th
is
)’, 
‘U
se
d 
cy
an
id
e 
ac
ry
la
te
 (s
up
er
gl
ue
) f
or
 n
ai
ls
 re
gu
la
rly
 fo
r 3
0 
ye
ar
s’.
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6
A
pp
en
di
x 
I  
Pe
rc
ei
ve
d 
ca
us
es
 o
f b
la
dd
er
 c
an
ce
r r
ep
or
te
d 
by
 D
ut
ch
 b
la
dd
er
 c
an
ce
r s
ur
vi
vo
rs
.
 C
at
eg
or
ie
s 
of
  
pe
rc
ei
ve
d 
ca
us
es
Pa
rt
ic
ip
an
ts
’ a
ns
w
er
s
Sm
ok
in
g
‘S
m
ok
in
g’
, ‘A
cc
or
di
ng
 t
o 
ph
ys
ic
ia
n 
du
e 
to
 s
m
ok
in
g’
, ‘S
m
ok
in
g 
ac
co
rd
in
g 
to
 m
y 
ur
ol
og
is
t’, 
‘P
ro
ba
bl
y 
be
ca
us
e 
of
 s
m
ok
in
g’
, ‘A
cc
or
di
ng
 
to
 s
pe
ci
al
is
t 
sm
ok
in
g 
is
 o
ne
 o
f 
th
e 
ca
us
es
’, ‘
D
oc
to
r 
cl
ai
m
s 
th
at
 s
m
ok
in
g 
co
ul
d 
be
 a
 c
au
se
 o
r 
at
 le
as
t 
an
 im
po
rt
an
t 
co
nt
rib
ut
io
n’,
 
‘A
cc
or
di
ng
 to
 th
e 
do
ct
or
: s
m
ok
in
g’
, ‘I
 th
in
k 
sm
ok
in
g’
, ‘C
ou
ld
 b
e 
sm
ok
in
g’
, ‘A
cc
or
di
ng
 to
 m
y 
ur
ol
og
is
t s
m
ok
in
g 
is
 th
e 
pr
im
ar
y 
ca
us
e 
of
 
m
y 
m
ou
th
 d
is
ea
se
 in
 1
98
1 
an
d 
th
e 
bl
ad
de
r p
ol
yp
s 
in
 1
99
4’,
 ‘P
eo
pl
e 
sa
y 
be
ca
us
e 
of
 s
m
ok
in
g’
, ‘A
t t
he
 ti
m
e 
I s
m
ok
ed
 ±
 2
0 
ci
ga
re
tt
es
 p
er
 
da
y’,
 ‘M
uc
h 
sm
ok
in
g’
, ‘A
cc
or
di
ng
 to
 th
e 
ur
ol
og
is
t, 
sm
ok
in
g 
m
ig
ht
 b
e 
a 
ca
us
e’,
 ‘M
y 
w
ife
 th
in
ks
 s
m
ok
in
g’
, ‘M
y 
sm
ok
in
g 
be
ha
vi
or
’, ‘S
m
ok
ed
 
lo
ts
 o
f c
ig
ar
et
te
s’,
 ‘P
os
si
bl
y 
sm
ok
in
g’
, ‘P
er
ha
ps
 s
m
ok
in
g 
be
ha
vi
or
’, ‘P
er
ha
ps
 d
ue
 to
 s
m
ok
in
g’
, ‘N
o 
ce
rt
ai
nt
y,
 b
ut
 s
om
et
im
es
 I 
su
sp
ec
te
d 
an
 a
ss
oc
ia
tio
n 
w
ith
 s
m
ok
in
g 
ho
m
e-
gr
ow
n 
ca
nn
ab
is’
, ‘C
ig
ar
 /
 p
ip
e 
sm
ok
in
g.
 D
id
 t
hi
s 
in
te
ns
iv
el
y 
fo
r 
m
an
y 
ye
ar
s 
be
fo
re
 t
he
 b
la
dd
er
 
tu
m
or
 w
as
 d
is
co
ve
re
d’
, ‘S
m
ok
in
g 
in
 th
e 
pa
st
’, ‘S
m
ok
in
g?
 H
av
en
’t 
sm
ok
ed
 m
uc
h 
in
 m
y 
yo
un
ge
r y
ea
rs
, f
ro
m
 a
bo
ut
 th
e 
ag
e 
of
 4
0 
to
 5
9 
I 
sm
ok
ed
 1
 p
ac
k 
pe
r d
ay
. T
w
o 
w
ee
ks
 b
ef
or
e 
m
y 
re
tir
em
en
t i
n 
19
93
 I 
qu
it 
an
d 
ne
ve
r s
m
ok
ed
 a
ga
in
’, ‘P
er
ha
ps
 s
m
ok
in
g’
, ‘S
m
ok
in
g,
 9
 p
er
 
da
y’,
 ‘I
t 
tu
rn
s 
ou
t 
sm
ok
in
g 
ca
n 
be
 a
 c
au
se
’, ‘
In
 h
in
ds
ig
ht
 m
y 
sm
ok
in
g 
ca
n 
be
 a
 p
os
si
bl
e 
ca
us
e’,
 ‘S
m
ok
in
g 
ca
n 
be
 a
 c
au
se
’, ‘
Sm
ok
in
g 
is
 
al
so
 a
 c
au
se
’, ‘N
ot
 s
ur
e,
 m
ig
ht
 b
e 
sm
ok
in
g’
, ‘A
cc
or
di
ng
 to
 p
eo
pl
e 
in
 R
ad
bo
ud
um
c:
 s
m
ok
in
g?
’, ‘P
ro
lo
ng
ed
 s
m
ok
in
g’
, ‘I
t i
s 
sa
id
 s
m
ok
in
g’
, 
‘P
ro
ba
bl
y 
a 
lo
t o
f s
m
ok
in
g’
, ‘A
cc
or
di
ng
 to
 th
e 
do
ct
or
s 
it 
is
 b
ec
au
se
 o
f s
m
ok
in
g’
, ‘S
m
ok
ed
 fo
r t
oo
 lo
ng
 a
nd
 to
o 
m
uc
h 
in
 m
y 
lif
e’,
 ‘M
ay
be
 
sm
ok
in
g?
’, ‘S
m
ok
in
g 
fo
r a
bo
ut
 2
0 
ye
ar
s’,
 ‘T
oo
 m
uc
h 
sm
ok
in
g’
, ‘P
ip
e 
sm
ok
in
g 
ca
us
in
g 
ta
r j
ui
ce
 to
 b
e 
sw
al
lo
w
ed
 (f
re
qu
en
tly
)’, 
‘I 
su
sp
ec
t 
by
 s
m
ok
in
g’
, ‘O
f c
ou
rs
e,
 s
m
ok
in
g 
be
ha
vi
or
’, ‘P
re
su
m
ab
ly
 s
m
ok
in
g’
, ‘P
os
si
bl
e 
co
nt
am
in
at
io
n 
of
 s
m
ok
in
g’
, ‘S
m
ok
ed
 p
ro
fu
se
ly
 fo
r 3
8 
ye
ar
s’,
 
‘U
se
d 
to
 s
m
ok
e 
fir
m
ly
 fo
r 2
6 
ye
ar
s’,
 ‘S
m
ok
ed
 fr
om
 th
e 
ag
e 
of
 1
6 
to
 5
1’,
 ‘L
on
g-
te
rm
 s
m
ok
in
g’
, ‘S
m
ok
ed
 in
 e
ar
ly
 c
hi
ld
ho
od
’, ‘S
m
ok
in
g 
at
 a
 
yo
un
ge
r a
ge
’.
O
cc
up
at
io
na
l 
ex
po
su
re
‘A
t 
N
V 
Ph
ili
ps
 w
e 
w
or
ke
d 
w
ith
 v
ar
io
us
po
llu
ta
nt
s 
lik
e 
C
lo
ph
en
 (h
yd
ro
ch
lo
ric
), 
ar
al
di
et
ha
rd
er
s, 
va
rio
us
 s
ol
ve
nt
s’,
 ‘E
m
pl
oy
m
en
t 
hi
st
or
y’,
 
‘W
or
ki
ng
 w
ith
 h
ig
hl
y 
to
xi
c 
 su
bs
ta
nc
es
’, ‘D
ur
in
g 
m
y 
w
or
k 
in
 th
e 
cl
ot
hi
ng
 in
du
st
ry
, I 
ca
m
e 
in
to
 c
on
ta
ct
 w
ith
 c
he
m
ic
al
 w
as
hi
ng
 p
ro
du
ct
s’,
 
‘D
ur
in
g 
st
ud
y 
(c
he
m
is
tr
y)
 a
nd
 w
or
k 
(p
ai
nt
 in
du
st
ry
) c
er
ta
in
 c
he
m
ic
al
s 
th
at
 I 
ha
ve
 b
ee
n 
in
 c
on
ta
ct
 w
ith
 c
an
 b
e 
th
e 
ca
us
e’,
 ‘W
or
ke
d 
w
ith
 t
ex
til
es
?’,
 ‘W
or
ke
d 
a 
lo
t 
w
ith
 a
rs
en
e,
 s
el
en
iu
m
 a
nd
 io
di
ne
 a
t 
th
e 
fa
ct
or
y’,
 ‘W
or
k 
w
as
 n
ot
 a
lw
ay
s 
cl
ea
n,
 p
ro
ba
bl
y 
du
e 
to
 m
y 
w
or
k 
ac
tiv
iti
es
’, ‘
W
or
ki
ng
 w
ith
 c
he
m
ic
al
s’,
 ‘W
or
ki
ng
 w
ith
 B
is
on
 K
it 
(g
lu
e)
’, ‘
W
or
k’,
 ‘W
or
ki
ng
 w
ith
 B
is
on
 K
it 
(g
lu
e)
’, ‘
H
av
e 
w
or
ke
d 
a 
lo
t 
w
ith
 
ha
rm
fu
l s
ub
st
an
ce
s 
(g
lu
e,
 e
tc
.)’,
 ‘A
s 
a 
pa
in
te
r, 
w
or
ke
d 
ex
te
ns
iv
el
y 
w
ith
 d
ilu
tio
ns
 e
sp
ec
ia
lly
 m
et
hy
le
ne
’, ‘P
er
ha
ps
 w
or
ki
ng
 w
ith
 a
sb
es
to
s’,
 
‘V
er
y 
ca
re
le
ss
ly
 h
an
dl
in
g 
ph
ot
o 
ch
em
ic
al
s’,
 ‘W
as
hi
ng
 h
an
ds
 w
ith
 b
en
ze
ne
 (i
n 
19
54
) +
 p
es
tic
id
es
 (1
96
0)
’, ‘
W
or
k 
at
 t
he
 p
la
nt
 n
ur
se
ry
, 
w
or
ke
d 
a 
lo
t 
w
ith
 p
es
tic
id
es
 w
ith
ou
t 
pr
ot
ec
tiv
e 
m
ea
su
re
s’,
 ‘L
ot
s 
of
 c
on
ta
ct
 w
ith
 a
sb
es
to
s’,
 ‘W
or
ke
d 
m
an
y 
ye
ar
s 
(±
 2
0)
 a
s 
a 
pr
oj
ec
t 
m
an
ag
er
 in
 m
os
tly
 a
lu
m
in
um
 p
ro
ce
ss
in
g 
in
du
st
rie
s 
(a
lu
m
in
um
 m
el
tin
g 
fu
rn
ac
es
) a
nd
 c
er
am
ic
 a
nd
 m
et
al
 h
ar
de
ni
ng
 fu
rn
ac
es
’, ‘
M
y 
w
or
k 
w
ith
 to
xi
c 
su
bs
ta
nc
es
. C
ar
el
es
sl
y 
ha
nd
lin
g 
th
es
e 
su
bs
ta
nc
es
 fo
r m
or
e 
th
an
 3
5 
ye
ar
s’,
 ‘W
or
ke
d 
a 
lo
t w
ith
 u
nh
ea
lth
y 
st
uff
’, ‘W
el
di
ng
 
fu
m
es
 a
nd
 m
et
al
 v
ap
or
s, 
le
ad
 p
oi
so
ni
ng
’, ‘
Po
ss
ib
le
 c
on
ta
m
in
at
io
n 
du
e 
to
 c
he
m
ic
al
s 
du
rin
g 
la
bo
ra
to
ry
 w
or
k’,
 ‘O
cc
up
at
io
n 
as
 p
ai
nt
er
 
m
ai
nt
en
an
ce
’, ‘W
or
ke
d 
w
ith
 p
ho
to
co
pi
er
, s
uff
er
ed
 a
 lo
t e
sp
ec
ia
lly
 fr
om
 c
ou
gh
in
g’
, ‘C
le
an
in
g 
ai
r h
an
dl
in
g 
un
its
, w
or
ki
ng
 w
ith
 d
ie
se
l d
ue
 
to
 c
le
an
in
g 
oi
l b
oi
le
rs
, w
or
ki
ng
 w
ith
 d
et
er
ge
nt
s’,
 ‘P
ai
nt
s, 
tu
rp
en
tin
e,
 p
ai
nt
 th
in
ne
rs
, p
ai
nt
 re
m
ov
er
s u
se
d 
as
 a
 p
ai
nt
er
’, ‘I
 th
in
k 
th
e 
re
as
on
 
fo
r t
hi
s 
lie
s 
in
 th
e 
pe
rio
d 
of
 1
98
1-
19
85
 (w
or
k)
’, ‘D
ur
in
g 
th
e 
pe
rio
d 
(1
95
5-
19
67
) I
 w
or
ke
d 
in
 a
 g
ra
ph
ic
s 
co
m
pa
ny
 a
nd
 w
or
ke
d 
a 
lo
t w
ith
 
pr
in
tin
g 
in
ks
 st
ai
ne
d-
so
lv
en
ts
 su
ch
 a
s g
as
ol
in
e,
 d
ie
se
l a
nd
 k
er
os
en
e’,
 ‘S
m
ok
in
g 
so
lv
en
ts
. I
 sp
en
t 1
5 
ye
ar
s o
n 
av
er
ag
e 
8 
ho
ur
s p
er
 m
on
th
 
m
ak
in
g 
pr
in
ts
 in
 a
 p
oo
rly
 v
en
til
at
ed
 a
re
a’,
 ‘T
he
 u
se
 o
f p
es
tic
id
es
’, ‘D
ur
in
g 
ho
m
e 
fu
rn
is
hi
ng
 I 
w
or
ke
d 
w
ith
 N
ov
ilo
n 
ca
rp
et
. 
W
hi
ch
 c
on
ta
in
ed
 a
sb
es
to
s 
an
d 
th
e 
ha
nd
lin
g 
of
 g
lu
e’,
 ‘A
t t
he
 a
ge
 o
f 1
6,
 w
or
ke
d 
ne
ar
 a
 p
ai
nt
 s
ho
p 
fo
r 6
 m
on
th
s.’,
 ‘O
cc
up
at
io
na
l d
is
ea
se
 
th
ro
ug
h 
w
or
k’,
 ‘D
ue
 t
o 
au
to
ge
no
us
 a
nd
 e
le
ct
ric
 w
el
di
ng
 w
or
k,
 n
ot
 t
he
 r
ig
ht
 s
af
et
y 
m
ea
su
re
m
en
ts
 t
ak
en
 (
un
sa
fe
, l
ow
 v
en
til
at
io
n)
’, 
‘B
ec
au
se
 o
f 
m
y 
jo
b,
 d
ai
ly
 c
on
ta
ct
 w
ith
 f
ue
ls
 a
nd
 a
ut
o 
ga
s’,
 ‘A
lw
ay
s 
w
or
ke
d 
in
 a
 c
oo
lin
g 
co
m
pa
rt
m
en
t’, 
‘P
re
pa
ra
tio
ns
 c
yt
os
ta
tic
 f
or
 
ch
em
ot
he
ra
py
’, ‘
U
se
 o
f t
ox
ic
 s
ub
st
an
ce
s’,
 ‘U
si
ng
 g
un
 o
il 
PX
10
 d
ur
in
g 
pe
rio
d 
19
65
-1
99
5’,
 ‘E
xp
os
ed
 t
o 
tr
ic
hl
or
oe
th
yl
en
e,
 fi
ne
 a
sb
es
to
s 
du
st
, m
an
y 
ot
he
r 
so
lv
en
ts
’, ‘
W
or
ki
ng
 w
ith
 s
ilk
sc
re
en
s 
pr
in
te
rs
, c
le
an
in
g 
pr
od
uc
ts
, t
hi
nn
er
s/
in
k’,
 ‘R
oo
fin
g/
ro
of
 c
ov
er
in
g’
, ‘
Pr
oc
es
se
d 
as
be
st
os
. S
aw
in
g 
in
 th
e 
ye
ar
s 
19
69
-1
97
0.
 S
hi
el
di
ng
 h
ea
te
rs
’, ‘P
re
pa
ra
tio
n 
an
d 
di
st
rib
ut
in
g 
cy
to
st
at
ic
’, ‘M
ay
be
 p
ai
nt
s/
dy
es
’, ‘W
or
ke
d 
w
ith
 
pa
in
t 
fo
r 
ca
r 
sp
ra
yi
ng
 fo
r 
32
 y
ea
rs
’, ‘
W
or
ke
d 
w
ith
 h
az
ar
do
us
 s
ub
st
an
ce
s 
(A
rg
on
, E
ld
rin
 e
tc
.)’,
  
 ‘T
he
 u
se
 o
f 
pe
st
ic
id
es
’, ‘
W
or
ki
ng
 w
ith
 
pe
st
ic
id
es
’, ‘
Su
gg
es
te
d 
th
at
 t
hi
s 
m
ay
 b
e 
re
la
te
d 
to
 e
xp
os
ur
e 
to
 c
he
m
ic
al
s 
in
 t
he
 la
bo
ra
to
ry
 (f
or
m
al
de
hy
de
, e
tc
.).
 T
w
o 
co
lle
ag
ue
s 
at
 
th
e 
la
b 
ha
ve
 b
ee
n 
di
ag
no
se
d 
w
ith
 b
la
dd
er
 c
an
ce
r’, 
‘P
ai
nt
 (p
ai
nt
in
g)
’, ‘R
ad
ia
tio
n,
 u
se
d 
to
 p
re
pa
re
 c
yt
os
ta
tic
 u
np
ro
te
ct
ed
’, ‘
W
or
ke
d 
w
ith
 
ep
ox
y 
re
si
n,
 P
er
sp
ex
 a
dh
es
iv
es
, p
ro
ce
ss
in
g 
Pe
rs
pe
x,
 s
ol
ve
nt
s 
(t
hi
nn
er
, t
ol
ue
ne
, t
ur
pe
nt
in
e)
, p
ol
ys
ty
re
ne
, a
cr
yl
ic
’, ‘S
pr
ay
in
g 
ca
rs
 w
ith
ou
t 
pr
op
er
 p
ro
te
ct
io
n’,
 ‘P
ai
nt
 s
pr
ay
in
g 
(la
cq
ue
r)’
, ‘H
an
dl
in
g 
X-
ra
ys
 in
 m
y 
pr
of
es
si
on
, h
an
dl
in
g 
ch
lo
ra
la
ct
ofi
no
l i
n 
m
y 
pr
of
es
si
on
’, ‘
W
or
ke
d 
in
 a
 la
bo
ra
to
ry
 fr
om
 t
he
 a
ge
 o
f 1
6 
to
 2
6’,
 ‘W
or
ki
ng
 w
ith
 a
sb
es
to
s 
(w
hi
ch
 w
as
 fo
rm
er
ly
 u
se
d 
in
 b
ra
ke
 li
ni
ng
)’, 
‘P
er
ha
ps
 d
ye
s/
co
lo
ra
nt
s 
(p
ai
nt
er
)’, 
‘P
es
tic
id
es
 o
r 
di
si
nf
ec
ta
nt
s’,
 ‘U
se
 o
f 
sp
ra
y 
bo
tt
le
 w
he
n 
iro
ni
ng
’, ‘
In
ha
lin
g 
so
lv
en
ts
 fo
r 
in
k’,
  
 ‘C
he
m
ic
al
s 
du
rin
g 
w
or
k’,
 ‘P
la
st
ic
 
pr
oc
es
si
ng
 v
ap
or
s 
(s
ty
re
ne
)’, 
‘W
or
ki
ng
 w
ith
 p
ho
to
 p
ro
ce
ss
in
g 
ch
em
ic
al
s, 
in
ha
la
tio
n 
of
 le
ad
-c
on
ta
in
in
g 
su
bs
ta
nc
es
/g
as
es
 d
ur
in
g 
th
e 
fir
in
g 
of
 a
m
m
o’,
 ‘P
rin
tin
g’
, ‘A
sb
es
to
s’,
 ‘D
ue
 to
 p
ro
fe
ss
io
n’,
 ‘C
he
m
ic
al
s 
du
e 
to
 s
pr
ay
in
g 
an
d 
w
el
di
ng
’, ‘
Te
m
po
ra
ril
y 
ha
nd
lin
g 
ph
ot
og
ra
ph
ic
 
ch
em
ic
al
s 
in
 p
oo
rly
 v
en
til
at
ed
 a
re
as
’, ‘W
or
ke
d 
w
ith
 s
om
e 
re
gu
la
rit
y 
w
ith
 d
up
lic
at
or
 d
ur
in
g 
th
e 
jo
b’,
 ‘C
ar
el
es
sl
y 
w
or
ki
ng
 w
ith
 c
he
m
ic
al
s’,
 
‘U
ra
ni
um
 in
 m
is
si
on
 a
re
a’,
 ‘P
ro
lo
ng
ed
 c
on
ta
ct
 w
ith
 p
rin
tin
g 
in
ks
, a
dh
es
iv
es
 b
oo
kb
in
di
ng
’, ‘
In
ha
le
d 
fo
rm
al
de
hy
de
 v
ap
or
s 
fo
r 8
 y
ea
rs
?’,
 
‘E
le
ct
ro
m
ag
ne
tic
 r
ad
ia
tio
n 
(ra
da
r 
eq
ui
pm
en
t)
’, ‘
La
bo
ra
to
ry
 w
or
k 
w
ith
 t
he
 u
se
 o
f 
m
an
y 
ki
nd
s 
of
 s
ol
ve
nt
s, 
eg
. B
en
ze
ne
, c
hl
or
of
or
m
, 
ac
et
on
e 
et
c’,
 ‘W
or
k’,
 ‘C
le
an
in
g 
up
 a
sb
es
to
s’,
 ‘P
ai
nt
 c
he
m
is
tr
y 
(c
om
po
ne
nt
s)
, i
nd
us
tr
ia
l 
fa
br
ic
s’,
 ‘E
xp
os
ur
e 
to
 h
az
ar
do
us
 s
ub
st
an
ce
s’,
 
‘P
os
si
bl
e 
ca
us
e 
th
at
 I 
do
 n
ot
 ru
le
 o
ut
: s
an
di
ng
 p
la
te
 w
ith
 a
sb
es
to
s’,
  ‘W
el
di
ng
 fu
m
es
’,  
‘L
ab
or
at
or
y 
ac
tiv
iti
es
’.  
 
Pa
ss
iv
e 
sm
ok
in
g
‘A
s 
a 
ch
ild
 e
xp
os
ed
 to
 “p
as
si
ve
 s
m
ok
in
g”
 a
 lo
t’, 
‘S
ec
on
d-
ha
nd
 s
m
ok
in
g,
 w
he
n 
st
ay
in
g 
in
 s
m
ok
y 
en
vi
ro
nm
en
ts
 (f
re
qu
en
tly
) i
t s
ee
m
s 
th
at
 
th
e 
po
ly
ps
 c
om
e 
ba
ck
’, ‘S
ec
on
d-
ha
nd
 s
m
ok
in
g 
fo
r m
an
y 
ye
ar
s’,
 ‘D
ur
in
g 
w
or
k 
I w
as
 a
lw
ay
s 
su
rr
ou
nd
ed
 b
y 
sm
ok
er
s, 
ev
en
 a
ft
er
 I 
ha
d 
qu
it 
m
ys
el
f’, 
‘S
ec
on
d-
ha
nd
 s
m
ok
in
g’
, ‘A
lw
ay
s 
sm
ok
ed
 p
as
si
ve
ly
’, ‘
Fa
th
er
 w
as
 a
 s
m
ok
er
. B
ee
n 
ex
po
se
d 
to
 s
m
ok
e 
a 
lo
t 
vi
a 
pa
ss
iv
e 
sm
ok
in
g’
, 
‘P
as
si
ve
 s
m
ok
in
g 
in
 th
e 
offi
ce
’, ‘S
m
ok
ed
 p
as
si
ve
ly
 fo
r 2
0 
ye
ar
s’.
En
vi
ro
nm
en
ta
l a
nd
 
ch
em
ic
al
 e
xp
os
ur
e
‘N
uc
le
ar
 te
st
in
g 
in
 th
e 
ye
ar
s 
19
45
-1
98
0 
an
d 
sp
ra
yi
ng
 p
es
tic
id
es
’, ‘U
se
d 
to
 g
o 
sw
im
m
in
g 
fre
qu
en
tly
 in
 th
e 
IJs
se
lm
ee
r n
ea
r i
ro
n 
fo
un
dr
y,
 
a 
lo
t 
of
 ir
on
 in
 w
at
er
’, ‘
C
he
rn
ob
yl
 (r
ad
ia
tio
n)
, c
ow
s 
ha
d 
to
 g
o 
in
si
de
, w
as
 n
ot
 n
ec
es
sa
ry
 fo
r u
s 
an
d 
ou
r c
hi
ld
re
n.
 O
r p
es
tic
id
es
’, ‘
I h
av
e 
liv
ed
 o
n 
th
e 
si
te
 o
f a
 p
ai
nt
 fa
ct
or
y 
fro
m
 b
irt
h 
un
til
 th
e 
ag
e 
of
 1
6’,
 ‘P
er
ha
ps
 z
in
c 
pl
an
t i
n 
Bu
de
l?
’, ‘I
 li
ve
d 
in
 a
 h
ou
se
 a
t t
he
 S
ch
aa
ps
dr
ift
 
in
 A
rn
he
m
 fo
r 3
6 
ye
ar
s. 
Th
e 
so
il 
or
 g
ro
un
d 
w
at
er
 w
as
 c
on
ta
m
in
at
ed
’, ‘L
iv
ed
 in
 H
ev
ea
do
rp
 fr
om
 b
irt
h 
til
l t
he
 a
ge
 o
f 2
1.
 W
e 
liv
ed
 n
ea
r a
 
ru
bb
er
 fa
ct
or
y,
 w
he
re
 I 
us
ed
 to
 p
la
y 
as
 a
 c
hi
ld
’, ‘I
s 
dr
in
ki
ng
 w
at
er
 n
ot
 th
e 
ca
us
e?
’, ‘E
xh
au
st
 fu
m
es
’, ‘E
xh
au
st
 a
nd
 g
as
ol
in
e 
fu
m
es
’, ‘ 
Cy
cl
ed
 
to
 a
nd
 fr
om
 w
or
k 
fo
r 2
0 
ye
ar
s 
(1
4 
km
 t
he
re
 a
nd
 1
4k
m
 b
ac
k)
 a
lo
ng
 c
ar
s, 
tr
affi
c 
ja
m
s 
an
d 
in
du
st
ria
l a
re
as
 (A
KZ
O
, B
A
SF
, B
ill
ito
n)
.  
U
se
d 
ex
tr
a 
eff
or
t 
rig
ht
 a
t 
th
e 
pl
ac
e 
th
at
 c
on
ta
in
ed
 a
 lo
t 
of
 h
ar
m
fu
l d
us
t’, 
‘A
ir 
po
llu
tio
n,
 e
nv
iro
nm
en
ta
l p
ol
lu
tio
n’,
 ‘P
ro
lo
ng
ed
 e
xp
os
ur
e 
to
 
ex
ha
us
t f
um
es
’, ‘A
sp
ha
lt 
pl
an
t i
n 
th
e 
im
m
ed
ia
te
 s
ur
ro
un
di
ng
s’,
 ‘In
ha
le
d 
fir
ep
la
ce
 fu
m
es
 fo
r 2
0 
ye
ar
s’,
 ‘E
xh
au
st
 fu
m
es
’, ‘P
ar
tic
ul
at
e 
m
at
te
r 
(h
ig
hw
ay
/p
ow
er
 p
la
nt
)’, 
‘M
ot
or
/a
ir 
po
llu
tio
n 
in
 H
on
g 
Ko
ng
. I
 h
av
e 
liv
ed
 in
 H
on
g 
Ko
ng
 fo
r f
ou
r y
ea
rs
’, ‘T
he
 u
se
 o
f c
he
m
ic
al
s i
n 
fo
od
 su
ch
 
as
 g
ro
w
th
 h
or
m
on
es
, e
tc
’, ‘P
os
si
bl
y:
 h
av
e 
be
en
 d
rin
ki
ng
 w
at
er
 (d
ur
in
g 
sp
or
ts
) f
ro
m
 a
 d
is
po
sa
bl
e 
pl
as
tic
 b
ot
tle
, w
hi
ch
 w
as
 m
el
te
d 
in
 
th
e 
sa
un
a,
 fo
r a
 lo
ng
 t
im
e 
(y
ea
r)’
, ‘C
he
m
ic
al
 s
tu
ff
’, ‘
C
he
m
ic
al
s’,
 ‘C
he
m
ic
al
s 
da
rk
ro
om
’, ‘
H
ai
r d
ye
 (h
ai
rd
re
ss
er
 d
en
ie
d 
th
is
)’, 
‘U
se
d 
cy
an
id
e 
ac
ry
la
te
 (s
up
er
gl
ue
) f
or
 n
ai
ls
 re
gu
la
rly
 fo
r 3
0 
ye
ar
s’.
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Chapter 6
A
pp
en
di
x 
I  
Co
nt
in
ue
d.
 C
at
eg
or
ie
s 
of
  
pe
rc
ei
ve
d 
ca
us
es
Pa
rt
ic
ip
an
ts
’ a
ns
w
er
s
H
er
ed
ity
‘P
re
su
m
ab
ly
 h
er
ed
ita
ry
 p
re
di
sp
os
iti
on
; M
y 
fa
th
er
 d
ie
d 
of
 a
cu
te
 re
na
l f
ai
lu
re
’, ‘
G
en
et
ic
al
ly
 d
et
er
m
in
ed
’, ‘
H
er
ed
ity
, m
y 
fa
th
er
 h
ad
 t
he
m
’, 
‘G
ra
nd
pa
 a
nd
 u
nc
le
?’,
 ‘M
y 
fa
th
er
 a
ls
o 
ha
d 
bl
ad
de
r 
po
ly
ps
, b
ut
 m
y 
si
bl
in
gs
 d
on
’t’,
 ‘M
ay
be
 b
ec
au
se
 o
f t
he
 g
en
es
 (m
at
er
na
l)’,
 ‘P
os
si
bl
e 
he
re
di
ta
ry
’, ‘H
er
ed
ita
ry
’, ‘D
ur
in
g 
th
e 
w
ar
 fa
th
er
 in
 h
os
pi
ta
l b
ec
au
se
 o
f b
la
dd
er
. P
at
er
na
l a
un
t d
ia
gn
os
ed
 w
ith
 p
ol
yp
 a
t a
ge
 6
0 
an
d 
liv
ed
 
til
l t
he
 a
ge
 8
5.
 T
he
y 
al
l u
se
d 
to
 w
or
k 
in
 t
he
 t
ex
til
e 
in
du
st
ry
. H
er
ed
ita
ry
?’,
 ‘P
er
ha
ps
 in
he
rit
ed
 fa
th
er
’s 
si
de
?’,
 ‘H
er
ed
ita
ry
, p
at
er
na
l s
id
e’,
 
‘H
er
ed
ita
ry
, f
at
he
r a
nd
 m
ot
he
r’, 
‘P
os
si
bl
y 
he
re
di
ta
ry
’, ‘A
cc
or
di
ng
 to
 th
e 
ur
ol
og
is
t I
 w
as
 b
or
n 
w
ith
 it
’, ‘R
un
s i
n 
th
e 
fa
m
ily
’, ‘H
er
ed
ita
ry
: f
at
he
r 
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ad
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 d
ue
 to
 m
al
ig
na
nt
 c
an
ce
r. 
A
cc
or
di
ng
 to
 d
r. 
at
 R
ad
bo
ud
um
c,
 w
he
re
 
I w
as
 s
til
l u
nd
er
 tr
ea
tm
en
t a
t t
ha
t t
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 c
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r s
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 p
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ad
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ad
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ac
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 b
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” m
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 b
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 b
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 m
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 p
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f m
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 p
ill
s’,
 ‘T
he
 u
se
 o
f 
ac
en
oc
ou
m
ar
ol
’, ‘
Re
si
st
an
ce
 re
du
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 m
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 d
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at
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 d
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at
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f c
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t c
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s d
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t d
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at
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 d
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, l
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 d
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r o
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ra
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Chapter 7
Abstract 
Background: A healthy lifestyle may reduce the risk of non-muscle-invasive bladder 
cancer (NMIBC) recurrence. The objective of this study was to obtain insight in whether 
NMIBC patients are aware of possible risk factors for (bladder) cancer, adhere to lifestyle 
recommendations for cancer prevention, received lifestyle advice from their physician, 
and what their attitudes are towards physicians giving lifestyle advice.
Methods: Patients with newly diagnosed NMIBC between 2014-2017 participating in the 
UroLife cohort study completed questionnaires and a survey at 6 and 12 weeks after 
diagnosis about awareness of (bladder) cancer risk factors, adherence to lifestyle recom-
mendations, reception of lifestyle advice, and attitudes towards physicians giving lifestyle 
advice. 
Results: A total of 969 NMIBC patients were included. Most patients (89%) were aware 
that smoking is a risk factor for cancer, but only 44% reported smoking as a risk factor for 
bladder cancer. Knowledge of other risk factors for cancer varied between 29% (fruit and 
vegetable consumption) and 67% (overweight). Adherence to cancer prevention recom-
mendations varied between 34% (body weight) and 84% (smoking). Of the smokers, 70% 
reported they were advised to quit. Only 19% of all patients indicated they received other 
lifestyle advice. More than 80% of patients had a positive attitude towards receiving 
lifestyle advice from their physician. 
Conclusion: These findings show that awareness of (bladder) cancer risk factors and 
adherence to cancer prevention lifestyle recommendations among NMIBC patients is low 
and that physicians’ information provision should be improved. 
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Introduction 
 Patients with non-muscle-invasive bladder cancer (NMIBC) have a high five-year risk of 
recurrence (1), necessitating a burdensome and expensive follow-up program (2). A healthy 
lifestyle has been associated with several positive clinical outcomes in patients with 
various cancer types, i.e. reduced cancer risk, better prognosis, and reduced risk of secondary 
malignancies and lifestyle-related comorbidities (3, 4). In bladder cancer, cigarette smoking 
is responsible for about one-third of all diagnoses (5), and there is limited evidence for an 
association with overweight (6), physical activity (7), and fruit and vegetable consumption 
(8). Recent meta-analyses suggest that cigarette smoking (9) and overweight (10) are also 
associated with an increased risk of NMIBC recurrence. 
 A cancer diagnosis is often seen as a teachable moment at which the patient is highly 
motivated to change lifestyle behaviour (11). Also, NMIBC patients have been shown to be 
more likely to accept smoking as a cancer risk factor when this information was provided 
by their urologist (12). This highlights the importance of physicians discussing lifestyle with 
their patients and raising their awareness of known cancer risk factors. 
 We aimed to obtain more insight in whether NMIBC patients are aware of possible risk 
factors for (bladder) cancer, adhere to lifestyle recommendations for cancer prevention, 
received lifestyle advice from their physician, and what their attitudes are towards physicians 
giving lifestyle advice.
Patients and methods 
Participants
This study was part of the population-based, prospective cohort study UroLife (Urothelial 
cancer: Lifestyle, prognosis and health-related quality of Life), conducted in 22 hospitals in 
The Netherlands. Before the start of the study, permission was asked from all participating 
urologists to identify their eligible patients in the Netherlands Cancer Registry (NCR), held by 
the Netherlands Comprehensive Cancer Organization (IKNL). Patients diagnosed between 
April 1, 2014 and April 25, 2017 were identified approximately 4 weeks after diagnosis and 
invited on behalf of their urologist to participate in this study. Eligible patients were Dutch 
speaking men and women between 18 and 80 years old and diagnosed with a histologically 
confirmed primary Ta, T1 or Tis tumour that was surgically removed with a transurethral 
resection. Patients with a previous cancer diagnosis in the past five years, and those with 
a positive lymph node or distant metastasis were excluded. Written informed consent was 
obtained from all participants. UroLife was approved by the Committee for Human 
Research region Arnhem-Nijmegen (CMO 2013-494). 
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Questionnaires 
Patients completed web-based or paper-and-pencil-based questionnaires at approximately 
six and twelve weeks after diagnosis. Web-based questionnaires were collected using 
the data collection tool of the Patient Reported Outcomes Following Initial treatment and 
Long term Evaluation of Survivorship (PROFILES) registry (13). The baseline questionnaire 
included questions on socio-demographic characteristics. Both questionnaires included 
questions on smoking, body mass index (BMI), physical activity, alcohol consumption, and 
dietary supplement use at the time of filling out the questionnaires. 
 Smoking status was assessed by asking whether patients smoked or had smoked in 
the past and, if applicable, the date/age of smoking cessation. Patients were categorized 
into never, former (quit >6 months before diagnosis; quit £6 months before or after diagnosis), 
and current smokers. BMI (kg/m2) was calculated based on self-reported weight and 
height, and classified as underweight (≤18·4 kg/m2), normal weight (18·5-24.9 kg/m2), 
overweight (25-29.9 kg/m2), and obese (≥30 kg/m2) (14). Habitual physical activity was 
assessed using the validated Short QUestionnaire to ASsess Health-enhancing physical 
activity (SQUASH), which measures average time and intensity of different activities in a 
normal week (15). Activities were classified as light, moderate, or vigorous by combining 
their Metabolic Equivalent of Task (MET) score with their self-reported intensity. Alcohol 
consumption was assessed by questions about the number of days per week and the 
average number of drinks per day for week days and weekend days, separately. Dietary 
supplement use was assessed by asking whether patients (ever) used supplements (at six 
weeks after diagnosis) or in the previous three months (at twelve weeks after diagnosis). 
Patients were categorized into never, former, and current users.
 We classified former and never smokers as adhering to the guideline of not smoking. 
Patients adhering to the World Cancer Research Fund/American Institute for Cancer 
Research (WCRF/AICR) recommendations for cancer prevention were defined as (1) having 
a normal weight (BMI 18·5-25 kg/m2), (2) being moderately active (commuting activities, 
sports, and leisure activities of 3-4 MET with high intensity, or of ≥4 MET with low, moderate 
or high intensity) for at least 210 minutes per week, (3) consuming a maximum of two 
drinks and one drink of alcohol per day for men and women, respectively, (4) former or 
never using dietary supplements. 
Survey 
A survey was included in the second questionnaire. Awareness of risk factors for cancer in 
general was assessed with a prompted list of 13 known risk factors on a four-point Likert 
scale. An open-ended question was used to ask patients to report which of these 13 or 
other risk factors were risk factors for UBC. For analysis, responses were categorized into 
the same categories as for the 13 cancer risk factors, with an additional category for other 
responses. Furthermore, patients were asked if their physician asked about their smoking 
behaviour, and gave them advice about smoking cessation, weight loss, physical activity, 
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and a healthy diet. Patients who stated that they quit smoking after diagnosis were asked 
to indicate if their physician offered help and their main reason for smoking cessation. 
Finally, patients’ attitudes towards physicians giving advice on smoking cessation, a 
healthy diet, physical activity, and weight loss were assessed for four positive and four 
negative attitudes on a four-point Likert scale (16). 
Statistical Analysis
Standard descriptive statistics were calculated to describe baseline characteristics of the 
cohort, and results for awareness, adherence, advice, and attitudes. Multivariable logistic 
regression analyses were used to determine whether age, gender, and educational level 
were associated with adherence to the lifestyle recommendations for smoking, body 
weight, physical activity, alcohol consumption, and supplement use. Also, it was determined 
whether awareness of smoking, body weight, physical activity, and alcohol use being risk 
factors for cancer was associated with adherence to these lifestyle recommendations. All 
tests were two-sided and a p-value less than 0·05 was considered statistically significant. 
All data were analyzed using IBM SPSS Statistics, Version 22. 
Results 
Of all 2,134 invited NMIBC patients, 1,193 agreed to participate and 1,117 filled out at least 
one questionnaire (response rate 52%). Thereafter, 148 patients were excluded because of 
a previous cancer diagnosis in the past five years (n=4), metastases at diagnosis (n=1), or 
no completed first (n=10) or second questionnaire (n=133). In total, 969 (87%) patients 
were included in the current study. Median age at diagnosis was 68 years, the majority of 
patients were men, and almost half was lower educated (Table 1). 
 Eighty-nine percent of patients recognized smoking as risk factor for cancer, but 
other lifestyle factors were known by only 29-67% (Table 2). Sixty-one percent of patients 
reported one or more possible risk factors for UBC, with smoking being most frequently 
reported (44%) (Table 2, Appendix Table 1). Patients who reported smoking as a risk factor 
were younger and higher educated but did not differ according to smoking status (data 
not shown). 
 Adherence to lifestyle recommendations for cancer prevention at 6 weeks after 
diagnosis was lowest for body weight (34%) and highest for smoking (84%) (Table 3). 
Ninety-one patients (9%) quit smoking in the period of six months before until six weeks 
after diagnosis. They more often reported smoking as UBC risk factor than patients who 
continued smoking (78% vs. 60% respectively, data not shown). Their most important 
reasons for quitting were the NMIBC diagnosis (51%), general health (21%), advice of their 
physician (13%), or another reason/not applicable/no reason (15%). At 12 weeks after 
diagnosis, adherence to the lifestyle recommendations was similar, apart from a decrease 
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for physical activity (from 70% to 60%) and an increase for alcohol consumption (from 42% 
to 62%). Adherence was generally higher for patients who were older, male, and higher 
educated (Appendix Table 2). Patients who were aware of overweight, insufficient physical 
activity, and alcohol as being risk factors for cancer were more likely to meet the corresponding 
cancer prevention recommendations at baseline (Appendix Table 3). At follow-up, this 
difference only remained for alcohol. 
Table 1  Sociodemographic characteristics of 969 Dutch non-muscle-invasive  
bladder cancer patients at baseline.
Variable1
Age at diagnosis (y), median (IQR) 68 (61-73)
Sex, n (%)
   Male 771 (80%)
   Female 198 (20%)
Educational level2, n (%)
   Low 469 (48%)
   Medium 257 (27%)
   High 242 (25%)
European ancestry, n (%) 953 (98%)
Living situation, n (%)
   Alone 35 (4%)
   With partner, with or without children 821 (85%)
   Divorced or widow(er) 93 (10%)
   Other 20 (2%)
Comorbidities, n (%)
   No comorbidities 106 (11%)
   ≥1 lifestyle-related comorbidity3 107 (11%)
   ≥1 other comorbidity 303 (31%)
   ≥1 lifestyle-related and ≥1 other comorbidity 441 (46%)
Weeks between diagnosis and first questionnaire,
median (IQR)
6 (5-8)
Weeks between diagnosis and second questionnaire, median (IQR) 13 (12-14)
1 Where scores do not total 100% this is due to missing values; 2 Low (primary -, secondary -, vocational education), 
medium (intermediate vocational education, higher general secondary education, pre-university education), 
high (university of vocational education, university); 3 Heart disease, high blood pressure, diabetes mellitus type 
II. Abbreviations: IQR: interquartile range; y: year.
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Eighty percent of patients indicated that their physician asked about their smoking 
behaviour (data not shown). Of the 226 patients who smoked at diagnosis, 159 (70%) were 
advised to quit (Table 4). Forty-three of those (27%) were offered help with smoking 
cessation, mainly consisting of advice about nicotine replacement (data not shown). 
Nineteen percent of all patients reported to have received advice on one or more other 
lifestyle behaviours, mostly on physical activity (Table 4). Noteworthy is that 31% of the 
overweight patients reported that weight loss advice was not applicable to them.
 At least 80% of the patients thought it would be beneficial, helpful, and encouraging 
if physicians would give lifestyle advice, and approximately 70% agreed that it was the 
doctor’s duty (Table 5). Fifteen percent or less believed it was insensitive, interfering, and 
unnecessary, and around 25% thought it was placing the blame on the patient.   
Table 2  Awareness of risk factors for cancer in general and reported risk factors for 
bladder cancer among 969 Dutch non-muscle-invasive bladder cancer patients.
Risk factors Cancer in general1 Bladder cancer
Agree or 
Strongly 
agree
 n (%)
Disagree 
or Strongly 
disagree 
n (%)
Reported by 
patient as risk factor 
(yes/no)
n (%)2
Smoking 866 (89%) 61 (6%) 428 (44%)
Second-hand smoking 802 (83%) 117 (12%) 40 (4%)
> 1 glass alcohol a day 394 (41%) 496 (51%) 109 (11%)
< 5 servings vegetables and fruit a day 285 (29%) 608 (63%) 13 (1%)
Red or processed meat ≥ once a day 468 (48%) 417 (43%) 46 (5%)
Overweight 646 (67%) 262 (27%) 41 (4%)
Sunburn > once as a child 504 (52%) 370 (38%) 10 (1%)
Age > 70 years 464 (48%) 428 (44%) 53 (6%)
First-degree relative with cancer 625 (65%) 268 (28%) 70 (7%)
Infection with Human Papilloma Virus3 175 (18%) 115 (12%) 4 (0.4%)
Insufficient physical activity 524 (54%) 373 (39%) 22 (2%)
Using solarium 784 (81%) 133 (14%) 23 (2%)
Exposure to radiation 796 (82%) 94 (10%) 103 (11%)
1 Where scores do not total 100% this is due to missing values; 2 16% reported risk factors other than risk factors 
listed for cancer in general (Appendix II) 3 For Infection with Human Papilloma Virus the option ‘I don’t know’ was 
added, which was chosen by 638 patients (66%).
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Table 3  Lifestyle habits of 969 Dutch non-muscle-invasive bladder cancer patients  
at six and twelve weeks after diagnosis.
Lifestyle factor Six weeks  
after diagnosis n (%)1
Twelve weeks  
after diagnosis n (%)1
Smoking status 
Never
Former2 
Former3
Current
173
549
90
150
(18%)
(57%)
(9%)
(16%)
173
547
87
155
(18%)
(57%)
(9%)
(16%)
Body mass index (kg/m2) 
    ≤18.4
    18.5-24.9
    25.0-29.9
    ≥30.0
9
322
457
171
(1%)
(34%)
(48%)
(18%)
9
311
458
181
(1%)
(32%)
(48%)
(19%)
Physical activity (min/week moderately active) 
    ≥210
    <210 
675
284
(70%)
(30%)
575
384
(60%)
(40%)
Alcohol consumption (glasses/day) 
    ≤1 (female) or ≤2 (male) 
    >1 (female) or >2 (male) 
405
552
(42%)
(58%)
591
366
(62%)
(38%)
Supplement use 
    Never
    Former
    Current
534
94
324
(56%)
(10%)
(34%)
502
177
273
(53%)
(19%)
(29%)
1 Only reported for patients who filled out both questionnaires. Percentages in bold indicate adherence to the 
lifestyle recommendations for cancer prevention; 2 Former smokers who quit more than six months before 
diagnosis; 3 Former smokers who quit less than six months before diagnosis or shortly after diagnosis.
Table 4  Advice on lifestyle behaviour by physicians as reported by 969 Dutch 
non-muscle-invasive bladder cancer patients.
n (%)1
Smoking cessation (smokers at diagnosis, n=226) 
   Yes 159 (70%)
   No 62 (27%)
   Not applicable 1 (0.4%)
Physical activity 
   Yes 142 (15%)
   No 807 (83%)
Healthy diet 
   Yes 75 (8%)
   No 875 (90%)
Weight loss (patients with BMI>25 kg/m2, n=631) 
   Yes 39 (6%)
   No 381 (60%)
   Not applicable 198 (31%)
1 Where scores do not total 100% this is due to missing values
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Discussion 
In this large cohort of NMIBC patients, most patients recognized smoking as risk factor for 
cancer. Other cancer risk factors, and smoking as a risk factor for UBC, were less well-known. 
Adherence to the lifestyle recommendations for cancer prevention varied, with lowest 
adherence for a healthy body weight and highest adherence for not smoking. Patients 
indicated that they were not routinely advised about a healthy lifestyle by their physician, 
except for smoking cessation. However, the majority of patients had a positive attitude 
towards receiving lifestyle advice from their physician.  
 Awareness of cancer risk factors in NMIBC patients in our study is fairly comparable 
with that in the general population (17). Thus, a cancer diagnosis by itself does not seem 
to increase awareness of risk factors. This may be of concern, because cancer recurrence, 
the development of a second primary cancer, or lifestyle-related comorbidities (e.g., 
cardiovascular disease, diabetes) may be partly caused by the same risk factors that were 
involved in the etiology of the primary cancer (3). Moreover, awareness of risk factors and 
perception of one’s own cancer risk may be important in the motivation to change 
unhealthy behaviours (18). 
 Awareness of smoking as a UBC risk factor greatly differs between studies, ranging 
from 10-85% (19). These differences can be explained by age, educational level, the type 
of question posed (open versus closed), and whether the question referred to UBC in 
general or to the patients’ own disease. For example, our recent study in 1,793 Dutch UBC 
survivors asked about possible causes of their own UBC, and only 12% of ever smokers 
reported smoking as a possible cause (19). In our previous and current study, patients also 
reported non-established risk factors for UBC. Therefore, it remains important to educate 
NMIBC patients about established risk factors, to prevent them from focusing on causes or 
behaviours that do not influence disease (20). 
 Information on awareness in combination with information on adherence to lifestyle 
recommendations provides insight into whether knowledge is put into practice. The 
majority of patients did not smoke, which is similar to the findings of a Canadian study in 
586 UBC patients (21). However, it is important to be aware that former smokers are prone 
to start smoking again as a coping mechanism in stressful situations (22). Only about 
one-third of the patients had a healthy body weight, which is similar to findings in cancer 
survivors as well as in a healthy population (23). Since the time between the two 
questionnaires was short, we did not expect large changes in BMI categories. The shifts 
we found were mainly caused by patients who had a BMI on the border of the categories 
and thus had a plausible weight loss or gain, although the possibility of misreporting 
cannot be excluded. The majority of patients adhered to the physical activity recommendation. 
However, physical activity is frequently over-reported (24). In the Canadian study in UBC 
patients, only one-third adhered to the physical activity recommendation (21), but a 
different questionnaire and different criteria for adherence were used. The increased 
163
Awareness, adherence, practice and attitude
7
adherence to the lifestyle recommendation on alcohol from baseline to follow-up was 
also found in studies in other cancer survivors (25). Lastly, two-third of the patients adhered 
to the recommendation not to use supplements, which was higher than in US cancer 
survivors (26). Patients who were aware of smoking, overweight, insufficient physical 
activity, and alcohol as risk factors for cancer were more likely to quit smoking or adhere 
to the corresponding lifestyle recommendations. Awareness of risk factors may thus be of 
importance for actual behaviour.
 Knowing whether and what kind of advice is given by physicians about risk factors 
and lifestyle can be used to improve provision of lifestyle advice in clinical practice. 
Although the majority of patients were asked about their smoking behaviour and the 
majority of smokers were advised to quit, still not all physicians follow the EAU guideline 
for NMIBC (27).  Given the fact that a cancer diagnosis is seen as a teachable moment (11), 
and that advice from a physician greatly increases the chances of success with smoking 
cessation (12), all physicians should be encouraged to advise smoking cessation. Patients 
were not routinely informed about other lifestyle factors, possibly because convincing 
evidence for an association with UBC prognosis is still lacking. 
 The positive attitudes of NMIBC patients towards lifestyle advice observed are in line 
with those found in a similar survey in cancer survivors conducted in the UK(16). Since 
patients sometimes agreed with both a positive (e.g., ‘helpful’) and negative attitude (e.g., 
‘placing the blame’), discretion in providing lifestyle advice is required. Training of health 
care professionals in this area may be needed, since physicians have been shown not to 
feel well equipped to deliver smoking cessation interventions (28), and this likely also 
applies to providing advice on other lifestyle factors. 
 The UroLife study is the first to extensively investigate the combination of awareness, 
adherence, practice, and attitudes regarding lifestyle recommendations. This provides 
valuable information for physicians and health promotion initiatives. Furthermore, patients 
were included shortly after diagnosis and followed up prospectively, minimizing the 
reliance on memory. Also, much effort was put into complete retrieval of the data by 
follow-up telephone calls. 
 Limitations include the reliance on self-reported questionnaires that are inherently 
accompanied by the risk of bias such as over- or underestimation because of social 
desirability. Furthermore, the prompted question format for the question about cancer 
risk factors as opposed to an open question may have led to an overestimation of 
awareness (29), but made our study comparable to most previous research. Lastly, 
follow-up measurements are needed to determine whether durable lifestyle changes 
have been made. 
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Conclusions
Many cancer risk factors were relatively unknown among NMIBC patients and adherence 
to cancer prevention recommendations varied widely. Although patients generally have a 
positive attitude towards receiving lifestyle advice, they were not routinely informed 
about risk factors and a healthy lifestyle by their physician. Therefore, information provision 
on lifestyle recommendations for cancer prevention to NMIBC patients by urologists and 
other health professionals should be improved.
Author contributions
Alina Vrieling had full access to all the data in the study and takes responsibility for the 
integrity of the data and the accuracy of the data analysis.
Study concept and design: Vrieling, Kiemeney, Kampman, Witjes.
Acquisition of data: Westhoff.
Analysis and interpretation of data: Westhoff, Vrieling.
Drafting of the manuscript: Westhoff, Hendriks.
Critical revision of the manuscript for important intellectual content: Vrieling, Kampman, 
Kiemeney, Witjes.
Statistical analysis: Westhoff.
Obtaining funding: Vrieling, Kiemeney, Witjes.
Administrative, technical, or material support: None.
Supervision: Vrieling, Kampman, Kiemeney, Witjes.
Other: None.
Financial disclosures
Alina Vrieling certifies that all conflicts of interest, including specific financial interests and 
relationships and affiliations relevant to the subject matter or materials discussed in the 
manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock 
ownership or options, expert testimony, royalties, or patents filed, received, or pending), 
are the following: None.
Funding/Support and role of the sponsor
A research grant (KUN 2013-5926) from Alpe d’HuZes/Dutch Cancer Society
Acknowledgements
We are grateful to all the patients who participated in this study and we would like to 
thank the following hospitals for their involvement in recruitment for the UroLife study: 
Amphia Ziekenhuis, Breda/Oosterhout (Drs. D.K.E. van der Schoot); Ziekenhuis Bernhoven, 
Uden (Drs. A.Q.H.J. Niemer); Canisius-Wilhelmina Ziekenhuis, Nijmegen (Dr. D.M. Somford); 
165
Awareness, adherence, practice and attitude
7
Catharina Ziekenhuis, Eindhoven (Dr. E.L. Koldewijn); Deventer Ziekenhuis, Deventer (Drs. 
P.L.M. van den Tillaar); Elkerliek Ziekenhuis, Helmond (Drs. E.W. Stapper †, Drs. P.J. van Hest); 
Gelre Ziekenhuizen, Apeldoorn/Zutphen (Drs. D.M. Bochove-Overgaauw); Isala Klinieken, 
Zwolle (Dr. E. te Slaa); Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch (Dr. J.R. Oddens); 
Meander Medisch Centrum, Amersfoort (Drs. F.S. van Rey); Medisch Spectrum Twente, 
Enschede (Dr. M. Asselman); Maxima Medisch Centrum, Veldhoven/Eindhoven (Dr. L.M.C.L. 
Fossion); Maasziekenhuis Pantein, Boxmeer (Drs. E. van Boven); Radboudumc, Nijmegen 
(Prof. Dr. J.A. Witjes); Rijnstate, Arnhem/Velp/Zevenaar (Drs. C.J. Wijburg); Slingeland 
Ziekenhuis, Doetinchem (Drs. A.D.H. Geboers); St. Anna Ziekenhuis, Geldrop (Drs. A. 
Sonneveld); Elisabeth-TweeSteden Ziekenhuis, Tilburg/Waalwijk (Dr. P.J.M. Kil; Drs. R.J.A.M. 
Davits); St. Jansdal Ziekenhuis, Harderwijk (Drs. W.J. Kniestedt); VieCuri, Venlo (Drs. G. 
Yurdakul); Ziekenhuis Gelderse Vallei, Ede (Drs. M.D.H. Kortleve); Ziekenhuisgroep Twente, 
Almelo/Hengelo (Dr. E.B. Cornel). In addition, we thank Monique Eijgenberger for her 
assistance in data collection. We also thank the registration team of the Netherlands 
Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands 
Cancer Registry as well as IKNL staff for scientific advice.
166
Chapter 7
References 
1. Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC Nomograms and Risk 
Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle- 
invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette- 
Guerin. Eur Urol. 2016;69(1):60-9.
2. Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic Burden of Bladder Cancer Across the European 
Union. Eur Urol. 2016;69(3):438-47.
3. Doyle C, Kushi LH, Byers T, Courneya KS, Demark-Wahnefried W, Grant B, et al. Nutrition and physical activity 
during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 
2006;56(6):323-53.
4. Ligibel J. Lifestyle factors in cancer survivorship. J Clin Oncol. 2012;30(30):3697-704.
5. van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP. Quantified relations between exposure to 
tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol. 
2016;45(3):857-70.
6. Zhao L, Tian X, Duan X, Ye Y, Sun M, Huang J. Association of body mass index with bladder cancer risk: 
a dose- response meta-analysis of prospective cohort studies. Oncotarget. 2017;8(20):33990-4000.
7. Keimling M, Behrens G, Schmid D, Jochem C, Leitzmann MF. The association between physical activity and 
bladder cancer: systematic review and meta-analysis. Br J Cancer. 2014;110(7):1862-70.
8. World Cancer Research Fund / International American Institute for Cancer Research. Continuous Update 
Project Report: Diet, Nutrition, Physical Activity and Bladder Cancer. 2015. www.wcrf.org/bladder-cancer-2015.
9. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial 
carcinoma: a systematic review of the literature. Eur Urol. 2014;65(4):742-54.
10. Westhoff E, Witjes JA, Fleshner NE, Lerner SP, Shariat SF, Steineck G, et al. Body mass index, diet-related factors, 
and bladder cancer prognosis: a systematic review and meta-analysis. Bladder Cancer. 2018;4(1):pp. 91-112.
11. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting 
long-term health after the diagnosis of cancer. J Clin Oncol. 2005;23(24):5814-30.
12. Bassett JC, Gore JL, Chi AC, Kwan L, McCarthy W, Chamie K, et al. Impact of a bladder cancer diagnosis on 
smoking behavior. J Clin Oncol. 2012;30(15):1871-8.
13. van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK, et al. The Patient 
Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, 
rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer 
survivorship cohorts. Eur J Cancer. 2011;47(14):2188-94.
14. WHO BMI Classification http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Last Accessed 4 Aug 2017.
15. Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity of the short 
questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003;56(12):1163-9.
16. Williams K, Beeken RJ, Wardle J. Health behaviour advice to cancer patients: the perspective of social network 
members. Br J Cancer. 2013;108(4):831-5.
17. Ryan AM, Cushen S, Schellekens H, Bhuachalla EN, Burns L, Kenny U, et al. Poor awareness of risk factors for 
cancer in Irish adults: results of a large survey and review of the literature. Oncologist. 2015;20(4):372-8.
18. Low CA, Beckjord E, Bovbjerg DH, Dew MA, Posluszny DM, Schmidt JE, et al. Correlates of positive health 
behaviors in cancer survivors: results from the 2010 LIVESTRONG survey. J Psychosoc Oncol. 2014;32(6):678-95.
19. Westhoff E, Maria de Oliveira-Neumayer J, Aben KK, Vrieling A, Kiemeney LA. Low awareness of risk factors 
among bladder cancer survivors: New evidence and a literature overview. Eur J Cancer. 2016;60:136-45.
20. Dumalaon-Canaria JA, Hutchinson AD, Prichard I, Wilson C. What causes breast cancer? A systematic review of 
causal attributions among breast cancer survivors and how these compare to expert-endorsed risk factors. 
Cancer Causes Control. 2014;25(7):771-85.
21. Blanchard CM, Courneya KS, Stein K. Cancer survivors’ adherence to lifestyle behavior recommendations and 
associations with health-related quality of life: results from the American Cancer Society’s SCS-II. J Clin Oncol. 
2008;26(13):2198-204.
22. Oh DL, Heck JE, Dresler C, Allwright S, Haglund M, Del Mazo SS, et al. Determinants of smoking initiation 
among women in five European countries: a cross-sectional survey. BMC Public Health. 2010;10:74.
167
Awareness, adherence, practice and attitude
7
23. Hawkins ML, Buys SS, Gren LH, Simonsen SE, Kirchhoff AC, Hashibe M. Do cancer survivors develop healthier 
lifestyle behaviors than the cancer-free population in the PLCO study? J Cancer Surviv. 2017;11(2):233-45.
24. Vassbakk-Brovold K, Kersten C, Fegran L, Mjaland O, Mjaland S, Seiler S, et al. Cancer patients participating in a 
lifestyle intervention during chemotherapy greatly over-report their physical activity level: a validation study. 
BMC Sports Sci Med Rehabil. 2016;8:10.
25. Hackshaw-McGeagh LE, Penfold CM, Walsh E, Donovan JL, Hamdy FC, Neal DE, et al. Physical activity, alcohol 
consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: 
opportunities for lifestyle modification. Int J Cancer. 2015;137(6):1509-15.
26. Velicer CM, Ulrich CM. Vitamin and mineral supplement use among US adults after cancer diagnosis: a 
systematic review. J Clin Oncol. 2008;26(4):665-73.
27. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU Guidelines on Non-Muscle-invasive 
Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71(3):447-61.
28. Keto J, Jokelainen J, Timonen M, Linden K, Ylisaukko-oja T. Physicians discuss the risks of smoking with their 
patients, but seldom offer practical cessation support. Substance Abuse Treatment, Prevention, and Policy Vol 
10 2015, ArtID 43. 2015;10.
29. Waller J, McCaffery K, Wardle J. Measuring cancer knowledge: comparing prompted and unprompted recall. 
Br J Psychol. 2004;95(Pt 2):219-34.

General discussion
8

171
General discussion
8
General discussion
The aim of this thesis was to investigate the association of smoking, fluid intake, and 
dietary patterns with risk of recurrence and HRQoL in NMIBC patients. Additionally, we 
aimed to investigate patients’ awareness of and adherence to lifestyle recommendations 
for cancer prevention, whether they received lifestyle advice, and what their attitudes are 
towards receiving lifestyle advice from their physician. In a review of the literature, we 
found that evidence for an association of pre- and post-diagnostic dietary and lifestyle 
factors with bladder cancer prognosis is limited, with some evidence that NMIBC patients 
who were overweight or obese at diagnosis had a higher risk of recurrence compared to 
those with a healthy weight. In a cohort of US NMIBC patients with data on dietary intake 
in the year before diagnosis, we found a higher risk of recurrence in patients who adhered 
most to a so-called Western diet, which is high in fried food, and red and processed meat. 
In preliminary analyses within the UroLife study, smoking at diagnosis and post-diagnostic 
fluid intake were not markedly associated with risk of recurrence nor with HRQoL in a 
fifteen-month period after diagnosis. HRQoL of NMIBC patients in the UroLife study was 
worse than HRQoL of a normative population for multiple domains, both directly as well 
as 15 months after diagnosis. Also, we found that complaints of appetite loss, diarrhea, 
urinary symptoms, and emotional concerns persisted until the last measurement at 15 months 
after diagnosis. Lastly, we showed that awareness of (bladder) cancer risk factors and 
adherence to cancer prevention lifestyle recommendations among NMIBC patients is low 
and that physicians’ information provision with respect to lifestyle should be improved.
 In the current chapter, our findings are placed in a broader perspective by elaborating 
on eleven statements. Also, recommendations for policy makers, clinical practice, and 
future research are provided.
An association between lifestyle and bladder cancer prognosis is 
mechanistically plausible
Even though the biologic mechanisms underlying the association of lifestyle factors with 
urinary bladder cancer (UBC) prognosis are not yet completely understood (1), there are 
numerous hypotheses how lifestyle habits can influence UBC (2). Potentially harmful 
substances from food and cigarettes, such as polycyclic aromatic hydrocarbons and 
heterocyclic aromatic amines, are excreted through the urinary tract. These substances 
are known to have a carcinogenic effect on the entire urinary system (2). They come into 
close contact with urothelial cells and may directly act on the urothelium, causing DNA 
damage and promoting pathogenesis (3-9). Further, components of tobacco smoke are 
involved in immune modulation (10, 11), and may induce specific mutations in genes 
related to DNA repair or tumor suppression such as ERCC2 (12) and TP53 (13). Through the 
same mechanisms known or hypothesized to be involved in etiology, smoking is thought 
to be associated with more aggressive tumours with a less favourable prognosis (14-21). 
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However, other studies did not find an association of smoking with tumours with a worse 
prognosis (22-30) and more research is needed into the exact mechanism through which 
smoking may be associated with worse prognosis. A recent study in MIBC patients found 
that smoking was associated with a more aggressive molecular subtype (31). This finding 
has not yet been replicated in NMIBC patients, and deserves further research.
 Fluid intake could potentially act as an effect-modifier or intermediate in the excretion 
of carcinogens through the urinary tract. A larger fluid volume intake is thought to dilute 
carcinogens in the urine, and decreases contact time with the urothelium through an 
increased micturition frequency (6). However, the role of fluid intake is complicated and 
dependent on micturition frequency, the types of fluid consumed, and the nutritional 
content of both diet and fluids. Together, they influence the concentrations of carcinogenic 
and anti-carcinogenic substances in the urine and the transit time and this could be 
associated with both risk and prognosis of NMIBC (6, 32).
 Overweight and obesity may increase the risk of recurrence in NMIBC  by inducing 
systemic and local biochemical and immunological changes, including altered levels of 
insulin, insulin-like growth factor-1, leptin, adiponectin, steroid hormones, and cytokines 
(33, 34). For example, a higher amount of body fat leads to elevated secretion of pro- 
inflammatory cytokines which induces chronic inflammation. Inflammation causes an 
increased cell proliferation and a decreased insulin sensitivity (35). In NMIBC patients, 
markers of systemic inflammatory response have indeed been associated with increased 
risk of recurrence and progression (36). Also, potential difficulties in performing a complete 
transurethral resection of the bladder in obese patients may play a role (37, 38). 
Conclusion: The association of lifestyle with bladder cancer prognosis is mechanistically 
plausible. Because of the good survival but relapsing nature, NMIBC is an excellent model 
to investigate the association of lifestyle with disease outcome. 
There is not sufficient evidence that dietary and lifestyle factors 
influence bladder cancer prognosis
To date, research has primarily focused on the role of diet and lifestyle in cancer etiology. 
Due to earlier diagnosis, more effective treatments and an ageing population, the number 
of patients in the Western world is rapidly increasing (39). However, research on the effects 
of lifestyle on cancer prognosis lags behind. Most studies on lifestyle and prognosis in 
bladder cancer were focused on pre-diagnostic smoking (40-42). Evidence is increasing 
that current and former compared to never smokers have a higher risk of tumour 
recurrence (40-42), and possibly a higher risk of cancer-specific mortality as well (41, 42). 
Evidence for an association between smoking and disease progression is weak (42) and 
results of studies on smoking cessation are inconsistent (40, 43-46). Especially the impact 
of smoking cessation shortly before or after diagnosis remains unclear (46-50). Two 
historical cohort studies (47, 48) found a protective effect of quitting smoking after 
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diagnosis, but this has not yet been confirmed by prospective cohort studies (46), 
including our own study (chapter 3). The lack of an association in our study, as well as in 
some other studies, may support the hypothesis of ‘field cancerization’ (51, 52). Long term 
exposure to carcinogens in e.g. tobacco can cause genetic alterations in stem cells, which 
can result in the replacement of fields of normal mucosa with preneoplastic cells. When 
only the primary tumour has been removed, the remaining fields of precancerous cells 
may eventually lead to disease recurrence, independent of whether someone quits 
smoking or not. 
 Our systematic review and meta-analysis of the available evidence regarding the impact 
of body mass index (BMI), diet and dietary supplements complemented the reviews on 
smoking (chapter 2). An increased risk of recurrence was found for overweight and obese 
compared to normal weight NMIBC patients in a meta-analysis of three studies. Observational 
studies on diet and intervention studies with dietary supplements showed inconsistent 
results. Some reported protective associations of single foods and supplements with risk of 
recurrence or cancer-specific mortality, but others did not find evidence of an association. 
Studies on physical activity were not available. 
 In general, studies performed to date had methodological shortcomings and no 
firm conclusions can be drawn. Many studies were retrospective, small, based on single 
pre-diagnostic measurements, and did not report patient characteristics and methods 
in a clear way. Also, analyses were often not stratified by stage and grade, although risk 
of recurrence, progression, and mortality are known to differ by stage and grade (53). 
Therefore, possible associations with lifestyle and disease outcomes could have been 
masked. 
Conclusion: Evidence-based recommendations with respect to diet and lifestyle cannot 
be given to NMIBC patients yet. Until conclusive evidence is available, patients should be 
advised to quit smoking based on the association with several comorbidities and possibly 
the risk of second primary cancers. Further, patients should be referred to the general 
lifestyle recommendations for cancer prevention of the World Cancer Research Fund / 
American Institute for Cancer Research  (54).
A Western dietary pattern may increase the risk of NMIBC recurrence
In a large ongoing cohort study performed at the M.D. Anderson Cancer Center and 
Baylor College of Medicine, we found that adhering most to a Western dietary pattern was 
associated with a higher risk of recurrence in NMIBC (chapter 4). There seemed to be a 
trend for higher risk of progression as well. Our findings are in line with a study on bladder 
cancer risk (55), with a study on colorectal cancer recurrence (56), and with a meta-analysis 
on breast and colorectal cancer and overall mortality (57). 
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A classical Western dietary pattern is high in animal products, especially red and processed 
meat, refined grains, and high-fat and high-sugar snacks (57-59). These food items contain 
several potentially carcinogenic compounds (N-nitroso-compounds, polycyclic aromatic 
hydrocarbons and heterocyclic aromatic amines) that are excreted through the urine (5, 60). 
Nevertheless, it is not yet possible to draw firm conclusions. 
 Foods and nutrients may be correlated and potentially interact with each other (61). 
Analysis of dietary patterns instead of single foods or nutrients takes into account the 
multidimensionality of the diet and resembles a more real-life situation (62-64). However, 
it is important to consider the complexity of this type of analysis. At several times during 
the analysis, rather subjective choices have to be made, e.g. which foods to include, 
whether and how to group foods, how many factors to retain, and what cut-off point to 
choose to decide which foods or food groups contribute to the retained factors. These 
choices influence the rest of the analysis and thus the results. Therefore, it is recommendable 
that at least two researchers perform this analysis separately, to compare the outcomes, 
and to discuss and resolve any disagreements. Depending on the aim of the research, it 
might be also an option to use an existing diet quality index and score patients accordingly, 
instead of using a data-driven approach like factor analysis.
Conclusion: Evidence-based recommendations with respect to diet cannot be given to 
patients yet. Since a classical Western diet is generally high in unhealthy products, replacing 
foods typical for the Western diet by e.g. fruits, vegetables, and high-fibre products can be 
advised for general health benefits. 
Prospective cohort studies with repeated lifestyle measurements  
are needed to obtain more insight in the role of dietary and lifestyle 
factors in NMIBC prognosis and HRQoL
Because of methodological shortcomings of available studies, there is an urgent need for 
prospective cohort studies specifically designed to study dietary and other lifestyle 
factors in relation to NMIBC prognosis and HRQoL. There are several considerations with 
regard to the design of such studies. First of all, newly diagnosed NMIBC patients should 
be recruited as shortly after diagnosis as ethically and logistically possible. In that way, an 
assessment of pre-diagnostic dietary and lifestyle habits is still possible. Preferably, this 
assessment is followed by multiple post-diagnostic assessments of lifestyle until at least 
five years after diagnosis to be able to capture any (long-term) changes. With this study 
design, the most relevant question for the patient can be addressed, i.e. whether lifestyle 
changes at the time of, or after diagnosis can favourably alter disease prognosis and HRQoL. 
 Since lifestyle habits may be correlated and (un)healthy habits may be clustered within 
persons (65-68), it is important to assess multiple lifestyle habits. Preferably, measurement 
of habitual dietary intake should be combined with measurements of smoking, physical 
activity, sedentary behaviour, and a measure of abdominal obesity. Waist circumference, 
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waist-hip ratio, or waist-height ratio should be considered as a more suitable measure of 
abdominal obesity than the often used BMI (69-72). 
 Objective measurements should complement self-reported questionnaires where 
possible These can overcome issues inherently associated with self-reported measures, 
including socially desirable answers, over- and underreporting of food intake, and misin-
terpretation of questions, and prevent bias. Examples of more objective measures are 
blood samples to investigate biomarkers of fruit and vegetable intake, and accelerometers 
as a measure of physical activity and sedentary behaviour. Naturally, these measures have 
other disadvantages to take into account. Therefore, a combination of both self-reported 
measures and objective measurements should be strived for. 
Conclusion: Prospective studies with self-reported and objective lifestyle measurements, 
taking into account lifestyle factors before and after diagnosis, are needed to obtain more 
insight in their role in NMIBC prognosis and HRQoL.
The Netherlands Cancer Registry is an essential partner  
for the recruitment of patients and clinical data collection for  
a prospective cohort study
With almost complete coverage, the Netherlands Cancer Registry (NCR) is an excellent 
infrastructure for population-based patient recruitment. The objective of the NCR is to record, 
report, improve and regulate information about every patient with cancer (73). However, 
in our opinion the NCR is in the perfect position to be, and should also function as, a logistic 
framework to recruit patients and to collect both clinical and patient-reported data. 
 In our study UroLife, we asked permission from all urologists of the participating 
hospitals to identify their eligible patients in the NCR. Patients were then identified and 
invited by the NCR on behalf of their urologist to participate in the study. In this way, 
patients were invited as quickly as possible after their diagnosis, with no additional effort 
for the urologists, resulting in a satisfactory response rate of around 50%. An alternative 
would be that patients are directly invited by their physician. However, this will likely have 
negative consequences for accrual for studies that do not focus on treatment interventions 
(74). It has been shown that physicians experience multiple barriers to recruiting patients 
for research, such as additional workloads without compensation, conflicts of interest 
when multiple studies are being performed at the same time, beliefs and/or attitudes 
toward clinical research, protection of their patients, and a lack of knowledge about the 
study (74-76). Therefore, it is essential that the NCR remains involved in the recruitment of 
patients. Low recruitment rates can hamper the validity of the results because of possible 
selection bias, reduce the statistical power to detect associations, and extend the study 
duration (77). 
 The recording and reporting of data by the NCR is currently focused on tumour- 
specific clinical data. Given the increasing number of cancer survivors, patient-reported 
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outcomes (PRO) such as HRQoL and quality of care are becoming more important and 
constitute a prominent research area (78-80). A PRO captures the patients’ perspectives on 
how disease, therapy, and the provided care are impacting their well-being. When 
routinely collected, it can be used to work towards evidence-based, personalised health 
care (78). 
Conclusion: The NCR is in a unique position to recruit patients for prospective studies and 
to routinely collect PRO on almost all patients diagnosed with cancer in the Netherlands.
The optimal statistical analysis of prospective cohort studies with 
repeated measurements and multiple outcomes is still unclear
Apart from our study UroLife, several prospective cohort studies in the field of lifestyle and 
bladder cancer are being performed at this moment (81-84). Even though some of them 
are in the phase of (preliminary) data analysis, methods for the statistical analysis of such 
studies still need to be improved. It is especially challenging how to make optimal use of 
the repeated measurements to evaluate lifestyle changes in relation to prognosis. E.g. 
what time span should be kept as a minimum between the lifestyle measurement and the 
outcome? How to deal with patients with fluctuating lifestyle behaviour? Joint efforts are 
needed from both lifestyle researchers and statisticians to resolve these issues. 
 Also, the starting point of follow-up of patients is not always clear. Follow-up should 
start when a patient is at risk of the outcome of interest. In many studies this is immediately 
after diagnosis or removal of the primary tumour. However, NMIBC patients are theoretically 
not immediately at risk of a recurrence after the transurethral resection of the bladder 
tumour (TURBT) for the primary tumour when a re-TURBT is planned. Therefore, in case a 
re-TURBT was carried out, we started follow-up at the date of the re-TURBT. Also, we 
considered all tumour tissue found within 90 days of the resection of the primary tumour 
to be part of the primary tumour, as this is standard practice in the NCR. Thus, theoretically 
a NMIBC patient would not be at risk of a recurrence within 90 days after the first resection. 
This time period of 90 days is nonetheless quite arbitrary and should be reconsidered.
 Lastly, many NMIBC patients have multiple recurrences. Traditionally, either time to 
first recurrence or the number of recurrences is assessed as an outcome. However, time to 
first recurrence does not take into account what happens subsequently, and the number 
of recurrences does not take into account how much time there is between multiple 
recurrences. For example, two patients who both have their first recurrence at 9 months 
after diagnosis will be treated equally in the analysis, but might have a totally different 
course of disease after their first recurrence. Similarly, a patient with a recurrence at 2 and 
5 years after diagnosis might be different from a patient with two recurrences within the 
first year after diagnosis who is lost to follow-up thereafter. This information should be 
better addressed in the statistical analyses. 
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Conclusion: Currently available statistical methods are not being used in an optimal way. 
Improvements can be made especially by better defining when a patient is at risk, and by 
using multiple lifestyle measurements and including multiple outcomes. 
Urinary symptoms and future worries can persist for a longer time 
and are dependent on adjuvant treatment 
Even though overall scores in the urinary symptoms domain improved, the presence of 
one or more individual urinary symptoms was still reported by 40% of the patients at the 
end of follow-up. Pollakiuria and nocturia were the most common complaints. The 
improvement in the urinary domain was observed in other studies as well (85, 86), but 
individual symptoms were not reported. As we showed that a substantial number of 
patients still has symptoms, this should not be neglected by only taking into account 
overall scores. Twenty-four percent of the patients had one or more emotional concerns 
at the end of the fifteen-month follow-up period, of which health in the future was the 
main concern. The persistence of emotional concerns for a longer period was also 
observed in studies performed in the UK and Korea (87, 88). Despite the good prognosis of 
NMIBC, the considerable number of patients with concerns indicates a potential need for 
psychological support. Scores on all other domains of both the EORTC QLQ-C30 and the 
disease-specific EORTC QLQ-NMIBC24 improved over time or remained constant, as was 
also observed in other studies (85-88).
 Patients treated with intravesical immunotherapy or chemotherapy reported more 
future worries and intravesical treatment issues compared to patients treated with TURBT 
only. This may be partly due to their generally more aggressive disease. A Spanish study 
comparing different treatments in 244 NMIBC patients also found differences with regard 
to treatment. Here, patients treated with intravesical chemotherapy improved over a 12 
month period in the sexual domain compared to patients treated with TURBT only, and 
patients treated with immunotherapy improved in the bowel domain (86). Additionally, 
patients in our study who received bacillus Calmette-Guérin immunotherapy had more 
urinary symptoms as compared to patients treated with TURBT only, as observed in other 
studies (85, 89, 90). However, neither in our study, nor in most other studies (85, 86, 91), 
immunotherapy had an impact on other aspects of HRQoL that are often worse in other 
cancer survivors, such as fatigue and functioning scales (92, 93). This indicates that 
intravesical immunotherapy, outside of NMIBC-specific complaints, is generally well 
tolerated. 
Conclusion: HRQoL of NMIBC patients improved in most domains after diagnosis, but 
attention should be paid to persistent urinary symptoms and future worries, especially in 
patients treated with intravesical immunotherapy. 
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Awareness of (bladder) cancer risk factors and adherence to cancer 
prevention recommendations among bladder cancer patients is low 
We found that most NMIBC patients recognized smoking and passive smoking as risk 
factors for cancer in general, but other established lifestyle-related factors were less well 
known (chapter 7). Low levels of awareness of lifestyle risk factors other than smoking 
were also observed in other studies (94-99). Even though around one-third of all bladder 
cancer cases is attributable to smoking, this was mentioned as a risk factor for bladder 
cancer by less than 50% in our study. Only 11% of ever smokers reported smoking as a 
perceived cause for their own disease (chapter 6). 
 Ignoring risk factors that might have been within the patients’ control may be a 
strategy to shield themselves against negative emotions, such as blame from self or others 
(100). Also, it is known that people tend to attribute causes for negative events externally 
(100, 101). We also observed that many patients thought that environmental or chemical 
exposures that were out of their control could be a cause of bladder cancer in general 
(chapter 7) or of their own disease (chapter 6). External attribution often goes together 
with a fatalistic view that nothing can be done to prevent cancer or improve prognosis 
(102). These beliefs are important to address, since they may decrease the probability of a 
patient engaging in healthy behaviours (102, 103). Further, the way of questioning may 
play a role in the response given by patients. An open-ended format combined with the 
possibility of answering ‘no’, as we used in chapter 6, possibly gave patients the 
opportunity to avoid thinking about possible causes for their disease (104). This may have 
led to an underestimation of their actual awareness. In contrast, a prompted list of risk 
factors as in chapter 7 may have led to an overestimation of awareness. As just recognizing 
a risk factor when it is prompted is less likely to translate into behaviour change, 
open-ended questions may give a more useful indication of accessible knowledge that 
might influence more direct predictors of behaviour and behaviour change (104). 
 As awareness of risk factors and perception of one’s own cancer risk may be important 
in engaging in healthy behaviours (105), it is not surprising that we found a low adherence 
to lifestyle recommendations for cancer prevention except for smoking (chapter6). 
Our findings are in line with other studies in cancer patients with regard to smoking (106), 
body weight (107, 108), and alcohol (107). However, in our study a higher percentage of 
NMIBC patients was adhering to the recommendation for supplement use, i.e. not to take 
supplements for cancer prevention (109). For the physical activity recommendation, results 
are highly diverse and seem to vary with, among others, age, gender, and socio-economic 
status (106, 107, 110-112). In our study, adherence to cancer prevention recommendations 
was generally higher for patients who were older, male, and higher educated. Also, 
patients who were more aware of overweight, insufficient physical activity, and alcohol as 
being risk factors for cancer were more likely to meet the corresponding cancer prevention 
recommendation. It should be kept in mind though that patients could have given socially 
desirable answers that may have led to an overestimation of adherence (113). 
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Conclusion: Clearly, although awareness of cancer risk factors does not automatically 
translate into adherence to cancer prevention recommendations, it is an important 
element of behaviour change. 
Low awareness and adherence but positive attitudes towards  
lifestyle advice among NMIBC patients highlights the need for 
effective education
The low levels of awareness and adherence with regard to lifestyle in our study indicate a 
need for education. Awareness of the association between a risk factor and the disease 
can enhance the motivation to change it (114) and is thus essential when increased 
adherence to recommendations is the ultimate goal. Mass media campaigns focused on 
smoking for example have been proven to be successful in altering smoking behaviour 
(115, 116). The knowledge that has been gathered over the years of what bladder cancer 
survivors perceive as causes of their cancer (114, 117-119) also provides valuable information 
for health education and prevention initiatives. The reporting of risk factors that are not 
associated with risk or for which there is no evidence (yet) also highlights the importance 
of effective education to debunk myths. Focusing on factors that are not really risks may 
withhold patients from addressing behaviour that really matters (120).
 Even though patients’ lifestyle habits were often unhealthy, they had positive attitudes 
towards receiving lifestyle advice. Attitude is an important indicator of how receptive 
patients are for health promotion initiatives and how willing they are to make changes 
(121, 122). The government also has a role in providing clear, evidence-based and easily 
accessible information, as conflicting messages in the media cause uncertainty about 
what is true.  
Conclusion: The existing evidence on the association between lifestyle and (bladder) 
cancer should be used to educate patients, since their awareness of risk factors is low and 
their attitudes towards lifestyle advice are positive.
Urologists and other health care professionals should be better 
equipped to inform bladder cancer patients about a healthy lifestyle 
Although NMIBC patients have a positive attitude towards receiving lifestyle advice, they 
were not routinely informed by their physicians (chapter 7). About 20% of patients 
indicated that physicians did not ask about their smoking behaviour. Thus, information 
provision by physicians should be improved. There are several reasons for physicians not 
to give lifestyle advice to patients, as has been shown in different studies (123, 124). Barriers 
include time constraints, doubt of effectiveness, a lack of skills in the behavioural change 
field, and doubt about whether it is appropriate to interfere in patients’ lives, (123, 124). 
Further, they do not want to give patients the feeling that they are blamed for their own 
disease. This delicate balance needs skills of the physician that might not receive sufficient 
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attention during their education. Further, another barrier may be the lack of evidence for 
the effectiveness of lifestyle changes for the specific disease. Although there is no direct 
evidence for an association of lifestyle with NMIBC prognosis yet, advice on a healthy 
lifestyle already is relevant for these patients. Lifestyle-related comorbidities such as 
diabetes mellitus type II and cardiovascular disease are highly prevalent among cancer 
patients. In our study, more than half of the patients had at least one of these comorbidities. 
A better physical condition is advantageous when surgery or multiple treatments are 
necessary. Also, smoking cessation greatly reduces the risk of peri- and post-operative 
complications in case a cystectomy is necessary (125-127).
 Despite these barriers, the need for training of urologists and other health care 
professionals in this field is evident, since NMIBC patients have been shown to be more 
likely to accept smoking as a cancer risk factor when this information was provided by 
their urologist (128), and that a cancer diagnosis could be a teachable moment (129). 
 However, it takes a village to change. Behaviour change is a complicated process in 
which patients often need repeated personal appointments to be successful. This support 
cannot only be expected from urologists, but should also be provided by other health 
care professionals. Provision of lifestyle advice also does not change the environment 
patients live in, their social network, or the amount of support they receive. 
Conclusion: A systems approach to promote behaviour change is needed, and additional 
policy measures to support health promotion initiatives are necessary.
Setting up and obtaining valid results on cancer-specific  
outcomes from a prospective cohort study within the time frame  
of a PhD project is not feasible
Setting up and obtaining valid results on cancer-specific outcomes from a multi-center 
prospective cohort study is like a long and winding road. The study first needs to be 
approved by the ethics committee and then by the executive boards of all participating 
hospitals (or local committees on behalf of them). For UroLife, local committees of 
participating hospitals often did not only review the feasibility of the study, as they should 
(130), but also reviewed the protocol again. Together with delays due to a lack of clarity 
about the procedure, this made the local approval procedures very time consuming 
(average time 5 months, range 1.5-12 months). 
 After the introduction of the General Data Protection Regulation (131) in May 2018, 
setting up multi-center prospective cohort studies may become even more complicated. 
The new law may seriously interfere with doing epidemiological research and, among 
others, slow down the process of getting ethical and local approval (132-134). For example, 
currently patients often give permission to be approached again for future research. At 
that time, it is usually unclear what the future research exactly entails, because it is partly 
dependent on findings of the current research. With the new privacy law, the informed 
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consent needs to be more specific and if that is not possible, consent has to be obtained 
again. Also, rules concerning depersonalisation are much stricter. Where pseudonimisa-
tion of personal data used to be considered safe, it is not anymore. Further, changing 
privacy laws are a danger to complete coverage of the NCR (132), especially when the 
current opt-out system will be changed into opt-in (135-139). The balance between the 
improvement of health (care) through research and personal data protection appears to 
move in favour of the latter. Researchers, clinicians, and policy makers should join forces 
and cooperate to find the best solution for all parties.
 In order to be able to evaluate associations of diet and lifestyle with appropriate 
clinical disease outcomes, sufficient participants and a minimum duration of follow-up are 
necessary to observe sufficient outcomes to ensure sufficient statistical power. In NMIBC 
patients, tumour recurrence occurs relatively shortly after diagnosis (140), but still a 
follow-up time of at least two years and preferably five years is needed. 
Conclusion: Because of the lengthy local approval procedures and the prolonged 
recruitment period, it is evident that this four-year PhD project was not long enough to 
complete such a study. Since we could only include 550 instead of the initially planned 
1000 NMIBC patients in our preliminary analysis, with a median follow-up time of 19 
months, true associations between lifestyle and risk of recurrence may have been 
overlooked because of a lack of statistical power. Future analyses of the complete cohort 
will yield more information.
Recommendations for policy makers
To be able to make full use of the potential effects of lifestyle to improve health, and to 
increase research possibilities in the future, several recommendations for policy makers 
can be made. 
 Through policy the government can and has to give direction to the solution of social 
problems. One of these is the burden of Western diseases, in which the role of lifestyle is 
evident. The government has several tools to improve lifestyle behaviour and thereby 
reduce healthcare costs by primary, secondary and tertiary prevention. Through stricter 
policy around tobacco, alcohol and unhealthy food, the burden of many diseases can be 
reduced. For example, higher taxes on tobacco, and bans on advertising, promotion and 
sponsorship (116, 141). A topical issue in this field is the sugar-sweetened beverage tax. 
Taxes in different forms have been implemented in over twenty countries and have been 
shown to be effective in lowering sugar consumption (142).
 A less far-reaching tool is nudging, which is the use of positive reinforcement and 
indirect suggestions to guide behaviour in the desirable direction without limiting 
freedom of choice (143-147). Examples of nudging are footsteps directing people to the 
stairs instead of the elevator, placing a sign with “most sold in this supermarket” above the 
shelf with broccoli, and changing the default side order to vegetables instead of fries. 
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In contrast to the new privacy law, it should be considered to use the citizen service 
number for research purposes, as is now common practice in the Scandinavian countries 
(148). Use of the citizen service number would allow linkage between medical registers, 
preferably without explicit approval of the patients. The protection of the patients’ privacy 
is of utmost importance, but so is improving health and health care through research. 
Among others, this linkage enables researchers to estimate morbidity and mortality in 
various patient populations, perform high powered analyses, and evaluate sensitivity and 
specificity of new diagnostic techniques (148). 
Recommendations for clinical practice
This thesis underlined the need for and necessity of better information provision with 
regard to lifestyle. Urological practice would look different if we start treating lifestyle as a 
medicine in addition to regular treatment. Lifestyle should be a standard topic of 
conversation within urological practice, as smoking is the most important risk factor. 
However, knowledge of urologists how to approach such a sensitive topic, and more 
general knowledge about lifestyle, is suboptimal and should be improved. A prominent 
argument not to discuss lifestyle is the lack of convincing evidence for the association 
between lifestyle factors and the specific disease. For bladder cancer, only smoking has 
been consistently associated with risk, but evidence is still limited for an association with 
prognosis. Nevertheless, the WCRF/AICR lifestyle recommendations for cancer prevention 
(54) and the Dutch guidelines for healthy nutrition (149) are beneficial for everybody. 
Especially cancer patients, who often have a more unhealthy lifestyle predisposing them 
to several comorbidities, could benefit. We recommend that physicians register their 
patients’ lifestyle and eventual intentions to change it in a standardized way in the medical 
chart. In this way, all medical specialists have access to the same information and can use 
it to start a conversation on lifestyle. Further, prevention is not only a task of municipalities, 
Public Health Services, and the National Institute for Public Health and the Environment. It 
should be viewed and treated as a joint responsibility of aforementioned parties and 
general practitioners and medical specialists. As urological practice is not always the right 
place to give patients the support they need, referral to primary care is often desirable. 
Proper feedback between all parties is however essential to make prevention initiatives 
succeed, and improve patients’ health. 
 Lastly, clinicians need to be alert to individual impairments in HRQoL. We observed 
several clinically relevant differences between NMIBC patients and a normative population 
over a fifteen-month period after diagnosis. Most of these differences became less 
prominent over time, but complaints about appetite loss and diarrhea became present 
after 3 months after diagnosis and were still present at 15 months after diagnosis. 
Additionally, a substantial number of patients still reports urinary symptoms or emotional 
worries at 15 months after diagnosis. 
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Recommendations for future research
During this PhD project, we experienced a number of difficulties that made the 
performance of this research challenging. To avoid similar situations in the future, several 
recommendations can be made. 
 During the recruitment phase of UroLife, we often heard that patients were already 
participating in another study, or felt overwhelmed by numerous requests to participate 
in trials. For them, this could be a reason to refuse participation to UroLife, or to any study 
they were invited for. Also, patients participating in more than one study at a time often 
had difficulties understanding why questionnaires overlapped so much, or why they had 
to give blood multiple times. Sometimes these studies indeed had partly overlapping 
research aims. Cooperation in the form of better alignment or (partial) integration of 
studies would not only decrease the burden on patients but also highly increase the 
efficiency of research and the use of materials and budget. Another benefit of more 
cooperation between studies is to obtain a larger sample size and more statistical power 
to study progression, or detect associations that only exist in subgroups, and would 
remain undetected in smaller study samples. 
 Future studies should investigate associations between lifestyle and NMIBC prognosis 
by molecular subtype, as relevant disease outcomes are clearly different for these 
subgroups (150). Three molecular subtypes of NMIBC have been identified, i.e. urobasal, 
genomically unstable, and squamous-cell-carcinoma-like bladder cancer (151-153). T1 
tumours are mostly of the genomically unstable and squamous-cell-carcinoma-like 
subtypes and have a high risk of progression (152). Also, a study in MIBC patients found 
that former and current versus never smoking was more strongly associated with the 
genomically unstable than with the urobasal subtype (31). Therefore, future studies should 
collect tumour tissue to be able to investigate whether molecular subtypes can be seen 
as intermediate variables in the associations of smoking and possibly other lifestyle factors 
and NMIBC prognosis.
 As we experienced, numerous definitions of recurrence and progression are being 
used, making comparison between studies complicated (154, 155). It is recommended to 
let an expert panel decide upon the critical elements in the definitions so that all studies 
can report the same clinical endpoints in the future. In this way, integration of studies will 
be easier, which will allow high powered subgroup analyses. Similarly, more effort should 
be put into the standardization of other clinical data and into the standardization of the 
interpretation and comparison of HRQoL scores. Statistically significant HRQoL differences 
between groups or over time are too often being reported as the main outcomes of a 
study. However, when study size is large enough, these differences may be so small that 
they will not be relevant to the patient. The determination of how large the difference 
should be to be considered relevant for the patient and in clinical practice is difficult. 
Several HRQoL instruments have their own guidelines, but these are hard to compare and 
the distinction between a ‘small’ and a ‘medium’ clinically relevant difference is still hard 
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to grasp for both researchers and clinicians. The highly subjective nature of HRQoL further 
complicates the interpretation. A way to transfer HRQoL scores of different instruments in 
one uniform and easily interpretable scale should be a high priority on the research 
agenda.
Concluding remark
With UroLife, we have an enormous potential to discover what we can do with lifestyle to 
improve the HRQoL and prognosis of NMIBC patients. An exciting time lies ahead of us. 
With the collection of questionnaire data and blood samples at different time points, and 
tumor tissue for molecular subtyping, we are working towards a goldmine of information 
and possibilities to give the best possible support to the patients. 
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Urinary bladder cancer (UBC) is a common malignancy, which ranks ninth in worldwide 
cancer incidence. The most important risk factor for UBC is smoking. Smoking cigarettes 
is associated with an over three-fold increased risk of developing UBC, while smoking 
cessation can decrease the risk. The World Cancer Research Fund / International American 
Institute for Cancer Research concluded that there is limited suggestive evidence for a 
protective effect of fruit, vegetables, and tea. No conclusions could be drawn for other 
dietary factors, physical activity, or body mass index (BMI). However, recent meta-analyses 
also found a small increased UBC risk with a higher BMI, and a decreased risk with higher 
levels of physical activity and vitamin E. 
 Approximately 75% of UBC patients present with non-muscle-invasive bladder cancer 
(NMIBC). NMIBC has a high five-year recurrence rate (28-52%), necessitating an intensive 
follow-up and potentially multiple treatments. Lifestyle factors have been linked to the 
prognosis of several cancer types, but the role of lifestyle in NMIBC prognosis has scarcely 
been investigated. Studies conducted to date were mostly focused on smoking. Both 
former and current smokers may be at an over 20% higher risk of disease recurrence than 
non-smokers. 
 Apart from a potential effect on NMIBC prognosis, lifestyle may have an effect on 
health-related quality of life (HRQoL). NMIBC patients have been shown to have a worse 
mental and/or physical health compared to a normative population. As several health 
behaviours have been linked to HRQoL in survivors of other cancer types, a healthy 
lifestyle may improve HRQoL in NMIBC patients as well. Until now, there is only suggestive 
evidence for an association of higher physical activity levels with better HRQoL in UBC 
survivors.
 Besides the role of lifestyle before diagnosis, it is of great interest to know whether 
changes made after diagnosis can still beneficially alter the course of disease or have an 
impact on HRQoL. These questions are yet unanswered, leaving urologists with only 
general lifestyle advice when patients ask what they can do themselves to improve their 
prognosis. Ultimately, the development of evidence-based lifestyle advice specifically for 
NMIBC could aid urologists in giving lifestyle advice, and could give patients some control 
over their disease by involving them in their disease management.
 The aim of this thesis was to investigate the association of smoking, fluid intake, and 
dietary patterns with risk of recurrence and HRQoL in NMIBC patients. Additionally, we aimed 
to investigate patients’ awareness of, adherence to, and interest in lifestyle recommendations 
for cancer prevention. 
196
Chapter 9
This thesis starts with a general introduction on UBC etiology and prognosis, the role of 
lifestyle factors in the development and prognosis of UBC, HRQoL of patients and the 
association of lifestyle with HRQoL, and it introduces the complexity of behaviour change 
after diagnosis (Chapter 1). The aim and outline of the thesis is also presented. 
In Chapter 2, we give an overview of the existing evidence on the associations of BMI, 
diet, and dietary supplements with bladder cancer recurrence, progression, and mortality 
in the form of a systematic review and meta-analysis. We included 31 studies published 
until May 2017, 13 of which were focused on BMI. We found that evidence for an association 
of lifestyle factors with bladder cancer prognosis is limited. In a meta-analysis of three 
studies in NMIBC patients we showed that overweight and obesity compared to normal 
weight were associated with increased risk of recurrence. No association with risk of 
progression to muscle-invasive bladder cancer (MIBC) was found. Results of studies on 
BMI in relation to prognosis in NMIBC and MIBC patients combined, or restricted to MIBC 
patients, were inconsistent and sometimes even opposite. Some observational studies on 
diet and dietary supplementation studies found a potentially protective effect on recurrence, 
cancer-specific-, or all-cause mortality, but only for single foods and supplements. 
However, most studies had (severe) methodological shortcomings. Prospective cohort 
studies with repeated measurements focusing on appropriate clinical outcomes, and 
covering the entire diet are needed to develop evidence-based guidelines. 
In Chapter 3, we studied the association of self-reported smoking status at diagnosis, 
time since smoking cessation, cumulative smoking exposure, and post-diagnostic fluid 
intake with risk of NMIBC recurrence in our prospective cohort study UroLife. We included 
550 newly diagnosed NMIBC patients who completed a questionnaire on smoking at 6 
and 12 weeks after diagnosis and a 4-day diary on fluid intake at 12 weeks after diagnosis. 
Median follow-up time was 19 months, and 103 patients (19%) developed at least one 
recurrence. Most patients were former (58%) or current (26%) smokers and median average 
fluid intake was 1840 mL (interquartile range 1500 – 2215). In these preliminary analyses, 
smoking and fluid intake were not statistically significantly associated with risk of 
recurrence. Risk of recurrence was non-statistically significantly increased among former 
smokers. Among ever-smokers, having smoked the highest versus lowest amount of 
pack-years was associated with a non-statistically significant increased risk of recurrence. 
Future analyses with a larger sample size and longer follow-up time are needed before 
definitive conclusions can be drawn. However, smoking cessation should still be 
recommended based on its well-established general health benefits. 
Evaluation of the association of different empirically derived dietary patterns with risk of 
recurrence and progression in NMIBC was described in Chapter 4. Food-frequency 
questionnaire and clinical data from 595 newly diagnosed NMIBC patients from a large 
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ongoing cohort study performed at M.D. Anderson Cancer Center and Baylor College of 
Medicine were used. We identified four dietary patterns (“fruits and vegetables”, “Western”, 
“low-fat”, and “Tex-Mex”), which together explained 37% of the total variance. Patients 
adhering most to the Western dietary pattern had a 1.5 times higher risk of recurrence 
compared to patients adhering least. No statistically significant associations with risk of 
progression were found, or of the other dietary patterns with risk of recurrence and 
progression. As a Western diet is high in fried food, and red and processed meat, the 
harmful substances present in these foods may directly exert a carcinogenic effect on the 
urothelium when excreted in the urine. Our study thus supports the more general 
hypothesis that a Western diet plays a role in the etiology and prognosis of cancer. 
However, further research is needed to confirm our findings and elucidate the association 
of diet with NMIBC prognosis.
Chapter 5 describes the HRQoL of 541 NMIBC patients participating in the UroLife study 
over a fifteen month period after diagnosis and compared it with the HRQoL of an age- 
and sex-matched normative population. Further, we investigated whether HRQoL of 
patients was associated with treatment, smoking behaviour and fluid intake. HRQoL was 
assessed with the EORTC QLQ-C30 and the EORTC QLQ-NMIBC24. We showed that NMIBC 
patients had a worse self-reported role functioning, emotional functioning and social 
functioning, and reported more fatigue, dyspnoea, insomnia, appetite loss, and diarrhea 
than a normative population. Differences were of small clinical importance. Although 
HRQoL improved over time in most domains, complaints of appetite loss, diarrhea, urinary 
symptoms, and emotional concerns persisted in many patients until 15 months after 
diagnosis. Patients treated with intravesical chemotherapy or immunotherapy scored 
worse on several NMIBC-specific domains compared to patients treated with a transurethral 
resection of the tumour only. Patients treated with intravesical immunotherapy also had a 
higher urinary symptom burden. Smoking and fluid intake did not have a relevant impact 
on HRQoL. Caregivers should be alert as specific domains of HRQoL of NMIBC patients are 
worse than that of the general population, and symptoms and emotional worries may be 
present for a longer period of time. 
UBC patients’ perceptions about what they believe contributed to the development of 
their own disease is described in Chapter 6. For this purpose, data of the Nijmegen 
Bladder Cancer Study was used. The question ‘You have been diagnosed with bladder 
cancer. Do you have any idea what may have been the cause of your cancer?’ was 
evaluated. Of 1793 included patients, 366 (20%) reported a possible cause for their bladder 
cancer. Only 10% of all patients suspected that smoking could be the cause, followed by 
occupational exposure (5%), and heredity (2%). Even among ever smokers, only 11% 
perceived smoking as a possible cause of their disease. This is important knowledge for 
health prevention and education initiatives as it reflects the superficial knowledge about 
198
Chapter 9
smoking as risk factor for UBC. Also the fact that patients reported factors that are known 
to be not involved in (bladder) cancer etiology deserves attention. Focusing on these 
factors might prevent patients from focusing on changing real risk behaviours. 
In Chapter 7, we investigated whether NMIBC patients are aware of (bladder) cancer risk 
factors, and whether they adhere to several lifestyle recommendations for cancer 
prevention. Also, we evaluated whether they received lifestyle advice, and their attitudes 
towards receiving lifestyle advice from their physician. A total of 969 NMIBC patients 
participating in the UroLife were included. We showed that awareness of risk factors for 
cancer in general varied between 29% for fruit and vegetable consumption and 89% for 
smoking. Only 44% of the patients were aware of smoking as risk factor for UBC. Adherence 
to the cancer prevention recommendations varied between 34% for body weight and 
84% for smoking. Seventy percent of the smokers was advised to quit, but only 19% of all 
patients reported to have received other lifestyle advice. However, over 80% of the 
patients had a positive attitude towards receiving lifestyle advice from their physician. 
Therefore, information provision by physicians on a healthy lifestyle should be improved. 
This thesis ends with a general discussion of the studies described in this thesis in the 
context of relevant existing literature, including recommendations to policy makers, 
clinicians, and researchers (Chapter 8). In conclusion, we gathered valuable data on lifestyle 
in relation to different aspects of NMIBC: prognosis, HRQoL, and patients’ awareness. 
We found evidence for a higher risk of recurrence in NMIBC patients with a higher BMI in 
a meta-analysis of the literature, and with a Western diet in a US cohort. In preliminary 
analyses of UroLife, with repeated lifestyle and HRQoL measurements smoking and fluid 
intake were not markedly associated with risk of recurrence nor with HRQoL. HRQoL of 
NMIBC patients in our study was worse than that of a normative population in multiple 
domains and complaints of appetite loss, diarrhea, urinary symptoms, and emotional 
concerns persisted until 15 months after diagnosis. Finally, we showed that awareness of 
(bladder) cancer risk factors and adherence to cancer prevention lifestyle recommendations 
among NMIBC patients is low and that physicians’ information provision should be improved. 
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Blaaskanker is de negende meest veelvoorkomende vorm van kanker wereldwijd. De meest 
belangrijke risicofactor voor het krijgen van blaaskanker is roken. Het roken van sigaretten 
kan het risico op het ontwikkelen van blaaskanker met meer dan drie keer verhogen, maar 
stoppen met roken kan de schade gedeeltelijk ongedaan maken. Wat betreft andere leef-
stijlfactoren is er volgens het World Cancer Research Fund / International American 
Institute for Cancer Research beperkt suggestief bewijs voor een beschermend effect van 
de consumptie van fruit, groente en thee. Recente meta-analyses vonden daarnaast een 
licht verhoogd risico op het krijgen van blaaskanker bij een hogere body mass index (BMI) 
en een verlaagd risico bij meer fysieke activiteit en een hogere inname van vitamine E. 
 De meeste patiënten worden gediagnosticeerd met niet-spierinvasieve blaaskanker 
(non-muscle-invasive bladder cancer; NMIBC). NMIBC heeft een goede vijfjaarsoverleving 
(89-99%), maar een hoog risico op recidivering van de tumor binnen vijf jaar (28-52%) 
waardoor een intensieve follow-up en mogelijk meerdere behandelingen nodig zijn. 
Er zijn associaties gevonden van verschillende leefstijlfactoren met meerdere vormen 
van kanker, maar de rol van leefstijl in NMIBC prognose is nog nauwelijks onderzocht. 
De studies die tot op heden zijn uitgevoerd waren vooral gericht op roken en vonden dat 
zowel voormalige als huidige rokers een meer dan 20% hoger risico op recidief kunnen 
hebben. Vochtinname, een leefstijlfactor die vaak verondersteld wordt geassocieerd te 
zijn met het ontstaan van blaaskanker, is tot op heden nog niet onderzocht in relatie tot 
prognose. 
 Afgezien van een potentieel effect op NMIBC prognose kunnen verbeteringen in leefstijl 
ook een positief effect hebben op gezondheidsgerelateerde kwaliteit van leven (health-
related quality of life; HRQoL). Het is aangetoond dat NMIBC patiënten een slechtere 
mentale en/of fysieke gezondheid hebben ten opzichte van een normatieve populatie. 
Aangezien verschillende leefstijlgewoonten geassocieerd zijn met HRQoL in overlevenden 
van andere vormen van kanker, is het waarschijnlijk dat een gezonde leefstijl ook HRQoL 
van NMIBC patiënten kan verbeteren. Tot nu toe is er alleen suggestief bewijs voor een 
positieve associatie tussen meer fysieke activiteit en HRQoL in NMIBC overlevenden. 
 Naast de rol van leefstijl vóór diagnose is het van groot belang om te weten of 
veranderingen in leefstijl die gemaakt zijn na diagnose nog steeds het verloop van de 
ziekte, of HRQoL positief kunnen beïnvloeden. Deze vragen zijn vooralsnog onbeantwoord, 
waardoor urologen alleen algemeen leefstijladvies kunnen geven wanneer patiënten 
vragen wat zij zelf kunnen doen. Uiteindelijk zal de ontwikkeling van zogenaamde ‘evidence- 
based’ richtlijnen specifiek voor NMIBC patiënten urologen helpen bij het geven van leef-
stijladvies en patiënten enige controle over hun ziekte teruggeven en hen meer betrekken 
in de behandeling. 
 Het doel van het onderzoek beschreven in dit proefschrift was daarom de associatie 
tussen roken, vochtinname en voedingspatronen en risico op recidief en HRQoL in NMIBC 
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patiënten te onderzoeken. Daarnaast hadden we als doel te onderzoeken of patiënten 
zich bewust zijn van risicofactoren voor (blaas)kanker, of zij zich houden aan richtlijnen 
voor kankerpreventie, of zij op dit moment leefstijladvies ontvangen en wat hun houding 
is ten opzichte van het ontvangen van leefstijladvies van hun arts. 
Dit proefschrift begint met een algemene introductie over blaaskanker etiologie en 
prognose, de meest belangrijke bevindingen op het gebied van leefstijl en HRQoL tot nu 
toe en de complexiteit van gedragsverandering na diagnose (Hoofdstuk 1). Tevens wordt 
het doel van dit onderzoek gegeven, alsmede een kort overzicht van de opbouw van dit 
proefschrift.  
Daarna geven we een overzicht van de literatuur over de associaties tussen BMI, voeding 
en voedingssupplementen en blaaskankerrecidief, progressie en mortaliteit door middel 
van een systematische literatuurstudie en meta-analyse (Hoofdstuk 2). We includeerden 
31 studies gepubliceerd tot mei 2017 waarvan de meeste zich focusten op BMI. Uit deze 
literatuurstudie bleek dat het bewijs voor een verband tussen leefstijlfactoren en het 
verloop van blaaskanker beperkt is. Een meta-analyse van drie studies in NMIBC patiënten 
vond dat overgewicht en obesitas, in vergelijking met een gezond gewicht, geassocieerd 
waren met een verhoogd risico op recidieven. Er was ook een voorzichtige trend te zien 
voor een hoger risico op progressie naar spierinvasieve blaaskanker (muscle-invasive 
bladder cancer; MIBC) in patiënten met obesitas. De resultaten van onderzoeken naar het 
effect van BMI in een gecombineerde groep van NMIBC en MIBC patiënten, of in MIBC 
patiënten alleen was inconsistent en soms zelfs tegengesteld. Een meta-analyse van drie 
studies in NMIBC en MIBC patiënten gecombineerd liet echter een trend zien voor een 
lagere kankerspecifieke mortaliteit in patiënten met overgewicht in vergelijking met 
patiënten met een gezond gewicht. Sommige observationele studies naar voeding en 
voedingssupplementen vonden een potentieel beschermend effect op recidief, kanker-
specifieke mortaliteit of mortaliteit in het algemeen. Dit gold echter alleen voor afzonderlijke 
voedingsmiddelen en supplementen. Het feit dat de meeste studies (ernstige) methodo-
logische tekortkomingen hadden was misschien wel onze belangrijkste bevinding. 
Prospectieve cohortstudies met herhaalde metingen, die het hele dieet in beschouwing 
nemen en gericht zijn op geschikte klinische uitkomsten zijn nodig om evidence-based 
richtlijnen te ontwikkelen. 
In Hoofdstuk 3 beschrijven we de associatie tussen door de patiënt gerapporteerde 
rookstatus, tijd sinds stoppen met roken, cumulatieve blootstelling aan rook en postdiag-
nostische vochtinname met risico op NMIBC recidief in de prospectieve cohortstudie 
UroLife. We includeerden 550 patiënten met een primaire NMIBC diagnose. Deelnemers 
vulden 6 en 12 weken na diagnose een vragenlijst in over hun rookgedrag. Daarnaast 
hielden ze 12 weken na diagnose een vierdaags vocht- en urinedagboekje bij. Patiënten 
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werden opgevolgd voor een mediaan van 19 maanden. Hierin ontwikkelden 103 (19%) 
patiënten op zijn minst één recidief. De meeste patiënten hadden vroeger gerookt (58%) 
of rookten nog op het moment van invullen van de eerste vragenlijst (26%) en de mediane 
vochtinname was 1840 mL (interkwartielafstand 1500 – 2215 mL). Roken en vochtinname 
waren niet duidelijk geassocieerd met risico op recidief in deze voorlopige analyses van 
de UroLife studie. Een niet-statistisch significant verhoogd risico op recidief werd 
gevonden in voormalig rokers en in voormalig of huidig rokende patiënten met de 
hoogste versus de laagste cumulatieve blootstelling aan rook. Analyses in grotere studies 
met een langere follow-up zijn nodig voordat we definitieve conclusies kunnen trekken. 
Echter, stoppen met roken moet zeker worden aanbevolen op basis van de algemeen 
bekende en bewezen gezondheidsvoordelen. 
De evaluatie van de associatie tussen verschillende empirisch afgeleide voedingspatronen 
en het risico op recidief en progressie van NMIBC wordt beschreven in Hoofdstuk 4. 
Hiervoor gebruikten we voedselfrequentievragenlijsten en klinische gegevens van 595 
patiënten met primaire NMIBC uit een grote lopende cohortstudie uitgevoerd in M.D 
Anderson Cancer Center en Baylor College of Medicine. Uit de data identificeerden we 
vier voedingspatronen (“fruit en groente”, “Westers”, “vetarm” en “Tex-Mex”), die samen 
37% van de totale variantie verklaarden. Patiënten die het meest volgens het Westerse 
voedingspatroon aten hadden een 1.5 keer hoger risico op recidief dan mensen die het 
minst volgens dit voedingspatroon aten. Er leek ook een trend te zijn voor een hoger risico 
op progressie bij een Westers voedingspatroon. Voor de andere voedingspatronen 
werden er geen associaties met recidief of progressie gevonden. Een Westers voedings-
patroon is rijk aan voedingsmiddelen met veel schadelijke stoffen zoals gefrituurd voedsel 
en rood en bewerkt vlees. De schadelijke stoffen uit deze voedingsmiddelen zouden, 
wanneer ze via de urine worden uitgescheiden, een direct carcinogeen effect kunnen 
hebben op de urotheelcellen in de blaas. Onze studie ondersteunt dus de meer algemene 
hypothese dat een Westers eetpatroon een rol speelt in zowel het ontstaan als de 
prognose van kanker. Er is echter verder onderzoek nodig om onze bevindingen te 
bevestigen en deze complexe associatie tussen voeding en ziekte in meer detail te 
onderzoeken. 
Hoofdstuk 5 beschrijft de HRQoL van aan UroLife deelnemende NMIBC patiënten over 
een periode van vijftien maanden na diagnose. Ook vergelijken we de HRQoL van 
patiënten met de HRQoL van een normatieve populatie die gematcht is op basis van een 
vergelijkbare leeftijd en geslacht. Het laatste doel van deze studie was te onderzoeken of 
de HRQoL van onze patiënten afhing van het type behandeling, rookgedrag en 
vochtinname. De HRQoL is gemeten met de EORTC QLQ-C30 en EORTC QLQ-NMIBC24 in 
541 NMIBC patiënten binnen UroLife. We toonden aan dat NMIBC patiënten een slechter 
rol-, emotioneel- en sociaal functioneren rapporteren dan een normatieve populatie. 
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Daarnaast gaven ze aan meer klachten te ervaren op het gebied van vermoeidheid, 
benauwdheid, slapeloosheid, verlies van eetlust en diarree. Hoewel de HRQoL in de loop 
van de tijd verbeterde in de meeste domeinen, bleven klachten op het gebied van verlies 
van eetlust, diarree, urinewegsymptomen en emotionele zorgen bij veel patiënten 
aanwezig tot 15 maanden na diagnose. Patiënten die werden behandeld met intravesicale 
spoelingen met chemotherapie of immunotherapie scoorden slechter op een aantal ziek-
te-specifieke domeinen dan patiënten die alleen een transurethrale resectie van de tumor 
hadden ondergaan. Patiënten die werden behandeld met immunotherapie hadden 
daarnaast meer last van urinewegsymptomen. Rookstatus en vochtinname hadden geen 
relevant effect op HRQoL. Al met al is het belangrijk dat zorgverleners alert blijven op een 
slechtere HRQoL van NMIBC patiënten, ook voor een langere periode na diagnose. Tijdens 
deze studie ondervonden we dat de analyse van HRQoL uitdagend is vanwege de 
subjectieve aard van de gegevens. Er moet naar meer eenheid worden gestreefd in zowel 
de analyse als de interpretatie van deze zelfgerapporteerde uitkomsten. 
Welke factoren volgens overlevenden van blaaskanker hebben bijgedragen aan de 
ontwikkeling van hun eigen ziekte is beschreven in Hoofdstuk 6. Hiervoor werden 
gegevens van de Nijmegen Blaaskankerstudie (NBCS) gebruikt en de vraag “Bij u is een 
relatief goedaardige poliep of een kwaadaardige tumor in de blaas vastgesteld. Heeft u 
zelf enig idee wat hiervan de oorzaak zou kunnen zijn?” werd geëvalueerd. Van de 1793 
geïncludeerde patiënten rapporteerden slechts 366 (20%) patiënten een mogelijke 
oorzaak van hun tumor. Een opvallend lage 10% van alle patiënten vermoedde dat roken 
de oorzaak geweest zou kunnen zijn, gevolgd door beroepsmatige blootstelling aan 
toxische stoffen (5%) en erfelijkheid (2%). Zelfs onder rokers rapporteerde maar 11% dat 
roken mogelijk de oorzaak van hun ziekte zou kunnen zijn. Deze kennis is belangrijk voor 
initiatieven op het gebied van gezondheidspreventie en educatie, omdat het de geringe 
kennis over roken als risicofactor voor blaaskanker weergeeft. Ook het feit dat patiënten 
bepaalde risicofactoren als mogelijke oorzaak rapporteerden waarvan bekend is dat deze 
niet betrokken zijn bij het ontstaan van (blaas)kanker verdient aandacht. Wanneer 
patiënten zich op deze factoren richten, kan dit hen ervan weerhouden ongezonde 
leefgewoonten te veranderen.
Om onze kennis van bewustzijn en andere determinanten van gedragsverandering uit te 
breiden, hebben we onderzocht of NMIBC patiënten zich bewust zijn van risicofactoren 
voor (blaas)kanker en of zij zich houden aan richtlijnen voor kankerpreventie op het 
gebied van leefstijl in Hoofdstuk 7. Ook evalueren we in deze studie of patiënten advies 
over leefstijl kregen van hun arts en hoe zij ertegenover zouden staan leefstijladvies te 
krijgen van hun arts. In totaal werden 969 NMIBC patiënten die aan UroLife deelnamen in 
dit onderzoek geïncludeerd. Onze bevindingen tonen aan dat het bewustzijn van 
risicofactoren voor kanker in het algemeen varieerde tussen 29% voor consumptie van 
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fruit en groente en 89% voor roken. Slechts 44% van de patiënten was zich ervan bewust 
dat roken een risicofactor is voor het krijgen van blaaskanker. Het verschil met de studie 
die is beschreven in Hoofdstuk 6 wordt waarschijnlijk veroorzaakt door het verschil in het 
type vraagstelling (gesloten versus open vraag) en omdat er in deze studie werd verwezen 
naar blaaskanker in het algemeen, in tegenstelling tot de eigen ziekte in Hoofdstuk 6. 
Of patiënten zich hielden aan de richtlijnen voor kankerpreventie varieerde tussen 34% 
voor lichaamsgewicht en 84% voor roken. Zeventig procent van de rokers gaf aan te zijn 
geadviseerd te stoppen met roken, terwijl slechts 19% van alle patiënten rapporteerde dat 
zij advies hadden gekregen over andere leefstijlfactoren. Meer dan 80% van de patiënten 
had echter een positieve houding ten aanzien van het ontvangen van leefstijladvies van 
hun arts. Deze bevinding, in combinatie met het lage bewustzijn van risicofactoren en 
slechte leefstijlgewoonten, zouden artsen moeten aanmoedigen om hun patiënten vaker 
te adviseren over een gezonde leefstijl. 
Dit proefschrift eindigt met een algemene discussie van de studies die zijn beschreven 
waarbij zij in de context van relevante literatuur worden geplaatst (Hoofdstuk 8). Ook 
worden aanbevelingen gedaan aan beleidsmakers, clinici en onderzoekers. 
Samengevat hebben we waardevolle gegevens verzameld over leefstijl in verschillende 
aspecten van NMIBC: prognose, HRQoL en het bewustzijn van patiënten. We vonden dat 
het risico op recidivering van NMIBC hoger is in patiënten met een hoger BMI (in de 
literatuur) en in patiënten met een Westers voedingspatroon (in patiënten uit de VS). Met 
UroLife startten we de hoognodige prospectieve studie met herhaalde metingen van 
leefstijl en HRQoL. In voorlopige analyses waren roken en vochtinname niet duidelijk 
geassocieerd met het risico op recidief, noch met HRQoL. HRQoL van NMIBC patiënten in 
onze studie was echter wel slechter dan HRQoL van een normatieve populatie in meerdere 
domeinen. Ook bleven klachten op het gebied van verlies van eetlust, diarree, urineweg-
symptomen en emotionele zorgen vaak aanhouden tot 15 maanden na diagnose. Ten 
slotte tonen onze bevindingen aan dat patiënten zich maar matig bewust zijn van 
risicofactoren voor het krijgen van (blaas)kanker. Daarnaast houden zij zich slecht aan de 
richtlijnen voor kankerpreventie op het gebied van leefstijl en moet voorlichting door 
artsen op dit gebied worden verbeterd.  
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Een PhD lijkt als net afgestudeerde een enorm lang traject waar geen einde aan lijkt te 
komen, maar voor je het weet is het toch opeens voorbij gevlogen. De afgelopen jaren 
waren om meerdere redenen heel bijzonder, leerzaam en vooral leuk dankzij een heleboel 
mensen. Ik wil hier iedereen bedanken die aan mijn boekje heeft bijgedragen, sommigen 
heel concreet, anderen misschien iets minder concreet, maar niet minder waardevol. Ik zal 
deze tijd nooit vergeten, dank jullie wel!
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daardoor erg bijzonder. Het opstarten van een groot project als UroLife en daar uiteindelijk 
na hard werken de vruchten van plukken was een hele mooie uitdaging om samen aan 
te gaan. Ik heb onze samenwerking als enorm prettig ervaren, je had altijd tijd voor me 
en onze trips naar Lyon en Heidelberg waren naast leerzaam ook gewoon heel gezellig. 
Ik bewonder je kennis en oog voor detail en ben benieuwd wat jij na UroLife en ReLife 
nog meer gaat doen. Heel erg bedankt!
Bart, tijdens het eerste sollicitatiegesprek wist ik eigenlijk al dat het goed zat. Jouw 
nuchtere en pragmatisch reactie op dingen was soms een verademing als wij te lang in 
details bleven hangen. Je enthousiasme en doorzettingsvermogen werken aanstekelijk. 
En hoe jij in jouw overvolle agenda toch altijd tijd vond om een afspraak in te plannen als 
dat nodig was (ook dank aan Marie-Louise!) of mijn stukken te lezen snap ik nog steeds 
niet. Heel veel respect en hartelijk dank. En succes met de Tour!
Ellen, de combinatie van je ijzersterke professionele houding en je warme persoonlijkheid 
heb ik heel erg gewaardeerd. Overleggen met jou voelden als een gezellige bijeenkomst, 
maar daarna liep ik wel vol nieuwe informatie en ideeën weg. Daarnaast was het erg fijn 
om jouw inbreng als voedingswetenschapper mee te kunnen nemen. Ook al is er in het 
uiteindelijke proefschrift geen voeding meer te vinden, ik heb hier wel veel aan gehad. 
Ondanks dat we elkaar niet heel veel zagen ben je een inspiratie voor me geweest. 
Hartelijk dank!
Fred, jouw betrokkenheid als clinicus bij dit project heb ik erg gewaardeerd. Jouw inbreng 
en klinische blik waren in de verschillende fasen van het onderzoek onmisbaar, dank dat 
we je altijd om raad konden vragen. Daarnaast heb ik door met jou mee te mogen lopen 
op de polikliniek wat meer een inkijkje kunnen krijgen in o.a. wat voor impact bepaalde 
behandelingen op de patiënt hebben. Ook om jouw altijd weer razendsnelle reacties op 
artikelen heb ik me keer op keer verbaasd, maar vond ik bovenal natuurlijk erg prettig. 
Leden van de manuscriptcommissie: Judith Prins, Nicoline Hoogerbrugge en Matty Weijenberg 
hartelijk dank voor jullie bereidheid om zitting te nemen in de manuscriptcommissie en 
voor het lezen en beoordelen van dit proefschrift.
Monique, jij was en bent nog steeds van onschatbare waarde voor UroLife. Het voelt voor 
mij alsof we samen zijn meegegroeid met de studie. Dachten we na al die jaren alles wel 
gezien te hebben dan kwamen we toch nog nieuwe verrassingen tegen om weer een 
oplossing voor te verzinnen. En daarnaast, minstens zo belangrijk, van een rondje Brabant 
tot sorteren in de Biobank, het was altijd even gezellig. Heel erg bedankt voor de prettige 
samenwerking!
Zonder deelnemers geen onderzoek. Aan iedereen die de moeite heeft genomen onze 
(lange!) vragenlijsten in te vullen: hartelijk dank! Zonder uw hulp waren we hier nooit 
gekomen.
Drs. Van der Schoot (Amphia Ziekenhuis), Drs. Niemer (Ziekenhuis Bernhoven), Dr. Somford 
(Canisius-Wilhelmina Ziekenhuis), Dr. Koldewijn (Catharina Ziekenhuis Eindhoven), Drs. Van 
den Tillaar (Deventer Ziekenhuis), Drs. Stapper † en Drs. Van Hest (Elkerliek Ziekenhuis), Drs. 
Bochove-Overgaauw (Gelre Ziekenhuizen), Dr. Te Slaa, (Isala Klinieken) Dr. Oddens (Jeroen 
Bosch Ziekenhuis), Drs. Van Rey (Meander Medisch Centrum), Dr. Asselman (Medisch 
Spectrum Twente), Dr. Fossion (Maxima Medisch Centrum), Drs. van Boven (Maasziekenhuis 
Pantein), Prof. Dr. Witjes (Radboudumc), Drs. Wijburg (Rijnstate), Drs. Geboers (Slingeland 
Ziekenhuis), Drs. Sonneveld (St. Anna Ziekenhuis), Dr. Kil en Drs. Davits (Elisabeth-Twee-
Steden Ziekenhuis), Drs. Kniestedt (St. Jansdal Ziekenhuis), Drs. Yurdakul (VieCuri), 
Drs. Kortleve (Ziekenhuis Gelderse Vallei), Dr. Cornel (Ziekenhuisgroep Twente) en alle 
andere urologen die hun medewerking hebben verleend aan UroLife wil ik hierbij ook 
hartelijk bedanken.
Alle (contactpersonen van) de laboratoria: als ik namen ga noemen ga ik ongetwijfeld 
mensen vergeten. Dus bij deze hartelijk dank allemaal voor de fijne samenwerking, 
flexibiliteit en snelle reacties op onze vragen. 
Ook zonder de hulp van IKNL hadden we dit niet kunnen bereiken. Marjorie de Kok en 
Denise Plönissen dank voor jullie ondersteuning en het intern uitzetten van UroLife. Katja, 
door jouw positie binnen zowel IKNL als HEV kon jij ons goed helpen en ook de andere 
kant uitleggen als wij weer eens sneller of meer wilden dan eigenlijk haalbaar was. 
Daarnaast kon ik je lekker nuchtere reacties altijd wel waarderen. Trienika en Reini, ik weet 
nog zo goed dat het in het begin een halve dag duurde om twee patiënten uit te nodigen. 
Gelukkig ging het mede dankzij jullie hulp al gauw een stuk sneller! Ook later zijn we elkaar 
nog tegen gekomen. Trienika, dank voor je hulp met het opleveren van de databestanden 
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en Reini, zonder jouw ombouwsyntax zouden de klinische data een veel groter doolhof 
zijn geweest. Hartelijk dank aan alle datamanagers die voor UroLife hebben geregistreerd 
en die wekelijks werden gemaild voor aanvullende vragen, eerst door mij en later door 
Monique. Zo fijn dat jullie altijd bereid waren nog even in het dossier te kijken zodat voor 
ons alles duidelijk was. Monique de Groot, jij hebt in dit alles een hele belangrijke rol 
vervuld. Tot in den treure heb je je met en zonder mij over de registratielijst gebogen 
totdat het uiteindelijk iets was waarmee iedereen uit de voeten kon. Heel erg bedankt! 
Dorien, we kwamen elkaar al tegen op (voor mij) de eerste dag van onze studie, daarna 
werden we collega’s bij HEV en toen jij bij IKNL ging werken kregen we ook inhoudelijk 
weer met elkaar te maken. Dank voor je hulp bij het vullen van het RANK format, maar 
vooral voor de gezelligheid. Ik ben benieuwd wanneer onze wegen elkaar weer kruisen. 
Siem Klaver en Jos van Steenoven, dank voor jullie ondersteuning vanuit de Biobank en 
interesse in hoe het er voor stond met UroLife. Fijn dat we ook altijd last-minute nog bij 
jullie terecht konden voor koelboxen en droogijs, het kwam altijd goed. 
Zonder de infrastructuur van de Profielstudie hadden we het bij UroLife een stuk moeilijker 
gehad. Hartelijk dank aan Nicole Horevoorts en anderen die ervoor zorgden dat ook onze 
studie wat betreft het o.a. het registreren van deelnemers en het uitsturen van vragenlijsten 
vlekkeloos verliep. Ditzelfde geldt voor de medewerkers van Wageningen Universiteit die 
de FFQ tool beheren, hartelijk dank!
Dear Dr. Wu, thank you for giving me the opportunity to work with you and your team on 
dietary data of the bladder cancer cohort. I will always remember and cherish my time at 
the epidemiology department of MD Anderson Cancer Center in Houston. It felt special to 
be part of this immense institution that is solely focused on curing cancer. Special thanks 
to Huakang Tu for your help and your friendliness, Maosheng Huang for your statistical 
expertise, and Fangyu Lin, my ‘room’mate, for your company at work, the rides home and 
of course the baseball game. Beatriz, thank you very much for introducing me to the social 
life of Houston and its’ many nice people. Thanks Julia, Andrea, Miguel, Arantza, Norm and 
others I met along the way. It was quite an experience!
Mijn tijd bij de RIHS PhD council heeft de middelste jaren van mijn PhD wat extra’s 
gegeven. Juist in zo’n periode van veel praktisch werk en nog weinig resultaten bood de 
PhD council mij de broodnodige uitdaging en mogelijkheden tot ontwikkeling. In het 
bijzonder wil ik de workshopcommissie waar ik onderdeel van was bedanken: Kirsten, 
Karlijn, Simône, Carolien, Stein, Romy, Vincent en Yvonne. Met name de PhD retreats en de 
aanloop daar naar toe waren onvergetelijk en ik kijk met veel plezier terug op de fijne 
samenwerking en de leuke tijd. Ook dank aan Marieke, Karin en Dagmar voor jullie hulp!
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In de loop van de tijd heb ik een aantal stagiaires (mede) mogen begeleiden: Julia, Inge, 
alle dames van de science projecten, Babette en Manette. Bedankt! Ook voor mij waren 
jullie stages leerzaam en jullie hebben ieder om jullie eigen redenen indruk op mij 
gemaakt. Ik ben benieuwd waar jullie terecht komen!
HEV collega’s, ik wil jullie graag bedanken voor jullie collegialiteit en gezelligheid. Ik had 
me als nieuweling in Nijmegen geen betere afdeling kunnen wensen om me thuis te gaan 
voelen. De koffiepauzes, cake van de week, lunchwandelingen, RIP meetings en meer 
gaan mee als mooie herinneringen. Dank! 
Van een plek in de kelder met Marcia naar een bedompt kamertje op de derde met 
Elsemieke en uiteindelijk gelukkig gewoon een kamer met frisse lucht, het leven bij HEV is 
nooit saai. Elsemieke, ik vond het leuk om een groot deel van dit traject met jou te delen. 
Je had altijd mooie verhalen en zonder jou had ik de ontspannende werking van het 
geluid van wasmachines en andere white noise nooit leren kennen. Leuk dat we nu ook 
kort na elkaar deze tijd gaan afsluiten. Felix, Francis, Rozar and Brett, we have only spent a 
short time together at the department but it was fun to share experiences and thoughts 
about differences and similarities between our countries. 
Linda, ik vond het heel fijn om met jou als mede ‘alfa-brein’ op een verder toch wel 
behoorlijke bèta afdeling te kunnen praten. Over werk, maar vooral over alle zaken 
daarbuiten. Ik heb veel respect voor wie je bent en wens je heel veel geluk met je zoontje! 
Roomies Scott en Sander, buren Anouck, Michail, Rana en Romy en buren van de buren 
Liesbeth en Tamara. Ik had me geen betere (bijna-)kamergenoten kunnen wensen! Romy, 
ik vind het heel erg leuk dat jij straks naast me staat als paranimf. Ik heb je heel erg 
gewaardeerd als collega bij zowel HEV als bij de council. Je nuchterheid werkt relativerend 
en het was altijd gezellig! Liesbeth, we hebben niet lang samengewerkt, maar ik vind het 
heel erg leuk dat jij nu met UroLife verder gaat. Op naar nog meer mooie artikelen! Scott, 
naast de lol die we gehad hebben was het ook heel fijn om een kamer te delen met 
iemand die met een soortgelijke studie bezig was. Gedeelde smart is halve smart en 
gedeelde vreugde is dubbele vreugde ging zeker op! De lol die we gehad hebben om 
een niet bij naam te noemen familie laat me nog regelmatig lachen. Bedankt allemaal! 
Nieuwe collega’s van Significant Groep, ik had me geen betere volgende stap in mijn 
carrière kunnen wensen. Soms weet je vanaf moment één dat het goed zit, dat was ook 
hier het geval en dat gevoel is nog geen moment weggeweest. Ik kan me niet meer 
voorstellen om iets anders te doen. Hartelijk dank voor het warme bad en de mooie 
projecten die ik al heb mogen doen. Ik kijk uit naar de komende jaren! 
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Naast collega’s wil ik graag nog andere mensen bedanken die met hun support, oprechte 
interesse in mijn onderzoek en voor het soms vooral niet informeren naar de voortgang 
van mijn proefschrift mede hebben bijgedragen aan dit boekje.
Familie, ik ben er de laatste jaren minder vaak bij geweest, maar weet dat ik me gelukkig 
prijs met jullie en de wetenschap dat jullie er altijd willen zijn. Leo en Jaco, ik hoop dat jullie 
niet al te teleurgesteld zijn dat ik jullie niet heb gevraagd als paranimfen. Vanuit de zaal is 
het beleven van deze dag trouwens ook een stuk relaxter. 
Nico, die boekjes die je me ooit gaf hebben toch effect gehad. Bedankt dat je er voor me 
wil zijn en fijn dat je er vandaag bij bent!
Marlies en Marcel, ook jullie zie ik veel minder vaak dan ik zou willen, maar als we elkaar 
zien dan is het gewoon goed. En juist dat maakt onze vriendschap voor mij heel bijzonder!
De Fabulous ladies, in wisselende samenstelling, maar met Anne, Evianne, Joni, Laura, 
Maartje, Martine en Paulien als vaste kern. Onze vriendschap is mij heel erg dierbaar. 
En vergeet de aanhang niet! Jullie zorgen voor wat broodnodige mannelijke nuchterheid 
in ons kippenhok en Max, fijn dat we onze ‘problemen’ af ten toe kunnen delen ;). Evianne, 
dat jij nu als paranimf naast me staat vind ik heel fijn. Weer een mooie herinnering om aan 
onze lijst toe te voegen!
Mama, niks wat ik hier kan zeggen zou recht doen aan wat je voor me betekent. Je on-
voorwaardelijke liefde en steun, of het nou goed gaat of minder goed en of je het nou 
met me eens bent of niet. Je hebt me altijd aangemoedigd om de keuzes te maken en 
dingen te doen waar ik gelukkig van zou worden. Bedankt! Papa kan er niet meer bij zijn, 
maar ik weet dat hij ontzettend trots op me geweest zou zijn, zoals hij altijd was. En dat 
gevoel neemt niemand me af. 
Pieter, wat begon als gezelligheid tussen kamergenoten eindigde als een relatie. Ik was zo 
iemand die verkondigde echt nooit iets met een collega te beginnen, maar zie hier. Ik ben 
je dankbaar voor de ruimte en steun die je me geeft en het gevoel dat ik bij jou 100% 
mezelf kan zijn, dat is me veel waard. Dankjewel voor alles!
Ellen
There is a crack in everything, that’s how the light gets in. (Leonard Cohen, 1934-2016)

